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ABSTRACT 
 
Background:  Amyloidosis is a multisystem disorder characterised by abnormal protein 
folding, in which proteins adopt an abnormal conformation and deposit as insoluble 
fibrils that disrupt tissue structure and function. 
Aims and Methods: To characterise the phenotype of the heredo-familial forms of 
systemic amyloidosis, the role of solid organ transplantation in the different systemic 
amyloidosis syndromes and to evaluate the gastroenterological and hepatological causes 
and sequaelae of systemic amyloidosis.  These features were sought in patients followed 
at the UK National Amyloidosis Centre between 1984 and 2011. 
Results and Conclusions:  Familial amyloid polyneuropathy associated with the T60A 
transthyretin variant has a prominent cardiac phenotype, which negatively impacts upon 
prognosis.  Furthermore this cardiac phenotype has a negative impact upon survival in 
those who undergo liver transplantation to eliminate variant transthyretin, which is 
synthesised in the liver, not only by increasing operative risk but also as there is likely 
ongoing cardiac amyloid deposition associated with wild-type transthyretin from the 
liver graft.  In the face of failing organ function, liver and renal transplantation in 
hereditary lysozyme amyloidosis (ALys) appears feasible, despite ongoing 
amyloidogenesis and the risk of recurrent graft amyloid, due to slow turnover of 
amyloid.  Similarly, renal and cardiac transplantation in AL amyloidosis and renal 
transplantation in AA amyloidosis appear favourable when strategies to suppress 
amyloidogenic precursor protein production are employed in tandem.   
Gastrointestinal and hepatic amyloid are recognised in systemic amyloidosis.  In 
ALys both are prevalent; the former is associated with endoscopic abnormalities and the 
latter may be asymptomatic or present as hepatic rupture.  In patients diagnosed with 
amyloid by liver biopsy after presenting with deranged liver biochemistry, AL 
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amyloidosis is the commonest cause and although this presentation has been historically 
associated with a poor prognosis as there is frequently concomitant extra-hepatic 
amyloid, in those who achieve a good clonal response to chemotherapeutic regimes in 
the modern era of treatment a survival advantage is conferred.  Primary gastrointestinal 
disease, such as inflammatory bowel disease, can cause systemic AA amyloidosis.  
Tight inflammatory control, guided by serial serum amyloid A protein levels, benefits 
amyloidotic kidneys, as does aggressive treatment of physiological renal stresses, such 
as sepsis.  Systemic AL amyloidosis is commonly associated with malnutrition, 
especially when there is multisystem amyloid.  Malnutrition in this group is associated 
with a poor quality of life and worse survival and it would appear therefore to be a 
potential target for intervention studies.   
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Chapter 1 
Introduction 
 
Amyloid Structure 
Amyloidosis is a disorder characterised by abnormal protein folding, in which proteins 
adopt an abnormal conformation and deposit as insoluble fibrils that disrupt tissue 
structure and function.  Amyloidosis can be acquired or hereditary and amyloid 
deposition can be localised or systemic.  Over 20 different proteins are known to form 
amyloid fibrils in vivo, but not all cause overt disease.  Amyloid is identified by the 
pathognomonic finding of apple-green dichroism when tissue is stained with the dye 
Congo red and visualised under cross-polarised light.  The characteristic appearance of 
amyloid fibrils under the electron microscope is that of rigid non-branching fibrils with 
a diameter of ~10 nm.
1
  Despite the heterogeneity of the precursor proteins which form 
amyloid fibrils, diffraction studies have highlighted that the structure and properties of 
all amyloid fibrils are remarkably similar and adopt a -sheet structure.2  The 
protofilament structure of amyloid fibrils is made up of ß-sheets, which run parallel to 
the axis of the protofilament, with their component ß-strands perpendicular to the fibril 
axis.
3
 
Non-fibrillar constituents of amyloid deposits include glycosaminoglycans, 
proteoglycans and amyloid P component, which is identical to and derived from the 
normal plasma glycoprotein serum amyloid P component (SAP).  Glycosaminoglycans 
are located primarily on the surface of cells in the extracellular matrix and consist of 
negatively charged unbranched polysaccharides containing a repeated disaccharide unit.  
Though universal in all amyloid deposits, their role is unclear.  Heparan sulphate 
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proteoglycans are also a universal component of amyloid deposits, which are thought to 
contribute to and maintain the conformational changes required for amyloid formation.  
Serum amyloid P component is another non-fibrillar constituent and is a member of the 
pentraxin family of plasma proteins.
4
  Its physiological role has not been fully clarified 
but it may be important in host defence
5
 or the development of autoimmunity.
6
  It is 
present in all amyloid deposits and has calcium-dependant binding motifs.  It is resistant 
to proteolysis and in-vitro binding of SAP to amyloid fibrils prevents degradation of 
amyloid by phagocytic cells and proteolytic enzymes.
7
  In amyloidosis circulating SAP 
exists in a dynamic equilibrium with the SAP bound to amyloid fibrils and only SAP 
molecules in the circulation undergo catabolism.  Its role in amyloidogenesis has been 
proven by the inability to induce experimental AA amyloidosis in SAP knockout mice.
8
   
 
Pathogenesis of amyloidosis 
Amyloidosis is characterised by aberrant folding of various precursor proteins.
9
  The 
pathogenesis of amyloid revolves around “off-pathway” folding of the various fibril 
precursor proteins into a ß-sheet structure with highly organised auto-aggregration as 
amyloid fibrils.
10
  Precursor protein homozygosity, such as SAA1 isotypes in AA 
amyloidosis
11
 and variant TTR
12
 promotes susceptibility to and severity of amyloidosis.  
Amino acid sequences of relevant proteins may dictate the potential of a protein to form 
amyloid on the background of a sustained supply of fibril precursor protein but the 
genetic and environmental factors that confer susceptibility to amyloid formation are 
not fully understood.
13
  Furthermore the factors that govern pattern of organ 
involvement and clinical manifestations are also not fully appreciated.  This is apparent 
both between and within different types of amyloidosis to such a degree that there can 
be major phenotypic differences between members of a kindred with the same genetic 
mutation that encodes for a particular hereditary form of systemic amyloidosis.  In 
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experimental mice models injection of amyloidotic tissue acts as a primer to develop 
AA amyloidosis within days of receiving an acute phase inflammatory stimulus in 
contrast to unprimed mice where there is a requirement of an inflammatory stimulus for 
many weeks.
14
  The amyloid fibrils themselves have been identified as the 
“amyloid-enhancing factor” (AEF) and increase the propensity of precursor protein in 
forming amyloid possibly by forming a template upon which continued supply of 
precursor protein can deposit in an exponential manner.
15
 
The pathological effects of amyloid are secondary to extracellular deposition of 
amyloid with disruption of tissue architecture and subsequent impairment of organ 
function.  There is some evidence of a cytotoxic effect of amyloid fibrils perhaps 
through apoptosis.
16
  This may account for the fact that the clinical and investigative 
parameters suggestive of organ damage may not correlate with body amyloid load or 
amyloid infiltration of affected organs.  The rate of amyloid deposition may also be a 
factor with potential time for functional compensation in amyloidotic organs in those 
where the turnover of amyloid is slower.
17
 
 
Amyloid degradation 
Left untreated the natural history of amyloidosis is one of progressive symptomatology, 
organ failure and death.  With treatments that eliminate or suppress the amyloidogenic 
precursor proteins one can see regression of amyloid from infiltrated organs.
18
  This is 
presumably because the balance between amyloid formation and deposition versus 
regression swings in favour of the latter.
1
  It has been postulated that macrophages may 
have a role in amyloid regression.  Infiltration of amyloid deposits by macrophages is 
followed by the formation of multinucleate giant cells, which surround, engulf and 
destroy the amyloid.  This has been highlighted in vivo by macrophage depletion with 
liposomal clodronate,
19
 which has been shown to retard amyloid regression.  Conversely 
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macrophage activation by GM-CSF (Pepys MB, unpublished data) can promote 
amyloid clearance.  It is quite possible that the differences in rates of regression of 
amyloid are secondary to differences in phenotype and function of macrophages or 
monocytes, as much as it is dependent on suppressing amyloidogenic precursor protein 
production.  The net effect of amyloid regression is stabilisation or improvement of 
organ function coupled with increased patient survival. 
Classification of systemic amyloidosis is based on the respective fibril precursor 
protein (Table 1.1).  Amyloid deposition may occur in several different situations – 
firstly, when there is a prolonged abnormally high concentration of a structurally 
normal, but weakly amyloidogenic protein e.g., Serum Amyloid A protein (SAA) in 
chronic inflammatory states or ß2-microglobulin in long-term end-stage renal failure; 
secondly, in the presence of an abnormal protein with inherently amyloidogenic 
potential e.g., certain monoclonal immunoglobulin light chains or variant proteins 
encoded by genetic mutations; and finally over a very long period when there is a 
normal concentration of a normal protein with weak amyloidogenic potential such as in 
senile systemic amyloidosis in which wild-type transthyretin accumulates as amyloid in 
the hearts of elderly patients.  The pattern of clinical features in systemic amyloidosis 
depends upon which organs are involved and sometimes suggests a particular amyloid 
type.  Studies in hereditary systemic amyloidosis have revealed a correlation between 
the phenotype and the size of the precursor protein fragment that is incorporated into the  
amyloid fibrils.  This may provide insights into the pathogenetic mechanisms in other 
forms of amyloidosis.
20
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Table 1.1  Classification of systemic amyloidosis. 
 
Type  
 
Fibril protein precursor  
 
Clinical syndrome  
 
AA Serum amyloid A protein Reactive systemic amyloidosis associated 
with chronic inflammatory diseases 
AL Monoclonal 
immunoglobulin light 
chains 
Systemic amyloidosis associated with 
monoclonal plasma cell dyscrasias 
AH
21
 Monoclonal 
immunoglobulin heavy 
chains 
Systemic amyloidosis associated with 
monoclonal plasma cell dyscrasias 
Aβ2M β2-microglobulin Systemic amyloidosis associated with 
long-term dialysis 
Dominant musculoskeletal symptoms 
ATTR Normal plasma 
transthyretin 
Senile systemic amyloidosis with 
prominent cardiac involvement 
ATTR Genetically variant 
transthyretin 
Autosomal dominant systemic amyloidosis 
Familial amyloid polyneuropathy or 
hereditary amyloid cardiomyopathy 
ALys Genetically variant 
lysozyme 
Autosomal dominant systemic amyloidosis 
Non-neuropathic with prominent visceral 
involvement 
AGel Genetically variant 
gelsolin 
Autosomal dominant systemic amyloidosis 
Cranial nerve involvement with lattice 
corneal dystrophy 
ACys Genetically variant 
cystatin C 
Hereditary cerebral haemorrhage with 
cerebral and systemic amyloidosis of 
Icelandic type 
AApoAI Genetically variant 
apolipoprotein AI 
Autosomal dominant systemic amyloidosis 
Predominantly non-neuropathic with 
prominent visceral involvement 
AApoAII Genetically variant 
apolipoprotein AII 
Autosomal dominant systemic amyloidosis 
Non-neuropathic with prominent renal 
involvement 
AApoAIV Wild-type apolipoprotein 
AIV 
Sporadic systemic amyloidosis associated 
with aging. 
AFib Genetically variant 
fibrinogen A α-chain 
Autosomal dominant systemic amyloidosis 
Non-neuropathic with prominent renal 
involvement 
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Clinical Amyloidosis Syndromes 
 
Systemic AL Amyloidosis 
This is the commonest form of amyloidosis in the developed world and is associated 
with an underlying clonal dyscrasia of plasma cells or B-lymphoid/ 
lymphoplasmacytoid cells, which may otherwise be benign.
22
  The age-adjusted 
incidence in the USA is 8.9 per million person-years.
23
  Approximately 2% of 
individuals with monoclonal gammopathies (MGUS) develop AL amyloidosis.
23
  The 
fibrils are formed from the N-terminal domain of monoclonal kappa or lambda 
immunoglobulin light chains, more commonly lambda than kappa, and consist of the 
whole or part of the variable (VL) domain, although intact light chains are sometimes 
present.  There is increasing evidence from sequence analyses of Bence-Jones proteins 
of both kappa and lambda type from patients with AL amyloidosis that these variable 
region polypeptides contain unique amino acid substitutions or insertions compared to 
non-amyloidogenic monoclonal light chains.
24
  The deletion 13q and ploidy changes 
occur more frequently in AL amyloidosis than MGUS or myeloma.
25
  Certain light 
chain variable region (VL) genes are over-represented in AL amyloidosis and may have 
an impact on organ tropism.
26
  A monoclonal protein can be identified by serum or 
urine electrophoresis in 65% and 86% of AL patients respectively.
22
  A monoclonal 
excess of FLC can be identified at diagnosis in 98% of patients.
27
 
Potentially, all organs can be directly affected by amyloid deposits besides the 
brain.  The symptoms at onset can be non-specific and include malaise and weight loss.  
Kidney involvement presents as proteinuria or renal impairment.  Cardiac amyloid 
usually manifests as a restrictive cardiomyopathy; typically there is concentric 
ventricular wall thickening resulting in diastolic dysfunction and impaired left 
ventricular filling resulting in congestive cardiac failure.  Low voltage complexes on 
- 7 - 
 
electrocardiogram in the context of these echocardiographic changes are strongly 
suggestive of cardiac amyloid.  Prognosis is poor with cardiac amyloid and median 
survival is 4-6 months after appearance of congestive cardiac failure.
28
  Cardiac 
biomarkers are useful in the diagnostic process and also provide prognostic 
information.
29
  Diastolic dysfunction and increased genetic expression of natriuretic 
peptide genes in the amyloid-infiltrated ventricles leads to an increase in plasma B-type 
natriuretic peptide (BNP) levels.
30
  A 30% reduction in N-terminal prohormone brain 
natriuretic peptide, which is co-secreted with BNP, after 3 doses of chemotherapy has 
been associated with improved survival.
31
  Autonomic nervous system involvement 
presents variably as orthostatic hypotension, impotence, urinary retention and with 
gastrointestinal dysfunction and also confers a poor prognosis.
32
  In those with a 
peripheral neuropathy there is a distal sensory deficit which can progress to a motor 
neuropathy in more advanced cases.  There are a plethora of potential soft tissue 
features in AL amyloidosis including pseudohypertrophy of skeletal muscle, 
arthropathy, cutaneous lesions, carpal tunnel syndrome, periorbital bruising, 
macroglossia, lymphadenopathy and nail dystrophy.
33
  Bleeding diatheses such as factor 
X and Factor IX deficiency are also recognised.
34
  Hepatomegaly is common and may 
result from amyloid infiltration or be secondary to congestive cardiac failure or both.  
The typical serum biochemical picture in hepatic amyloidosis is elevation in the alkaline 
phosphatase and gamma-glutamyl transferase, related to sinusoidal infiltration.
35
  
Occasionally liver failure may ensue.  Gastrointestinal tract involvement may cause 
motility disturbances (often secondary to autonomic neuropathy), malabsorption, altered 
bowel habit and gastrointestinal haemorrhage.
36
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Systemic AA Amyloidosis 
AA amyloidosis may occur in association with any kind of chronic inflammatory 
disorder.  The lifetime incidence of AA amyloidosis in those with chronic inflammatory 
conditions is 1-5%.
37
  In the developed world the most frequent predisposing conditions 
are the inflammatory arthritides, followed by chronic sepsis, inflammatory bowel 
disease and the hereditary periodic fever syndromes.  There are 5 forms of inherited 
periodic fever syndromes: familial Mediterranean fever (FMF), hyper-immunoglobulin 
D syndrome (HIDS), TNF receptor associated periodic fever syndrome (TRAPS), 
familial cold urticaria (FCU) and Muckle-Wells syndrome (MWS).  FMF is the 
commonest form.  It is inherited in an autosomal recessive manner and is characterised 
by recurrent self-limiting attacks of fever, serositis and sometimes arthritis or rash.
38
  It 
is prevalent in the Eastern Mediterranean.  Tuberculosis still remains a major cause of 
AA amyloidosis in the developing world.  Six percent of patients with AA amyloidosis 
have no clinically overt inflammatory disease.
39
  The amyloid precursor protein is the 
N-terminal fragment of the acute phase reactant SAA, an apolipoprotein constituent of 
high-density lipoprotein.  SAA is synthesised by hepatocytes and its gene transcription 
is regulated by cytokines, in particular IL-1 and IL-6.
40
  SAA concentration may rise 
1000-fold during inflammation and remain persistently elevated until the inflammation 
remits.  Although the median latency between onset of inflammation and diagnosis is 8 
to 14 years some individuals develop amyloid within months.  Outcome in AA 
amyloidosis is favourable when SAA concentration remains below 10mg/l.
41
  Nephrotic 
syndrome and/or renal impairment are common modes of presentation with 
approximately ¼ cases progressing to end-stage renal failure.  Liver involvement in AA 
amyloidosis is a feature of advanced disease and confers a poor prognosis.
42
  An 
amyloid cardiomyopathy and autonomic neuropathy are rare.
39
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Dialysis-associated/β2-microglobulin amyloidosis 
β2-microglobulin amyloidosis (Aβ2M) occurs in patients receiving long-term dialysis 
for end-stage renal failure and predominantly affects bones and joints.  β2M, which is 
the amyloidogenic precursor protein, is a non-glycosylated protein found in all 
nucleated cells that is normally metabolised in the kidney.  It is freely filtered at the 
glomerulus and then reabsorbed and catabolised by the proximal tubular cells.
43
  In 
Aβ2M, which occurs both in haemodialysis and peritoneal dialysis populations, β2M 
concentration in the blood is much increased.
44
  The clinical features include carpal 
tunnel syndrome, arthralgia of the shoulders, knees, wrists and small joints with 
associated swelling, tenosynovitis and occasionally haemarthroses.
45
  Subchondral 
erosions and cysts can contribute to pathological fractures. Gastrointestinal 
manifestations are rare but have been reported.
36
  The incidence of A2M is falling 
presumably because of newer dialysis membranes, cleaner dialysis fluids and 
higher-flux dialysis.
1
 
 
Hereditary systemic amyloidosis 
There are several forms of hereditary systemic amyloidosis, which are associated with 
genetically variant proteins, mostly comprising single amino acid substitutions.  They 
are inherited in an autosomal dominant manner with variable penetrance accounting for 
a frequent absence of a family history.  Age of onset, mode of presentation, pattern of 
organ involvement and rate of progression vary even within affected kindreds 
suggesting a contributory role of other factors.  Historically, there has been a division 
into neuropathic and non-neuropathic forms.  Familial amyloid polyneuropathy (FAP), 
which encompasses the former, is the commonest type (Table 1.1).   
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Familial amyloid polyneuropathy 
Patients with familial amyloid polyneuropathy possess a mutation in their transthyretin 
(TTR) gene.  TTR is synthesised predominantly in the liver.  It is a tetrameric protein 
responsible for transport of thyroxine and retinol-binding protein.  The commonest 
encoding mutation is a valine-for-methionine substitution at position 30 (V30M).  FAP 
was first described in 1952 in Portugese kindreds,
46
 affected members of which were 
later discovered to be heterozygous for the TTR mutation encoding the V30M variant.
47
  
Well-described foci occur in Sweden,
48
 Japan,
49
and Portugal.
50
  Overall, more than 100 
pathogenic mutations have been described.  It is estimated that there are somewhere in 
the region of 10000 affected cases (http://www.foldrx.com).  Tetramers of transthyretin, 
containing amyloidogenic variants, dissociate into monomers and form amyloid more 
readily than the wild-type protein.  Typical symptoms of familial amyloid 
polyneuropathy include progressive peripheral and autonomic neuropathy along with 
cardiac amyloid, all of which can result in profound wasting and malnutrition that 
usually leads to death within 9-13 years.
51
  In some countries, such as Sweden and 
Japan, a bimodal age distribution is recognised with a different phenotype and prognosis 
between the two age groups.
52
  Other potential manifestations include renal 
involvement,
53
 vitreous amyloid secondary to variant transthyretin derived from the 
retina and choroid plexus
54
 and oculoleptomeningeal amyloid deposition manifesting as 
encephalopathy, dementia, seizures and a radiculopathy.
55
 
 
Hereditary non-neuropathic systemic amyloidosis 
The non-neuropathic forms of hereditary systemic amyloidosis were first described by 
Ostertag in 1932.
56
  They are derived from variants of apolipoprotein AI (although this 
may occasionally cause neuropathy), apolipoprotein AII, lysozyme and fibrinogen A-α 
chain.
57
  A renal phenotype is dominant but cardiac amyloidosis, gastrointestinal 
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haemorrhage, soft tissue amyloidosis and even hepatic rupture are recognised depending 
upon the underlying amyloidogenic variant (Table 1.1). 
 
Senile Systemic Amyloidosis  
This is caused by deposition of amyloid derived from wild-type TTR, which is 
produced in the liver.
58
  The dominant clinical manifestations are related to cardiac 
amyloid (presenting as congestive cardiac failure or conduction disturbances), although 
carpal tunnel syndrome is common.  Senile systemic amyloidosis is usually confined to 
individuals over the age of 70 years and the cardiac features typically progress slowly.  
It is frequently mistaken for cardiac failure secondary to coronary artery disease.  
Subclinical gastrointestinal tract involvement, typically detected histologically within 
subserosal veins, is present in 41% of individuals with senile systemic amyloidosis aged 
over 80 years.
59
 
 
Localised amyloidosis 
Localised amyloidosis represents amyloid confined to a single organ or tissue which 
will not evolve into systemic amyloidosis.  In a series of 208 patients at the UK 
National Amyloidosis Centre (NAC) the commonest organ systems involved by 
localised amyloidosis were the urinary and respiratory tracts (unpublished data).  
Localised amyloidosis is thought to evolve from monoclonal light chains secreted by a 
localised focus of abnormal plasma cells.  Evidence for this comes from 
immunohistochemical analyses of amyloid coupled with molecular techniques and gene 
re-arrangement studies.
60
  Follow-up studies have revealed no evolution into systemic 
amyloidosis up to 20 years after diagnosis.
61
  It should however be borne in mind that 
localised amyloid may also be an early manifestation of systemic AL amyloidosis with 
the potential for other organ involvement at a later time.  For this reason, careful 
- 12 - 
 
follow-up of patients who are thought to have localised amyloidosis is needed,
62
 
particularly in the presence of a plasma cell dyscrasia.  Differentiating between 
localised and systemic amyloidosis is important since systemic chemotherapy is rarely 
required in localised amyloidosis.   
 
Diagnosis of Amyloidosis 
 
Histology 
The diagnosis of amyloidosis is often made at a late stage, long after onset of symptoms 
due to its non-specific and varied presentations that can mimic many other conditions.  
Diagnosis requires histological confirmation of amyloid and is achieved by staining 
amyloidotic tissue with Congo-red and observing the pathognomonic red-green 
birefringence under cross-polarised light visualised with light microscopy.
63
  Common 
biopsy sites include the gastrointestinal tract, kidneys and bone marrow.  A screening 
rectal biopsy remains the commonest means of obtaining a histological diagnosis of 
amyloid from the gastrointestinal tract when systemic amyloidosis is suspected due to 
the ease of the technique and an acceptable sensitivity of between 75-94%.
64
  
Abdominal fat aspiration is another means of acquiring histological confirmation of 
amyloid.  Liver biopsy via a percutaneous route is not recommended if amyloid is 
suspected because of haemorrhagic risk.
65
  Amyloid is commonly an incidental and 
unexpected biopsy finding which should trigger further investigations to determine the 
precise amyloid fibril type and extent of organ involvement.   
Immunohistochemistry to determine the amyloid fibril type should routinely be 
performed in any patient with amyloid but despite recent advances in 
immunohistochemical techniques, often remains inconclusive.
66
  Distinguishing 
between AL and hereditary amyloidosis by clinical manifestations and 
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immunohistochemistry alone may not be possible.  Monoclonal gammopathies are not 
infrequent in the general population, and although suggestive, the presence of a 
monoclonal gammopathy in a patient with amyloidosis does not prove AL-type and 
other investigations are required before a definitive diagnosis can be made.  Additional 
screening for mutations in the genes encoding known amyloid fibril proteins may be 
necessary to exclude hereditary forms of amyloidosis.
67
  Precise identification of the 
amyloid fibril type is critical since treatment is type-specific.   
 
SAP scintigraphy 
Another diagnostic method, which is available in a few specialised units, is SAP 
scintigraphy.  SAP binds to all amyloid fibrils.  When it is radiolabeled with iodine as a 
nuclear medicine tracer it can be utilised to quantify visceral amyloid deposits in vivo.
68
  
SAP scintigraphy can be used to monitor regression or progression of visceral amyloid 
and response to treatment.
18
  Furthermore, the distribution of visceral amyloid deposits 
may be a strong indicator of amyloid type.
69
  In AA amyloidosis, hepatic involvement is 
associated with a poor prognosis
42
 and total body amyloid load by SAP scintigraphy is 
critical in evaluating the risk/benefit ratio of treatments such as stem cell transplantation 
for AL amyloidosis.
1
  
 
Cardiac investigations 
The standard means of assessing cardiac amyloidosis is by echocardiography.  The 
characteristic findings are ventricular wall thickening, diastolic dysfunction and bi-atrial 
dilatation with relative sparing of systolic function until advanced stages of disease.  
Another corroborative feature is low voltage complexes on electrocardiogram, which 
contrasts the increased voltages that are typical of ventricular wall thickening due to 
hypertension.  Cardiac magnetic resonance imaging is a newer investigative modality 
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which shows promise.  Cardiac biomarkers have also proven very useful in studies of 
AL amyloidosis.  Troponin T and N-Terminal pro B-type Natriuretic Peptide can 
stratify patients in terms of survival and prognosis.
29
 
 
Other investigations 
Determining and monitoring the concentration of amyloidogenic precursors, such as 
monoclonal immunoglobulin light chains in AL amyloidosis and SAA in AA 
amyloidosis, is helpful diagnostically and is critical to determine the adequacy of 
treatment.  Serum free light chain concentration can now be measured by sensitive 
nephelometric immunoassay (Freelite) for a free light chain excess and should be 
accompanied by serum and urine electrophoresis, a bone marrow aspirate and a skeletal 
survey to characterise the underlying clonal disorder.  Genetic sequencing is very useful 
as hereditary forms of amyloidosis can occur in those without a family history due to 
the poor penetrance of the encoding mutations.
67
 
 
Treatment of amyloidosis 
Treatment of localised amyloidosis is via surgical resection, but only if symptomatic.  
Treatment of the systemic amyloidosis syndromes is more complicated and a two-fold 
approach should be pursued.  The universal aim, in the absence of amyloid-specific 
therapy, is reduction of the supply of the respective amyloid fibril precursor protein 
(Table 1.2) but meticulous organ support is frequently also needed.  Dialysis is useful in 
end-stage renal failure with approximately ¼ of patients (249 patients) with renal 
amyloid of AL-type requiring it during the course of the disease during follow-up at the 
NAC, with a median survival of 39 months from dialysis.
70
  Approximately 40% of  
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Table 1.2  Treatment: reduction or elimination of the supply of fibril precursors in 
systemic amyloidosis. 
 
 
Disease Aim of treatment Example of treatment 
AA 
amyloidosis 
Suppress acute phase 
response and thereby 
production of SAA 
Anti-inflammatory and 
immunosuppressive therapy in 
rheumatoid arthritis and Crohn‟s disease 
(e.g. anti-tumour necrosis factor) 
Colchicine for familial Mediterranean 
fever 
AL 
amyloidosis 
Suppress production 
of monoclonal 
immunoglobulin 
light chains 
Chemotherapy or stem cell 
transplantation directed at plasma cell 
dyscrasias 
Hereditary 
amyloidosis 
Reduce/eliminate 
source of genetically 
variant protein 
Orthotopic liver transplantation for 
familial amyloid polyneuropathy 
secondary to variant transthyretin or for 
selected cases of fibrinogen A α-chain 
and apolipoprotein AI amyloidosis. 
Haemodialysis 
amyloidosis 
Reduce plasma 
concentration of 
2-microglobulin 
Renal transplantation 
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patients with AA amyloidosis (158 patients), who have been followed up at the NAC 
have required dialysis with a median subsequent survival of 46 months.  The survival on 
dialysis in AA amyloidosis is comparable to non-diabetic causes of end-stage renal 
failure.
71
  Solid organ transplantation (heart, kidney or liver) to keep patients alive long 
enough to reap the benefits of reducing the relevant fibril precursor is another potential 
strategy.   
Reduction or elimination of the production of the amyloidogenic precursor 
protein may lead to regression of amyloid deposits and stabilisation or improvement in 
amyloidotic organ function.  Initial therapeutic efficacy is monitored in terms of 
reduction of precursor protein supply, which may be followed by improvement in 
amyloidotic organ function and accompanied by amyloid regression on SAP 
scintigraphy.  Importantly, regression of amyloid from organs does not always translate 
into recovery of function and conversely, recovery of amyloidotic organ function is not 
always accompanied by regression of deposits (they may remain stable).  Accumulation 
of amyloid however, almost always leads to deterioration in organ function.  
Determining and monitoring the serial concentrations of amyloidogenic precursor 
proteins, such as monoclonal immunoglobulin light chains in AL amyloidosis and SAA 
in AA amyloidosis, is extremely important in determining the adequacy of and guiding 
treatment.   
 
AL amyloidosis 
The prognosis of systemic AL amyloidosis has improved but there are still major 
challenges.
72
  The Italian amyloidosis group have reported a median survival of 46 
months in 705 patients visiting their centre recently.
73
  Poor prognostic factors include 
cardiac amyloid,
29
 autonomic neuropathy,
32
 jaundice
35
 and multisystem disease.
27
  
Treatment revolves around suppression of the underlying B-cell clone and therefore 
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production of amyloidogenic serum free light chains, which are the precursor proteins.  
The treatment regimes in AL amyloidosis have been adapted from those used in 
multiple myeloma, although there are important differences between treatment of 
myeloma and AL amyloidosis.  The plasma cell dyscrasias that underlie cases of AL 
amyloidosis tend to be subtle and low-grade, a complete haematological response is not 
the universal goal in AL amyloidosis since a partial response may be sufficient to lead 
to improved organ function,
27
 and toxicity of therapy is often substantial in patients with 
amyloidosis whose amyloidotic organs may have reduced functional reserve.  
Regression of amyloid is a gradual process, which may lead to measurable clinical 
improvement of organ function months or even years after successful suppression of the 
underlying clonal disorder.
74
  Mobilisation of amyloid from organs such as the heart is 
much slower than from the kidneys and the liver.
75
  
The choice of treatments is between chemotherapy with oral alkylators, 
intermediate dose chemotherapy, stem cell transplantation (SCT) or newer 
chemotherapeutic agents such as lenalidomide and bortezomib.
72
  The first 
chemotherapeutic regime adopted for AL amyloidosis was melphalan and prednisolone 
with slow responses in only about 20% of patients.
76
  In the United Kingdom 
intermediate dose chemotherapy regimes are used, such as cyclophosphamide, 
thalidomide and dexamethasone where clonal responses are achieved in 74%
77
 or 
melphalan and dexamethasone where clonal responses are achieved in 67%.
78
  
Bortezomib is a proteosome inhibitor and has a licence as a second-line agent in those 
with inadequate clonal responses to a prior line of treatment under NICE guidance for 
myeloma with amyloidosis as a myeloma-defining criterion according to International 
Myeloma Working Group classification.
79
  In one multi-centre study of bortezomib 
clonal responses were achieved in 71% within 2 months of treatment including 
complete clonal responses in 25%.
80
  It has the added attraction of being efficacious 
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without the need for concomitant steroid administration and therefore avoids the 
associated side-effects of the latter.  Lenalidomide has a licence as a third line agent 
under NICE guidance with observed clonal response rates in up to 67%.
81
  SCT can be 
offered to candidates with a good performance status and limited organ involvement.  
Although SCT is probably associated with the highest chance of a complete and 
sustained clonal response it is also associated with a significant chance (4-43%) of 
treatment-related mortality in patients with AL amyloidosis.  Careful patient selection is 
therefore needed and a favoured approach in the UK targets those without overt cardiac 
amyloid, no history of gastrointestinal haemorrhage, two or less vital organ involvement 
by amyloid and an age below 65 years.  There has been one small prospective 
randomised study comparing SCT with combination chemotherapy and the findings 
were not definitive.
82
   
 
AA amyloidosis 
In AA amyloidosis the aim is to reduce production of SAA.  Patient survival, 
amyloidotic organ function and change in amyloid load are directly influenced by SAA 
concentration with regression of amyloid in 60% of cases in a series of 374 patients, 
when sustained normal SAA values of <10 mg/l were achieved.
41
  Prognosis was 
dependent upon the degree of renal dysfunction at diagnosis of amyloidosis and age of 
diagnosis.
39
  As well as standard anti-inflammatory therapies, newer biologic agents that 
target pivotal inflammatory cytokines (e.g. TNFα and IL-1) have had an immense 
impact on the treatment of a variety of conditions that underlie AA amyloidosis 
including the inflammatory arthritides, Crohn‟s disease and the hereditary periodic fever 
syndromes.  In the case of Castleman‟s disease surgical excision of the lymphoid tissue 
producing IL-6 has a similar effect.
83
  In the case of familial Mediterranean fever 
(FMF), early use of colchicine usually prevents development of AA amyloidosis by 
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preventing inflammation; in established cases of AA amyloidosis due to FMF, 
colchicine can prevent ongoing amyloid accumulation. 
 
Familial amyloid polyneuropathy 
The treatment of hereditary systemic amyloidosis in cases where the amyloidogenic 
precursor protein is produced by the liver has been revolutionised by liver 
transplantation, which provides a form of “surgical gene therapy”.  It has been used 
most successfully in familial amyloid polyneuropathy.
84
  Transplantation results in rapid 
and near total replacement of the variant protein by donor wild-type TTR, since almost 
all circulating TTR is produced in the liver.
85
  If done at an early symptomatic stage of 
neuropathy then there is potential for improvement in survival and also stabilisation or 
even improvement of neuropathy.
86
  This has been seen in those with the V30M variants 
endemic to Portugal, Sweden and Japan.  In other variants where there might be cardiac 
amyloid this survival advantage may be lost because of the phenomenon of a 
paradoxical accelerated amyloid cardiomyopathy, where wild-type transthyretin 
deposits as amyloid on the template of cardiac amyloid secondary to variant 
transthyretin.  This happens in an accelerated manner resulting in progressive cardiac 
failure.
87
  Evidence for this has come from cardiac biopsy studies where there is an 
increase in the ratio of wild-type transthyretin compared to variant transthyretin in the 
amyloid fibrils of hearts of patients who have had liver transplants compared to those 
who have not.
88
  A potential inadvertent benefit of liver transplantation in this patient 
group is that the explanted liver can be a “domino” donor organ.89  The domino liver 
may be a source of variant transthyretin but is macroscopically and functionally normal.  
However there is a very small risk of “de novo” amyloid in domino graft recipients, 
which has been reported in a few case reports.
90
  Liver transplantation has also been 
used in other forms of hereditary systemic amyloidosis – fibrinogen A-α chain 
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amyloidosis and apolipoprotein AI amyloidosis – where the precursor protein is wholly 
or partially derived from the liver respectively.
91,92
  In those where transplantation is not 
an option symptomatic management has a role in those with cardiac complications, 
malnutrition, bladder and bowel dysfunction.
93
 
 
Dialysis-related amyloidosis 
The only effective treatment for dialysis-related amyloidosis is renal transplantation.
94
  
If undertaken there is a fall in serum levels of ß2–microglobulin accompanied by a rapid 
improvement in symptoms.  There can be regression of amyloid on serial SAP 
scintigraphy but at a slower rate than the improvement in symptomatology.  The 
anti-inflammatory properties of immunosuppression may also have a contributory role 
to this symptom resolution.
95
  Bone cysts tend to persist for many years and heal 
slowly.
96
  The incidence of A2M amyloidosis is falling presumably because of 
improvements in dialysis.
1
  Drug treatments including non-steroidal anti-inflammatory 
analgesics and steroids are not particularly effective.
97
 
 
Future prospects in treatment 
The mainstay of treatment in systemic amyloidosis currently revolves around reduction 
of the abundance of the relevant amyloid precursor protein.  More recently however, 
studies have focused on targeting different stages of the amyloidogenesis pathway, 
usually downstream from precursor protein production. 
Stabilisation of protein precursors is one potential therapeutic strategy.  This is 
being evaluated for transthyretin (TTR), which is weakly amyloidogenic in its wild-type 
form and more amyloidogenic in its variant forms which cause familial amyloid 
polyneuropathy.  Mutations render the tetrameric TTR protein less stable, allowing it to 
dissociate into monomeric components which can undergo conformational changes to 
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form amyloid fibrils.  The physiological role of TTR is to carry thyroxine and 
retinol-binding protein and its binding sites are well characterised.  Studies investigating 
drugs bound by TTR are in progress, including that of diflunisal, a non-steroidal 
anti-inflammatory drug that stabilises TTR in vitro.
98
  A phase II/III study of diflunisal 
in familial amyloid polyneuropathy is currently underway.  Iodinisation of candidate 
drugs such as diflunisal may also confer benefit by producing higher affinity binding.  
This concept was put forward after the newfound appreciation of the unique 
physiological properties of iodine atoms in thyroxine, which allows thyroxine to bind to 
TTR tightly in a stable conformation.
99
  Another TTR stabiliser which is currently being 
evaluated in a phase II/III trial in patients with familial amyloid polyneuropathy is 
Fx-1006A (FoldRx).  Although precursor protein stabilisation to date has focused on 
TTR, the principles could be applied to other types of amyloidosis.  Another potential 
therapeutic area in TTR-related amyloidosis is the targeting of hepatic synthesis of TTR 
with small interfering RNA‟s, antisense oligonucleotides and single-strand 
oligonucleotides.
100
   
Inhibiting fibrillogenesis is another potential treatment strategy.  The 
antimicrobial doxycycline has been found in transgenic mouse models of familial 
amyloid polyneuropathy to disrupt TTR amyloid fibrils
101
 and is currently being studied 
in a phase II clinical study.  Heparan sulphate proteoglycans are a universal component 
of amyloid deposits, which are thought to contribute to and maintain the conformational 
changes required for amyloid formation.  Analogues of N-acetylglucosamine inhibit 
binding of heparan sulphate and amyloid fibrils and orally administered low molecular 
weight sulphated molecules can inhibit development of experimentally induced AA 
amyloid in murine models.
102
  Further evidence for the role of heparan sulphate in 
amyloidogenesis comes from experiments with transgenic mice that overexpress human 
heparanase, an enzyme that degrades heparan sulphate.  They appear to be resistant to 
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the experimental induction of AA amyloidosis in certain murine organs.
103
  Subsequent 
to these findings a phase II/III clinical trial was undertaken comparing eprodisate 
(Kiacta, Neurochem), a low molecular weight analogue of heparan sulphate, and 
placebo in 183 patients followed up over 24 months.  Compared to placebo, eprodisate 
significantly reduced the risk of doubling of serum creatinine (p=0.02), increased the 
chance of a 50% reduction in creatinine (p=0.01) and favourably altered the slope of 
decline in creatinine clearance (p=0.02).  Progression to end-stage renal failure and risk 
of death were not significantly affected however.
104
  
Another potential treatment strategy that merits exploration is immunotherapy.  
Amyloid is relatively inert in vivo and exempt from immunological responses, but is 
nonetheless a good immunological target as amyloid fibrils, irrespective of the 
contributing precursor protein, have similar structural properties and epitopes that 
antibodies can target.
105
  Administered antibodies have induced amyloid regression in 
murine models of both AA and AL amyloidosis.
106
 
The efforts of the NAC have been focused on targeting serum amyloid P 
component, the non-fibrillar plasma glycoprotein, which is present in all amyloid 
deposits.  Its role in amyloidogenesis was proven by the inability to induce experimental 
AA amyloidosis in SAP knockout mice.
8
  These results have led to the development in 
the laboratories at the NAC of a drug, 
R-1-[6-[R-2-carboxy-pyrrolidin-1-y1]-6-oxo-hexanoyl] pyrrolidine-2-carboxylic acid 
(CPHPC), which inhibits the binding of SAP to amyloid fibrils.  It has a palindromic 
structure and cross-links SAP leading to its rapid clearance by the liver.
107
  Initial results 
from an open-label study suggest that there may be attenuation of amyloid deposition 
rather than amyloid regression.  However using a combination of CPHPC and 
anti-human SAP antibodies in human SAP transgenic mice there has been success in 
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inducing regression of amyloid.
108
  This novel approach is set to be translated into the 
clinical arena in collaboration with GlaxoSmithKline.  
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Aims and Scope of the Thesis 
The introduction to this thesis gives an outline of the current understanding of the 
pathogenesis, investigation and management of the different forms of systemic 
amyloidosis.   
The subsequent studies cover three broad themes, which perfuse throughout the 
thesis.  The first revolves around characterisation of the phenotype of the heredo-
familial forms of systemic amyloidosis; the second provides an analysis of the role of 
solid organ transplantation in the different forms of systemic amyloidosis; the third 
theme focuses on the assessment and treatment of the gastroenterological and 
hepatological aspects of the systemic amyloidosis syndromes.   
Solid organ transplantation has historically been stigmatised against in systemic 
amyloidosis because of the multisystem nature of the disease and furthermore there 
have been concerns about potential recurrence of amyloid in transplanted grafts.  To 
evaluate its role, there is firstly review of the role of liver transplantation, as a form of 
surgical gene therapy, in familial amyloid polyneuropathy (FAP) associated with the 
T60A TTR variant, which is the commonest form of FAP in the UK.  To date there has 
been scant data on its role outside of its use in the more common FAP V30M 
population.  There is also a focus on the effect of cardiac amyloid, which is more 
common in FAP T60A than in FAP V30M, on prognosis in both a transplanted and 
non-transplanted FAP T60A population.  There is subsequently assessment of the role 
of solid organ transplantation for amyloidotic organ failure in several forms of systemic 
amyloidosis throughout the thesis; liver and kidney transplantation in hereditary 
lysozyme amyloidosis (ALys), which currently has no anti-amyloid therapy and in 
which, therefore, there is risk of amyloid recurrence in grafts; liver, kidney and heart 
transplantation in the acquired forms of systemic amyloidosis (AL and AA).  For these 
latter conditions, which have therapeutic options to suppress amyloid formation, 
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potential algorithms are proposed encompassing a tandem approach of solid organ 
transplantation together with amyloid-specific treatment strategies.   
The gastrointestinal and hepatological sequaelae of systemic amyloidosis, 
though common, are less studied than several of the other potential complications.  A 
review of patients diagnosed with amyloidosis unexpectedly by liver biopsy highlights 
phenotypic, prognostic and treatment differences between the different amyloidosis 
types and provides opportunity to propose a diagnostic and treatment algorithm should 
systemic amyloidosis present in this manner.  There is also commentary on the 
prevalent combination of gastrointestinal and hepatological complications associated 
with the extremely heterogeneous ALys.  Gastrointestinal disease as a potential primary 
cause of systemic amyloidosis is emphasised in the analysis of systemic AA 
amyloidosis associated with inflammatory bowel disease.  There is focus on risk factors 
for disease development, analysis of progression of amyloidosis and suggestion of 
potential treatment goals.  There is also a prospective study of nutritional status in AL 
amyloidosis, which is one of the largest prospective studies performed in systemic 
amyloidosis to date.  Weight loss, though appreciated as a prevalent entity in this patient 
group, has gained little attention.  Disease-specific factors associated with malnutrition 
are identified and the effects of malnutrition on quality of life and survival are assessed. 
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Chapter Two 
Materials and Methods 
 
Declaration 
The concepts behind all of the studies, collection and analysis of data, recruitment and 
assessment of patients in the prospective study of nutritional status in systemic AL 
amyloidosis were all carried out by myself, as a clinical research fellow at the National 
Amyloidosis Centre, University College Medical School (Royal Free Campus), except 
where indicated below: 
 
Measurements for biochemical and haematological data were performed by the hospital 
and departmental laboratory service.   
 
Gene sequencing was performed by Dorota Rowczenio, Tonia Russell and Hadija 
Trojer. 
 
Histological and immunohistochemical analysis was performed by Janet Gilbertson and 
Toby Hunt and laser microdissection and mass-spectrometry based proteomic analysis 
on one specimen was performed by Ahmet Dogan (Mayo Clinic, Rochester, USA). 
 
Echocardiography was performed by Babita Pawarova and Carolyn McCarthy. 
 
123
I-SAP scintigraphy was performed by David Hutt and Dorothea Gopaul. 
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Data for the Canadian patients with familial amyloid polyneuropathy (T60A) was 
obtained from Dr. Angelika Hahn from the Department of Clinical Neurological 
Sciences, the University of Western Ontario, Canada and data for the Swedish patients 
with familial amyloid polyneuropathy (V30M) was provided by Professor Ole Suhr and 
Dr. Sadahisa Okamoto from Umea, Sweden. 
 
There was assistance with the statistics in the thesis from Zoe Fox from the Department 
of Population Sciences, Department of Medicine, UCL and Aviva Petrie from the 
Biostatistics Unit at UCL Eastman Dental Institute. 
 
Patients 
All of the patients in this thesis were seen at the UK National Amyloidosis Centre, 
except for three patients, who were seen at the Department of Clinical Neurological 
Sciences, University of Western Ontario, Canada.  In the 3-year period between 2008 
and 2010, during my studentship, there were approximately 8000 patient consultations 
in the centre of which nearly 25% were new referrals.  An access database in the centre 
has details of all of these patients, as well as other patients seen at the NAC over a 
period of approximately 20 years.   
 
Histology 
 
Congo-red staining 
Amyloid deposits stained with Congo-red give pathognomonic red-green birefringence 
when viewed under cross-polarised light and this remains the gold-standard diagnostic 
method for amyloid.
63
  This birefringence is dependent on a sufficient density of 
amyloid so formalin-fixed deparaffinised tissue sections were cut at 6-8 μm rather than 
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the usual 2-3 μm.  Before staining, the sections were rehydrated, counterstained with 
haematoxylin, 'blued' under running tap water, rinsed in pure water and then stained by 
a modified version of  the alkaline-alcoholic Congo-red method described by Puchtler 
et al. (1962).
63
  This method reduces any non-specific background staining.  The 
sections were then dehydrated through a series of ascending ethanol concentrations to 
xylene and mounted in DPX mounting medium.  Slides were then viewed under 
brightfield and high-intensity polarised light microscopy and the presence and extent of 
amyloid deposition noted.  Positive controls were obtained from a known Congo-red 
positive composite block validated by laser microdissection and mass-spectrometry 
based proteomic analysis and were always processed in parallel. 
 
Typing of amyloid by immunohistochemistry 
Congo-red staining of histology was followed by immunohistochemical staining of 
formalin-fixed deparaffinised sections of amyloidotic tissue to further characterise the 
amyloid type.  Immunohistochemical staining of the amyloid deposits was performed 
using a panel of anti-human monospecific antibodies reactive with SAA 
(Eurodiagnostica), TTR, lysozyme, kappa and lambda immunoglobulin light chains 
(Dako Ltd, Denmark House, Ely, UK), apolipoprotien A1 (Genzyme Diagnostics) and 
fibrinogen Aα-chain (Calbiochem).  For TTR staining, pre-treatment was performed for 
maximum antigen retrieval (10 minute incubation with 1% sodium periodate, wash, 10 
minute incubation with 0.1% sodium metabisulphate, wash, 5-hour incubation at room 
temperature with 6M Guanadine in 0.9% sodium chloride).  Duplicate sections were 
stained with each antibody +/- Congo red overlay to classify amyloid type. 
For immunohistochemical analysis sections were taken to water and endogenous 
peroxidase activity was quenched by 30 minute incubation in aqueous (0.3%) hydrogen 
peroxide (H2O2).  They were then rinsed in phosphate-buffered saline (PBS) containing 
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0.05% Tween (Calbiochem).  Prior to application of the primary antisera, non-specific 
tissue binding was abolished by 30 min incubation in normal non-immune serum from 
the species providing the secondary antibody (Vector Part of the ImmPRESS Kit).  
Sections were incubated overnight with primary antisera at 4ºC.  They were then rinsed 
with PBS containing 0.05% Tween (Calbiochem) and labelled with secondary 
antibodies from the appropriate part of the ImmPRESS Kit.  Sections were washed in 
PBS and bound enzyme-antibody complexes were visualised using a metal-enhanced 
DAB (Fisher Scientific solution).  Congo red overlay was also used in duplicate 
sections.  After a brief rinse in pure water, sections with immunohistochemical staining 
were counterstained in haematoxylin, „blued‟ under running tap water and stained with 
Congo-red.  Absorption controls were used when possible by incubating the primary 
antibody with its targeted antigen overnight at 4ºC prior to incubation with the tissue. 
 
Laser microdissection and mass-spectrometry based 
proteomic analysis 
This was performed in one patient with Leucocyte cell-derived chemotaxin 2 (LECT-2) 
amyloidosis at the Mayo Clinic, USA.
109
  Ten m sections of liver tissue were stained 
with Congo-red and then the amyloid deposits underwent laser microdissection.  
Microdissected fragments were digested with the proteolytic enzyme trypsin, the tryptic 
peptides were separated by reverse-phase high performance liquid chromatography and 
the peptides were analysed by electrospray tandem mass spectrometry (MS).  MS raw 
data files of molecular mass and peptide sequence were collated and compared against a 
database of proteins using different search engines such as MASCOT, which identified 
proteins present in the liver by using probability-based algorithms.  
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SAP Scintigraphy 
SAP scintigraphy is a sensitive and specific means of imaging amyloid deposits in 
vivo,
110
 with localisation of radiolabeled SAP to amyloid deposits in proportion to the 
amyloid present in viscera.  This quantitative technique therefore allows serial 
monitoring of amyloid load and its change.  Each subject undergoing SAP scintigraphy 
received by intravenous injection approximately 200μg of SAP bearing approximately 
190 MBq of 
123
I corresponding to an effective equivalent of 3.8 mSV, which is 
comparable to that from an intravenous urogram.  Thyroid uptake was blocked by 
administration of 60mg potassium iodide just before the study and 5 further doses over 
the course of 3 days.  Anterior and posterior whole body imaging was performed in 
each individual 6 or 24 hours after injection of 
123
I-SAP by means of an IGE-Starcam 
gamma-camera (IGE Medical Systems, Slough, UK).  Serial SAP scintigraphy was 
performed at 6-monthly or annual visits to gauge change in amyloid load.  
The whole body amyloid burden was classified as 0 when there was no 
abnormal localisation of tracer; as small when uptake in one or more organs was visible 
but the intensity of the blood-pool background signal remained normal; as moderate 
when abnormal uptake in one or more organs was sufficiently intense for the blood-pool 
background signal to be partially lost when the grey-scale was normalised to encompass 
the target organ signal; and as large when the blood-pool background was lost with 
adjustment of the grey scale to encompass the target organ uptake.  On serial scans 
regression of amyloid was defined as a reduction in tracer uptake in affected organs or 
an increase in the blood-pool background signal, or both; and accumulation of amyloid 
was defined as an increase in tracer uptake in affected organs, an abnormal tracer uptake 
in a previously unaffected organ, or a decrease in the blood-pool background signal; and 
a stable amyloid burden was defined as unchanged tracer localisation. 
 
31 
 
Cardiac assessment 
Cardiac amyloid is poorly visualised by SAP scintigraphy.  This is probably because of 
cardiac motility and a high blood-pool signal from the cardiac chambers.  Cardiac 
amyloidosis is better evaluated therefore with electrocardiography and 
echocardiography.
29
  Echocardiography was performed in all patients with 
two-dimensional and M-mode settings using a GE Vivid 7 system.  Views of the heart 
were obtained from the parasternal long axis and the apical long axis positions.  The 
presence of left ventricular wall thickening, left ventricular diastolic dysfunction, left 
ventricular systolic dysfunction (ejection fraction and fractional shortening) and left 
atrial diameter were measured using criteria defined by the British Society of 
Echocardiography (http://www.bsecho.org) and left atrial area was measured using 
criteria defined by the American Society of Echocardiography (http://www.asecho.org).  
The classical electrocardiographic features of low voltage QRS complexes, pathological 
“Q” waves (pseudo-infarct pattern) in the antero-septal leads and conduction 
abnormalities were recorded in all patients.  Limb lead low-voltage amplitude was 
defined by a mean QRS amplitude in leads I, II, III, aVL and aVF of less than 0.5 mV 
and in the chest leads by the sum of the S wave in lead V1 plus the mean of the R wave 
in leads V5 or V6 being less than 1.5 mV.
111
  Both electrocardiography and 
echocardiography were repeated at 6-monthly or annual visits.  
Cardiac biomarkers have been increasingly used in the assessment of cardiac 
amyloid and in the provision of prognostic information.
31
  N-terminus pro-B Natriuretic 
Peptide (NT-pro BNP) and Troponin T are two such biomarkers.  Their concentrations 
were measured at 6-monthly or annual intervals in patients.  Measurements were carried 
out using an electrochemiluminescence sandwich immunoassay (ECLIA, Roche) on a 
ROCHE Modular Analytics E170 platform.  Serum NT-proBNP levels are typically 
higher in women and increase with age, therefore upper reference limits (the 97.5 
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percentiles of healthy subjects) in men and women are, respectively, 10.1 pmol/L and 
15.3 pmol/L in subjects <50 years old; and 24.8 pmol/L and 33.9 pmol/L in individuals 
>50 years old (data generated by Roche from 712 normal subjects).  Within-run 
precision was determined to be 3.5% at 23.9 pmol/L (22 samples) and 2.6% at 1318 
pmol/L (22 samples); between-run precision was 3.9% at 25 pmol/L (22 samples) and 
3.1% at 1403.3 pmol/L (22 samples).  The detection limit reported by the manufacturer 
is 0.6 pmol/L.  The working range of the Troponin T assay is 0.003-10µg/l.  Troponin T 
within-run precision was determined to be 3.2% at 0.02µg/l (17 samples) and 1.3% at 
2.1 µg/l (18 samples); between-run precision was 3.7% at 0.02µg/l (17 samples) and 
2.2% at 2.2µg/l (17 samples).   
The Mayo staging system is a prognostic tool in AL amyloidosis using an 
amalgamation of Troponin T and NT-proBNP values.  It was designed with the 
understanding that cardiac amyloid is common in AL amyloidosis and that it has a 
significant bearing on survival in patients with AL amyloidosis.  Cardiac biomarkers are 
considered more sensitive and specific than echocardiography in the evaluation of 
cardiac amyloid, as the interpretation of the latter may be confounded by factors such as 
hypertension and co-existing coronary artery disease.  Furthermore the relatively slow 
rate of change of cardiac amyloid on echocardiography makes it less attractive as a 
prognostic tool.  Dispenzieri et al. therefore developed the Mayo staging system.  Mayo 
stage I classifies patients with a NT-proBNP value <332ng/L and Troponin T 
<0.035µg/l, stage II represents patients in whom one marker is below this threshold and 
stage III classifies patients in whom neither value is below this threshold.
112
  Their study 
found significant differences in patient survival based upon this simple prognostic 
scoring system with worst survival in those with Mayo stage III disease. 
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Renal Assessment 
Renal function was classified according to CKD staging (Table 2.1).
113
  It is a validated 
scoring system, which, irrespective of cause of renal disease, takes into account the fact 
that renal function may be normal or even increased in patients with damaged kidneys 
(i.e. eGFR>60 ml/min) and that in this population there is an increased risk of 
progressive loss of kidney function and furthermore an increased morbidity and 
mortality risk, in particular cardiovascular mortality.  This is very pertinent to patients 
with renal amyloid where proteinuric renal dysfunction frequently occurs in the 
presence of an eGFR>60 ml/min. 
 
Criteria for diagnosis of amyloid-related major organ 
involvement 
Organ involvement in patients with systemic amyloidosis was defined according to 
abnormal uptake on SAP scintigraphy and according to the international amyloid 
consensus criteria (Table 2.2)
114
 in those with AL amyloidosis and in the patients with 
familial amyloid polyneuropathy (T60A).  The latter criteria relies on abnormalities in 
investigations in the cases of renal, cardiac, hepatic, gastrointestinal or pulmonary 
amyloid, but relies on clinical examination for diagnosis of an amyloid neuropathy and 
soft tissue amyloidosis, as outlined in Table 2.2.  An amyloidotic peripheral neuropathy 
presents as a distal small fibre sensory dysfunction, which in more advanced stages 
progresses to a motor neuropathy and the autonomic neuropathy presents with 
symptoms of gastrointestinal dysmotility or pseudo-obstruction, urinary voiding 
dysfunction and frequently postural hypotension and, in men, impotence. 
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Table 2.1  Stages of CKD (Chronic kidney disease). 
 
Stage eGFR  
(ml/min) 
Description 
1 90+ Normal kidney function but urine findings or structural 
abnormalities or genetic trait point to kidney disease 
2 60-89 Mildly reduced kidney function, and other findings (as for 
stage 1) point to kidney disease 
3 30-59 Moderately reduced kidney function 
4 15-29 Severely reduced kidney function 
5 <15 or on 
dialysis 
Very severe or end-stage kidney failure 
 
35 
 
Table 2.2  International amyloid consensus criteria for organ involvement in AL 
amyloidosis. 
 
Organ involved Criteria 
Heart Echocardiography : Mean wall thickness >12 mm,  
no other cardiac cause 
Kidneys 24-hour urine protein >0.5g/day, predominantly  
albumin 
Liver Total liver span >15cm in the absence of heart  
failure or alkaline phosphatase >1.5 times upper  
limit of normal 
Peripheral neuropathy Clinical symmetrical lower extremity  
sensorimotor peripheral neuropathy 
Autonomic neuropathy Gastric emptying disorder, pseudo-obstruction,  
Voiding dysfunction not related to direct organ  
Infiltration 
Gastrointestinal tract Direct biopsy verification with symptoms 
Lung Direct biopsy verification with symptoms 
Interstitial radiographic pattern 
Soft tissue Tongue enlargement, clinical arthropathy,  
claudication of vascular origin, skin, myopathy by  
biopsy or pseudohypertrophy, lymph node,  
carpal tunnel syndrome 
36 
 
Performance status 
Performance status is an attempt to quantify cancer patients‟ general well-being and 
level of function with respect to daily activities.  It is a useful guide to determine 
whether they can receive treatment, whether dose adjustment is needed or whether 
palliation would be more suitable.  The Eastern Co-operative Group (ECOG) 
performance status (Table 2.3)
115
 was conceived by ECOG, which was established in 
1955 as a co-operative to run multi-centre cancer clinical trials in the USA.  This 
measure of performance status has been utilised in studies of patients with a variety of 
cancers and has also been used in patients with systemic AL amyloidosis.
116
  It was 
used in the study of solid organ transplantation in AL amyloidosis in this thesis (chapter  
7) 
 
Immunoassays 
 
C-reactive protein (CRP) 
CRP was measured in the serum using a high-sensitivity automated microparticle-
enhanced latex turbidimetric immunoassay (COBAS MIRA; Roche Diagnostics 
GmbH).
117
  The lower limit of detection was 0.2 mg/l with an inter-assay coefficient of 
variance (CV) of 4.2% at 4 mg/l and 6.3% at 1 mg/l. 
 
Serum amyloid A protein (SAA) 
SAA was measured in serum by latex nephelometry (BNII autoanalyser; Dade Behring, 
Marburg, Germany).
118
  The lower limit of detection was 0.7 mg/l, with an inter-assay 
CV of 2.6% at 15 mg/l and 3.7% at 80 mg/l.  Standardisation of both CRP and SAA 
assays was based on the respective WHO International Reference Standards (WHO 
1987).
119
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Table 2.3  Eastern Co-operative Group classification. 
 
Grade Summary Description 
0 
 
Normal Able to carry out normal activities  
without restriction 
1 With effort Restricted in physical strenuous activity 
Ambulatory, can do light work 
2 Restricted Ambulatory and capable of self-care 
Unable to carry out work 
3 Dependant Capable of only limited self-care 
Confined to bed or chair for more than 50% of 
waking hours 
4 Immobile Cannot carry out any self-care; 
Totally confined to bed or chair 
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Serum free immunoglobulin light chain assay 
Serum kappa and lambda free immunoglobulin light chains (FLC) were measured using 
a latex-enhanced immunoassay (The Binding Site, Birmingham, UK) on a Behring 
BNII autoanalyser (Dade Behring, Marburg, Germany).
120-122
  The assay utilises 
antibodies directed against FLC epitopes that are hidden in whole immunoglobulin 
molecules, and has a sensitivity of < 5 mg/l.  This compares with typical detection limits 
of 150-500 mg/l by immunofixation, and 500-2000 mg/l by electrophoresis.  The 
reference range was established using 100 healthy blood donor sera in which the mean 
concentrations of polyclonal free kappa and free lambda light chains were respectively, 
11.38 mg/l (95% confidence intervals, 7.41-16.77 mg/l) and 17.36 mg/l (95% 
confidence intervals, 8.91-29.87 mg/l), with a mean kappa to lambda ratio of 0.7 (95% 
confidence intervals, 0.37-0.95).  Monoclonal FLC was identified as values for kappa or 
lambda that exceeded the respective reference ranges and produced an abnormal kappa 
to lambda ratio. 
 
Gene sequencing 
Genomic DNA was isolated by a rapid method
123
 from frozen whole blood taken into 
EDTA.  The blood was added to NH4CL and the sample spun down, resuspended in 
0.9% NaCl, spun down and resuspended in 0.05M NaOH.  This was then incubated, 
cooled and neutralised with 1M Tris pH8.  The coding regions of the transthyretin 
(exons 2, 3 and 4), apolipoprotein AI (exons 3 and 4) and fibrinogen A -chain (exon 5) 
genes were amplified by the polymerase chain reaction (PCR) using Ready-To-Go tubes 
(GE Healthcare) and the lysozyme gene (exon 2) was amplified by PCR using the 
HotStarTaq DNA Polymerase kit (Qiagen).  The primers used as part of the PCR 
process are outlined in Appendix 1. 
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Study procedures specific to the study of nutritional status in 
AL amyloidosis 
 
Nutritional status assessment 
The patient–generated subjective global assessment (PG-SGA) was used to characterise 
nutritional status in treatment-naïve patients with AL amyloidosis in chapter 5 (Figure 
2.1).  It was initially intended for use in cancer patients
124
 but has since been applied to 
other patient groups, such as stroke patients.
125
  It consists of a check-box questionnaire 
with a section to be completed by the patient and a section to be completed by the 
clinician resulting in a score of 0 to 35 with higher scores related to greater 
malnourishment.  The four medical components (weight loss, nutrition impact 
symptoms, intake and functional capacity) are completed by the patient.  The assessing 
clinician completes a second part to the form (diagnosis, age and metabolic stress) and 
also conducts a physical examination assessing fat, muscle stores and fluid status.  The 
PG-SGA has been shown to have a high degree of inter-rater reproducibility and high 
sensitivity and specificity when compared with other validated nutrition tools.
124
  
 
Quality of life assessment 
Quality of life (QOL) was assessed by the EORTC QLQ-C30 questionnaire,
126
 which is 
composed of both multi-item scales and single-item measures (Figure 2.2).  It includes 5 
functional scales, 3 symptom scales, a global health status/QOL scale and 6 single 
symptom items.  Raw scoring is achieved by averaging the items in a given scale and a 
linear transformation standardises the raw score into a score ranging from 0-100.  High 
scores for a symptom scale/item represent a high level of symptomatology, high scores 
in a functional scale represent a high level of functioning and high scores in global  
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Figure 2.1  Scored Patient-Generated Subjective Global Assessment (1) (PG-SGA) 
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Figure 2.1  Scored Patient-Generated Subjective Global Assessment (2) (PG-SGA) 
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Figure 2.2  EORTC QLQ-C30 (Version 3 MODIFIED) 
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Figure 2.2  EORTC QLQ-C30 (Version 3 MODIFIED) 
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health status represent a high QOL.
127
  Its use in AL amyloidosis has already been 
validated in a randomised prospective phase II trial of chemotherapy in AL 
amyloidosis - UKATT study.
128
 
 
Statistical Analysis 
Statistical tests were performed using Graphpad Prism (Version 4), SPSS v20 (IBM 
SPSS) and the Stata 10.2 software package (StataCorp).  For the purpose of descriptive 
statistics data was expressed as a median (range) or median (interquartile range).  
Kaplan-Meier analyses were used in all of the studies to estimate survival and log-rank 
tests were used to compare the survival between different populations in the study of 
FAP T60A (chapter 3), the study of nutritional status in AL amyloidosis (chapter 5) and 
the study of solid organ transplantation in AL amyloidosis (chapter 7).  Cox 
proportional hazards regression was used to investigate factors associated with overall 
survival of patients in the study of FAP T60A, the study of nutritional status in AL 
amyloidosis and in the study of liver biopsies revealing amyloid (chapter 8).  The 
relationships between NT-proBNP and echocardiographic parameters (chapter 3) and 
between the PG-SGA score and amyloid-specific biochemical and clinical features 
(chapter 5) were evaluated by standard regression analysis.  The Pearson correlation 
coefficient was determined to assess the linear relationship between the QOL scores and 
the PG-SGA score (chapter 5). A p-value <0.05 was considered to be significant in all 
statistical analyses, except chapter 3 where p-values <0.2 were retained in a forward 
stepwise survival analysis and chapter 5 where all factors which were of statistical 
significance (p<0.10) in univariable analyses were included in the multivariable 
analysis.  
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Chapter 3 
Cardiac phenotype and clinical outcome of 
familial amyloid polyneuropathy secondary to 
variant transthyretin (T60A) 
 
Introduction 
Familial Amyloid Polyneuropathy (FAP) is the commonest form of hereditary systemic 
amyloidosis and is caused by mutations of the transthyretin (TTR) gene.  Tetrameric 
TTR is synthesised predominantly in the liver and when it contains amyloidogenic 
variants it can present as FAP.  The clinical presentation and disease course of FAP 
varies substantially not only between mutations but also amongst patients with the same 
mutation.  In fact, amyloidogenic TTR mutations are variably penetrant such that some 
individuals may carry a mutation and never develop FAP.   
The clinical features and natural history of FAP have been best characterised in 
the FAP V30M population.
46,129-131
  Typical features in this population include a 
progressive small fibre neuropathy affecting peripheral and autonomic nerves.  An 
amyloid cardiomyopathy, which is relatively uncommon in FAP V30M, may be a more 
prominent feature of FAP associated with other TTR mutations.
52
   
Liver transplantation (OLT) is the only established treatment for FAP and 
provides a form of surgical gene therapy,
84
 as previously described.  Favourable 
outcomes including a survival benefit have been reported with OLT in patients with 
FAP V30M, particularly if the procedure is undertaken early in the disease course.
86
  
However OLT in non-V30M FAP cases with pre-existing cardiac amyloidosis, has been 
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associated with poor outcomes, due to apparent acceleration of cardiac amyloid 
accumulation following the procedure.
87
   
FAP associated with the TTR T60A variant (FAP T60A) was first described in 
1986 in an Irish family.
132
  Although there is a major endemic focus in County Donegal 
in North-West Ireland,
133
 where it has been estimated that 1% of the population possess 
the relevant TTR mutation,
134
 FAP T60A has been identified widely around the 
world.
135
   
 
Aims 
This study aims to report the clinical presentation, in particular the cardiac phenotype, 
of FAP T60A in the largest series reported to date.  Most published series of FAP are 
based around the neuropathic features
46,129-131
 and the role of liver transplantation
86
 in 
FAP V30M.  Studies of the “non-V30M” FAP populations, which are considered to 
have a higher frequency of cardiac amyloid,
52
 are lacking and the few small studies that 
exist frequently encompass different TTR mutations.  Cardiac amyloid has a significant 
impact upon prognosis in AL amyloidosis
28
 but its potential impact upon survival in a 
large cohort of FAP patients with the same mutation and a high frequency of cardiac 
amyloid has not formally been studied.  Similarly, the role of liver transplantation in 
“non-Met30” FAP populations with cardiac amyloid, where there is a risk of a 
paradoxical accelerated amyloid cardiomyopathy,
87
 has largely been studied in small 
series of FAP with mixed “non-Met30” TTR mutations and has not been looked at 
systematically in a population with a single “non-Met30” TTR mutation with 
comparison to a non-transplanted cohort with the same TTR mutation.  The FAP 
(T60A) patients in this series provided a population to evaluate these two areas.  
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Methods 
 
Patients 
The study included all 60 patients with FAP T60A followed at the UK NAC and at the 
Department of Clinical Neurological Sciences, University of Western Ontario, Canada, 
who were first assessed between 1992, when a prospective clinical protocol was 
initiated, and December 2009.  The genetic diagnosis was proven in all cases by gene 
sequencing.  Immunohistochemistry was performed in all available biopsy specimens. 
Patients attended for their initial diagnostic evaluation and were re-assessed at 6-
monthly to annual intervals.  At each evaluation, patients underwent a detailed clinical 
review and were scheduled for electrocardiography and echocardiography along with 
blood and urine biochemistry.  Clinical review comprised history and examination 
including weight, supine and standing blood pressure and oxygen saturations.  
Biochemistry included tests of renal, hepatic and cardiac function.  Additional 
investigations, including tests of autonomic and peripheral nerve function, were 
undertaken periodically to support clinical findings.  Organ involvement by amyloid 
was defined according to the international amyloid consensus criteria, originally defined 
for AL amyloidosis.
114
 
 
Survival analyses and statistics 
Patient follow-up was censored in December 2009, and, in the single patient who was 
lost to follow-up, at his last clinic visit prior to this date.  Kaplan-Meier analyses and 
Cox proportional hazards regression were used to investigate factors associated with 
overall survival of all patients in the cohort.  Variables considered for inclusion in 
multivariate models were age, presence of peripheral neuropathy, presence of 
autonomic neuropathy, ejection fraction, grade of diastolic dysfunction, interventricular 
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septal (IVS) thickness, left ventricular posterior wall (LVPW) thickness, left atrial (LA) 
diameter, LA area and whether the patient experienced significant weight loss.  Cut 
points for NT-proBNP were according to previously published data in AL amyloidosis
70
 
and were the median values in the cohort for remaining variables.  The relationship 
between NT-proBNP and a number of echocardiographic parameters was evaluated by 
standard regression analysis.  Analyses were performed using the Stata 10.2 software 
package (StataCorp).  All reported p-values are two-sided.  A p-value <0.05 was 
considered to be significant, although all results with a p-value <0.2 were retained in a 
forward stepwise survival analysis. 
 
Results 
 
Patients 
Sixty Caucasian patients with FAP T60A were referred from a wide variety of clinical 
specialties; 18 from cardiologists, 8 from haematologists, 12 from neurologists, 6 from 
gastroenterologists, 3 from rheumatologists, 2 from nephrologists and 11 from a mixture 
of other specialities.  Forty patients had Irish ancestry and 5 were Scottish.  Only 22 
cases (37%) had a definite family history of amyloidosis.   
 
DNA analysis 
Direct DNA sequencing of the TTR gene revealed that all 60 patients were 
heterozygous for the previously reported single base substitution in exon 3 encoding 
alanine at residue 60 of the native protein.
136
  The remainder of the sequence was 
normal in all cases.   
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Histology 
The histological diagnosis of amyloidosis was made by gastrointestinal tract biopsy in 
25 cases (rectal in 16), by cardiac biopsy in 14 cases, by nerve biopsy in 4 cases and by 
biopsy from other sites in 9 cases.  The amyloid in each case stained with antibodies 
against TTR (Figure 3.1).  Histologic samples were not obtained in 8 patients who had 
typical clinical phenotypes, the T60A TTR variant, and characteristic echocardiographic 
and neurophysiological findings.  Four of these eight patients had a family history of 
biopsy-proven FAP T60A, and none had a plasma cell dyscrasia which might have 
raised the possibility of AL-type amyloidosis.  It was not deemed ethical to pursue 
biopsies in these 8 patients on various clinical grounds.  
Five patients, 3 of whom had inappropriately received chemotherapy for 
presumed systemic AL amyloidosis prior to review at the NAC, had a detectable plasma 
cell dyscrasia that proved incidental when TTR-type amyloid was confirmed 
immunohistochemically.   
 
Clinical course and outcome 
Median (range) age of development of symptoms was 63 (45-78) years.  Twenty-five of 
60 (42%) patients presented with cardiac symptoms; 25/60 (42%) and 14/60 (23%) 
presented with autonomic and peripheral neuropathy respectively, which in 4 patients 
developed concomitantly.  Median (range) delay from symptom onset to diagnosis of 
amyloidosis was 24 (2-132) months.  Although 42% patients presented with cardiac 
symptoms, 56/58 patients had echocardiographic evidence of advanced cardiac 
amyloidosis at diagnosis (Figure 3.2), and cardiac amyloidosis became evident in the 2 
remaining patients during follow-up.  Echocardiographic parameters at diagnosis are 
outlined in Table 3.1.  Increased left ventricular wall thickness and diastolic dysfunction 
were present at diagnosis in 93% and 97% of patients respectively and 57% also had  
50 
 
Figure 3.1  Cardiac biopsy from a patient with FAP T60A.  The panel on the top 
shows extensive amorphous pink material following staining with Congo-red dye 
when viewed under brightfield light.  The middle panel shows red-green 
birefringence, pathognomonic of amyloidosis, when the same section is viewed 
under cross-polarised light.  The panel on the bottom shows immunohistochemical 
staining of the same patient’s biopsy with a monoclonal anti-human TTR antibody 
confirming the presence of TTR within the amyloid deposits. 
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Figure 3.2  Echocardiographic investigations in a patient with FAP T60A.  
Parasternal long-axis (top) and two dimensional four-chamber view (bottom) 
showing enlarged atria, biventricular concentric wall thickening, thickened 
inter-atrial septum, thickened valves and a pericardial effusion. 
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Table 3.1  Echocardiography at diagnosis in familial amyloid polyneuropathy 
associated with TTR T60A variant. 
 
 
 
 
Echocardiography 
 
 
Median (Range)  
 
 
Normal values 
 
Percentage 
Abnormal 
 
 
Interventricular septal 
thickness in diastole 
(IVSd) 
(mm) 
 
 
17 (10-25) 
 
6-12 
 
93 
Left ventricular posterior 
wall thickness in diastole 
(LVPWd) (mm) 
 
17 (11-25) 6-12 93 
Diastolic dysfunction  
(Grade)                                      
 
Grade II (0-IV) 0 97 
Ejection fraction  (EF) 
(%) 
 
53 (22-73) >55 57 
Fractional shortening  
(%) 
 
24 (10-40) 25-43 50 
Left atrial diameter (LAd) 
(mm) 
 
45 (36-52) 27-38 43 
Left atrial area  
(cm
2
) 
 
21.1 (8.5-31.9) <20 40 
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systolic dysfunction but only 12% had an ejection fraction <40%.  Valve thickening was 
evident in 91% and pericardial effusions in 76% of cases.   
Electrocardiographic abnormalities were evident in 53/56 (95%) cases at 
diagnosis.  Only 7/44 patients with cardiac amyloid on echocardiography who had 
evaluable (i.e. non-paced) electrocardiograms had small QRS complexes, whereas the 
pseudo-infarction pattern of poor R wave progression in the chest leads was present in 
25/44 (57%) patients (Figure 3.3).   
Median (range) NT-proBNP concentration at diagnosis among 54 evaluable 
patients was 299 pmol/l (5-2146).  Relationship between NT-proBNP and 
echocardiographic parameters is shown in Table 3.2.  Higher NT-pro BNP was 
significantly and independently associated with both increased ventricular wall 
thickness and reducing LV ejection fraction but interestingly, was not associated with 
degree of diastolic dysfunction. 
Neuropathic symptoms at diagnosis of FAP are shown in Table 3.3.   
The cohort was followed for a median (range) of 31 months (0.4–132.0) from 
diagnosis.  Progression of amyloidosis was observed during follow-up in all evaluable 
patients, in three-quarters of whom the cardiac and neuropathic features worsened 
simultaneously.  Twenty-nine (48%) patients died at a median (range) age of 69 years 
(56-79).  Median (95% CI) survival by Kaplan-Meier analysis among 52 non-
transplanted FAP T60A patients from onset of symptoms was 6.6 years (95% CI: 6.1-
9.8), and from diagnosis was 3.7 years (95% CI: 2.9-5.1), which was significantly worse 
than the median survival from symptom onset and diagnosis of 12.0 years (95% CI: 5.9-
20.2) and 8.2 years (95% CI: 1.2-15.4) respectively in 26 Swedish FAP V30M patients, 
which represent a younger cohort with dominant neuropathic features (data provided by 
Professor O Suhr, Umea University, Sweden) (Figure 3.4).  Survival was not 
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Figure 3.3  Electrocardiogram showing atrial fibrillation and pseudoinfarction pattern in the anterior chest leads with no attenuation of QRS 
complex size. 
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Table 3.2  Relationship between NT-proBNP and echocardiographic parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Unadjusted analysis  Multivariable analysis 
Characteristic Regression coefficient  
(95% CI) 
P-value Regression coefficient  
(95% CI) 
 
P-value 
 
Diastolic dysfunction: 
 for each increase in grade 
 
 
-16.18 (-40.01, 7.66) 
 
 
0.18 
 
 
- 
 
 
- 
 
LVPWd thickness: 
 for each mm increase 
 
 
79.62 (45.70, 113.54) 
 
 
<0.0001 
 
 
- 
 
 
- 
 
IVSd thickness: 
 for each mm increase 
 
 
80.61 (47.07, 114.15) 
 
 
<0.0001 
 
 
50.71 (14.94, 86.46) 
 
 
0.007 
 
Left atrial diameter: 
 for each mm increase 
 
 
51.72 (22.90, 80.53) 
 
 
0.001 
 
 
24.30 (-2.80, 51.40) 
 
 
0.08 
 
Left atrial area: 
 for each cm
2
 increase 
 
 
46.96 (21.16, 72.77) 
 
 
0.001 
 
 
- 
 
 
- 
 
Ejection fraction: 
 for each unit increase 
 
 
 
-25.11 (-35.89, -14.33) 
 
 
<0.0001 
 
 
-18.46 (-29.06, -7.86) 
 
 
0.001 
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Table 3.3  Neurological features at diagnosis of familial amyloid polyneuropathy 
associated with TTR T60A variant. 
(Patient with multiple sclerosis excluded from analysis) 
 
 
 
Autonomic neuropathy 
 
44/59 (75%) 
 Postural hypotension 
 
28/59 (47%) 
 
 Altered bowel habit 
  Constipation 
  Diarrhoea 
  Alternating diarrhoea and constipation 
 
8/59 (14%) 
10/59 (17%) 
26/59 (44%) 
 
 Upper gastrointestinal tract symptom 
 (early satiety, dyspepsia, dysphagia, vomiting) 
15/59 (25%) 
 
 
 Urinary retention 
 
7/59 (12%) 
 
 Impotence 
 
26/43 (61%) 
Peripheral neuropathy 
 
32/59 (54%) 
 
 
No peripheral or autonomic neuropathy 
 
 
12/59 (20%) 
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Figure 3.4  Kaplan-Meier survival from symptom onset (top) and from diagnosis of 
amyloidosis (bottom) for 52 non-transplanted FAP T60A patients (thick line) 
compared to 26 non-transplanted Swedish FAP V30M patients (thin line) (top: 
p=0.002; bottom: p<0.001).  
 
 
 
0 5 10 15 20 25
0
25
50
75
100
FAP (V30M)
FAP (T60A)
Time (years)
P
e
rc
e
n
t 
s
u
rv
iv
a
l
 
0.0 2.5 5.0 7.5 10.0 12.5 15.0 17.5
0
25
50
75
100
FAP (V30M)
FAP (T60A)
Time (years)
P
e
rc
e
n
t 
s
u
rv
iv
a
l
58 
 
significantly different between 52 non-transplanted FAP T60A patients and those who 
underwent OLT (HR for transplanted patients 0.48 (95% CI: 0.16-1.43); p=0.19).   
In an analysis of all 60 FAP T60A patients in this series, age (Hazard ratio (HR): 
2.49 (95% CI: 1.28-4.85) for each 10 years older; p=0.007), IVS thickness (HR: 0.31 
(95% CI: 0.14-0.72) for <17 mm versus ≥17 mm; p=0.006), NT-proBNP (HR: 0.39 
(95% CI: 0.16-0.96) for <400 pmol/l versus ≥400 pmol/L; p=0.04), diastolic 
dysfunction (HR: 0.33 (95% CI: 0.12-0.91) for grade 0-1 versus grade 2-4; p=0.03), 
LVPW diameter (HR: 0.42 (95% CI: 0.18-0.95) for <17 mm versus ≥17 mm; p=0.04) 
and weight loss at diagnosis (HR: 2.85 (95% CI: 1.08-7.54) for weight loss versus no 
weight loss; p=0.03) were associated with reduced survival in univariable analyses.  
Factors that were significantly associated with reduced survival in multivariable 
analysis included NT-proBNP (HR: 0.17 (95% CI: 0.03-0.92) for <400 pmol/L versus 
≥400 pmol/L; p=0.04) and LVPW thickness (HR: 0.17 (95% CI: 0.03-0.97) for <17 mm 
versus ≥17 mm; p=0.05).  LA area was also a significant predictor of death after 
adjustment (HR: 9.24 (95% CI: 1.27-67.40) for >20 cm
2
 versus ≤20 cm2; p=0.03).  Ten 
deaths were directly related to cardiac amyloidosis, 5 were sepsis-related, and the 
precise cause was not ascertained in 14 cases.   
Cardiac arrhythmias were documented in 21/60 (35%) patients during the course 
of their disease including atrial fibrillation in 12 cases, complete heart block in 5 cases 
and ventricular tachycardia in 3 cases.  Seventeen (28%) patients required cardiac 
device insertion for an arrhythmia (16 pacemakers and 1 implantable 
cardioverter-defibrillator), 12 of which were inserted prior to establishing the diagnosis 
of FAP.  Six further patients received prophylactic pacemaker insertion during 
evaluation for potential OLT.   
OLT to eliminate hepatic production of variant TTR was performed in 8 patients 
of median (range) age of 60 (49-65) years.  One of these patients, who had severe 
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cardiac amyloidosis, received a combined cardiac and liver transplant aged 52 years.  
Median (range) time from onset of symptoms to transplantation was 28.5 (3.0-65.0) 
months, and 13.5 (2.0-56.0) months from diagnosis of FAP.  Standard anti-rejection 
immunosuppressive regimens were used in accordance with local protocols.  Median 
(range) follow-up from OLT was 4.5 (0.2-8.7) years during which there were no graft 
failures.  Four of 8 OLT patients died, 3 from cardiac amyloidosis and 1 from sepsis, 
0.2, 1.0, 1.9 and 3.9 years after surgery.  The 4 OLT recipients who died had reduced 
mobility because of peripheral neuropathy, symptomatic postural hypotension and 
marked weight loss indicating advanced disease at the time of transplantation in contrast 
to the 4 patients who survived for more than 5 years among whom these features were 
not present.  There had been progressive neuropathy and cardiac amyloidosis after OLT, 
the latter of which is highlighted in one patient in Figure 3.5, in all survivors of more 
than 5 years except the one patient who also received a heart transplant, who remained 
stable and well at census 100 months after the combined transplant.  Median (range) 
increase in NT-proBNP concentration per month after OLT alone was 
54 (1.3-79.8) pmol/L and median (range) increase in IVS wall thickness per year after 
OLT alone was 1.56 (0.72-2.6) mm. 
 
Discussion 
Several types of systemic amyloidosis may involve the heart and given the different 
prognosis and treatments of the different types,
52
 definitive diagnosis with 
immunohistochemical typing of amyloid, genetic studies and evaluation for a plasma 
cell dyscrasia is critical.  The heart is the chief site of amyloid deposition in senile 
systemic amyloidosis derived from wild-type TTR, and is very commonly involved in 
AL amyloidosis, which is by far the most commonly diagnosed type.  There is 
particular scope for misdiagnosis of FAP as AL amyloidosis, since there is frequently
60 
 
Figure 3.5  Progressive cardiac amyloidosis after orthotopic liver transplantation.  
Liver transplantation, timing of which is shown by the vertical arrow, was 
followed by an ongoing increase in inter-ventricular wall thickness (red line), a 
progressive fall in fractional shortening (blue line) and a marked rise in NT-
proBNP (black line).   
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no obvious family history with the former and the very heterogeneous presentation of 
the latter often includes autonomic and/or peripheral neuropathy.
67
  Chemotherapy, the 
treatment for AL amyloidosis, has no role in TTR amyloidosis and can be extremely 
harmful; the presence of an incidental plasma cell dyscrasia in 8% of the current cohort, 
which is a prevalence comparable with that in the general ageing population, 
underpinned misdiagnosis and administration of inappropriate chemotherapy in some 
cases.   
The characteristic echocardiographic features of cardiac amyloidosis in the FAP 
T60A cohort, which are common to all types of amyloid cardiomyopathy, were left 
ventricular wall thickening and diastolic dysfunction.  Systolic function was usually 
well preserved.  Differentiation between TTR and AL amyloid cardiomyopathy is not 
possible by echocardiography alone,
17
 although prognosis of AL amyloid 
cardiomyopathy is substantially worse than TTR-type in relation to the degree of LV 
wall thickening.
52
  The reasons are poorly understood but the slower accumulation of 
amyloid in a TTR-type cardiomyopathy
17
 and possible toxicity of certain amyloidogenic 
light chains on myocyte signalling have been postulated as causes.
137
  
Electrocardiographic analysis revealed attenuated QRS voltages in only 16% of cases in 
the current series, compared to 45-60% patients with AL cardiomyopathy.
138,139
   
The cardiac biomarker NT-proBNP has been shown to be a sensitive indicator of 
cardiac involvement and prognosis in AL amyloidosis,
31,140
 but it has been little studied 
in TTR amyloidosis.  In the present study, there were highly significant relationships 
between NT-proBNP concentration at diagnosis and both ventricular septal thickness 
and ejection fraction, consistent with observations of BNP in a small Swedish FAP 
V30M study.
141
  It is noteworthy that NT-proBNP concentration was not associated 
with degree of diastolic dysfunction.  These findings are analogous to AL amyloidosis 
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in which there is a correlation between fall in NT-proBNP and improvement in systolic 
function after chemotherapy.
142
   
To date, the greatest wealth of published information has been with regard to 
FAP associated with TTR V30M in which neuropathic features dominate and in which 
most of the outcome data following liver transplantation exists.
86
  This study highlights 
several important differences between FAP V30M, which is the commonest form of 
FAP worldwide and FAP T60A, which is the commonest variant in the British 
population and which constitutes 20% of the FAP patients in the NAC database.  The 
presence of cardiac amyloid in FAP T60A accounts for several of these differences.  
First, FAP T60A is predominantly a disease of the heart and autonomic nerves with less 
than one quarter of patients presenting with peripheral neuropathy and there being 
minimal progression of peripheral polyneuropathy during follow-up.  In fact, all of the 
patients in the current series developed cardiac amyloid during follow-up.  In contrast, 
FAP V30M typically manifests as a progressive autonomic and peripheral sensorimotor 
polyneuropathy and rarely causes heart failure.
52
  Second, FAP T60A characteristically 
presents at a later age than FAP V30M; the median age at onset of symptoms was 
63 years, and only 1 patient presented before age 50 years compared with FAP V30M in 
which onset during the third to fourth decade of life is most common.
50,143
  Third, 
prognosis in FAP T60A is distinctly worse than in FAP V30M, as is outlined in Figure 
3.4, and no doubt in part reflects a later age of onset and the frequency and severity of 
the cardiac involvement in FAP T60A.  The impact of cardiac amyloid in FAP T60A is 
further emphasised by the fact that all of the independent predictors of survival in this 
cohort were cardiac parameters (LVPW diameter and LA area by echocardiography, 
and NT-proBNP concentration), analogous to the impact of cardiac amyloid on survival 
in AL amyloidosis.
28
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Although OLT has been hailed as an appropriate treatment for FAP, only 7 
patients in the cohort underwent OLT and one additional patient, who had advanced 
cardiac amyloidosis at presentation, received a combined cardiac and liver transplant.  
The possibility of OLT was ruled out in the remaining patients on grounds of age, 
advanced disease and patient choice.  The potential impact of cardiac amyloid on OLT 
in FAP T60A patients is highlighted in this series.  Firstly, there was evidence of 
progression of amyloidosis in the hearts of all solitary OLT recipients who survived for 
more than 5 years.  Secondly, overall survival was poor with 4 patient deaths occurring 
within 5 years from OLT and three of these deaths were related to cardiac amyloid.  
These observations substantiate the critical significance of cardiac involvement in FAP 
patients who undergo OLT, both in terms of fitness to undergo major surgery such as 
OLT and with respect to the course of the amyloid heart disease following OLT.  Whilst 
it remains possible that the rate of disease progression might have been modified 
following OLT, the overall impression falls in marked contrast with published outcome 
data following OLT for FAP V30M in which progression of amyloid neuropathy is 
successfully halted by OLT, especially when OLT is undertaken early in the course of 
the disease.
86
  The progression of cardiac amyloidosis after OLT observed here extends 
previous reports of „paradoxical‟ worsening of amyloid in the heart.87,144  This cardiac 
phenomenon has been confirmed by pathologic studies that have revealed a 
disproportionate excess of wild-type TTR amyloid in the hearts of patients who had 
undergone OLT as compared to those who had not.
88
  The particular propensity for TTR 
protein to undergo conversion into amyloid fibrils in the heart is compellingly 
demonstrated by the syndrome of senile systemic amyloidosis in which wild-type TTR 
is deposited almost exclusively as cardiac amyloid in up to 25% of elderly 
individuals.
145
  The role of OLT for FAP T60A and indeed all “non-V30M” forms of 
FAP in which cardiac involvement is characteristic, therefore remains most uncertain.   
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Conclusion 
FAP T60A is a progressive condition dominated by cardiac amyloidosis and associated 
with varying degrees of autonomic and peripheral polyneuropathy.  The poor outcome 
is largely attributable to the presence of cardiac amyloid.  The role of OLT in FAP 
T60A remains uncertain, fuelling much hope for the various novel pharmacologic 
treatments currently in development, which include drugs to stabilise TTR protein in its 
non-amyloid conformation, RNA therapeutics to inhibit production of TTR, and 
monoclonal antibody therapy to eliminate existing amyloid deposits.
100,108
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Chapter 4 
Hereditary lysozyme amyloidosis - Phenotypic 
heterogeneity and the role of solid organ 
transplantation 
 
Introduction 
Hereditary non-neuropathic systemic amyloidosis was first described in 1932 by 
Ostertag.
56
  A number of mutations in genes encoding amyloidogenic variant precursor 
proteins have been identified: apolipoprotein AI (16 mutations), apolipoprotein AII (4 
mutations), fibrinogen Aα-chain (9 mutations) and lysozyme (6 mutations).  The 
phenotype of these conditions is variable in terms of penetrance, age of onset, organ 
involvement, rate of progression and prognosis, not only within a given amyloidosis 
type but even between those with the same mutation.   
ALys was first described in 1993 by Pepys et al. and in vitro studies with 
lysozyme have provided seminal insights into amyloid fibrillogenesis.
146
  The 
phenotype of ALys is heterogeneous and includes gastrointestinal symptoms, hepatic 
rupture, sicca syndrome, petechiae and purpura, renal failure and lymphadenopathy.  
Lysozyme is a bacteriolytic enzyme that is synthesised in the gastrointestinal tract, in 
macrophages and in hepatocytes.  Six different mutations of the lysozyme gene have 
been reported to encode amyloidogenic variants of the protein
146-150
 and a 
non-amyloidogenic polymorphism has also been reported.
151
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Aims 
The phenotype of ALys has largely been reported in case reports or kindred analyses.  
ALys tends to be referred to under the umbrella of hereditary non-neuropathic systemic 
amyloidosis and hence is often labelled as a disease of the kidneys.  In this series, which 
is the largest reported to date and which includes prolonged patient follow-up, there is 
characterisation of the clinical presentation of this disease with a focus on the dominant 
non-renal aspects, in particular the gastroenterological and hepatic features.  There is 
also review of its natural history, including the role of solid organ transplantation (liver 
and kidney) in the face of organ failure.  
 
Methods 
Sixteen patients with ALys who were followed up prospectively at the National 
Amyloidosis Centre (NAC) between 1988 and 2010 were identified retrospectively 
from the centre database.  Diagnosis of ALys required identification of amyloid deposits 
within tissues (by histology with immunohistochemistry and 
123
I-SAP scintigraphy in 
13 cases and by 
123
I-SAP scintigraphy alone in 3 cases) in combination with presence of 
a mutation in the lysozyme gene, corroborated by a family history of amyloidosis and 
absence of raised inflammatory markers or a clonal disorder.  Patients attended the NAC 
for their initial diagnostic evaluation and were followed up at regular (6 monthly to 
yearly) intervals for evaluation of organ function including detailed echocardiographic 
evaluation of the heart and monitoring of whole body amyloid load by serial 
123
I-SAP 
scintigraphy.  Additional investigations were undertaken when clinically indicated.  
Amongst cases where organ failure supervened, listing and procedure for organ 
transplantation was according to local transplant centre protocols.   
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Results 
 
Patients 
Sixteen patients (5 male) with ALys were identified and all were Caucasian.  Median 
(range) age of development of amyloid-related symptoms was 25 (9-70) years, delay 
from symptom onset to diagnosis of amyloidosis was 2.3 (0-29.3) years, and median 
(range) age of presentation to the NAC was 45 (18-72) years.  Patient 8 was referred for 
genetic screening and was the only asymptomatic case in the series and remained so 
until her death aged 72 years.  Her sister (Patient 7, Table 4.1) presented with renal 
amyloidosis aged 66 years.  
The clinical heterogeneity of ALys is highlighted in Table 4.1.  Presentation was 
most commonly from sicca syndrome from presumed amyloidotic salivary gland 
infiltration (6 cases), or with renal dysfunction (5 cases).  Presentation with rupture or 
haematoma of the liver occurred in 2 cases and gastrointestinal (GI) disturbance was the 
presenting feature in 2 cases.  One case was asymptomatic and was detected by family 
screening.  No patient had symptoms or investigations to suggest involvement of the 
heart by amyloid.   
 
Histology 
Amyloid was confirmed by histology in 13 patients from biopsies of the GI tract (7 
cases), kidneys (3 cases), explanted liver after rupture (2 cases) and spleen after rupture 
(1 case).  Positive immunohistochemical staining with antibodies against lysozyme and 
negative staining with all other antibodies confirmed the amyloid fibril protein to be 
lysozyme.   
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Serum amyloid P component (SAP) scintigraphy 
By the time of diagnosis, all symptomatic patients had amyloid in the liver and spleen 
and a large total body amyloid load by SAP scintigraphy.  The kidneys were obscured 
by hepatosplenomegaly on the planar images in 5 cases.  Amongst the remaining cases, 
the kidneys exhibited abnormal uptake in each of 6 with renal dysfunction and 2 of 5 
without renal dysfunction.  The asymptomatic patient (Patient 8, Table 4.1) had 
unequivocal amyloid in the spleen and kidneys by SAP scintigraphy but none in the 
liver.  This patient did not have any tissue biopsies.  Interestingly, amyloid did not 
continue to accumulate within native organs despite more than eight years follow-up in 
4 patients, contrasting recurrence of amyloid within 3 transplanted livers over a shorter 
time period.   
 
DNA Analysis and Genetics 
Twelve patients were heterozygous for a mutation in the lysozyme gene which encodes 
the D67H variant, 2 cases carried the W64R variant and 1 case each carried the I56T 
and D67G variants, all of which have been previously reported.  Four kindreds 
accounted for 11 of 12 patients with the D67H variant (Table 4.1).   
A family history of ALys was evident in every patient in the cohort.  All except 
Patient 6 had evidence of a 1st and 2nd degree relative with biopsy-proven amyloid or 
characteristic features of ALys.  Patient 6 had a 2nd degree relative with amyloid and is 
a 4th degree relative of Patients 4 and 5.  The highly penetrant nature of ALys is 
highlighted in the family tree of patient 14 (Figure 4.1).  The proband from this family 
developed sicca syndrome aged 13 years.  She had recurrent friable lesions on 
oesophagogastroduodenoscopy, which presented as abdominal pain and haemorrhage 
and, aged 30 years, underwent an emergency small intestinal resection for spontaneous 
small intestinal perforation.  Two of the proband‟s sisters (Figure 4.1, BVI and BVIII)
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Table 4.1  Clinical characteristics of ALys patients. 
 
 
Patient 
number 
(Gender) 
 
Family 
Number 
 
Lysozyme 
variant 
 
Mode (age) of  
presentation 
 
Age at diagnosis 
(Organ biopsy) 
 
Additional 
clinical 
features 
 
Gastrointestinal symptoms/Upper gastrointestinal tract endoscopic 
findings 
 
Dead (D) or Alive 
(A)/ Time from 
diagnosis to death 
or census (years) 
        
1 (F) 1 D67H Sicca syndrome (11) 28 (GI) B Nausea and vomiting / Oesophageal and gastric nodules A / 2.5 
2 (M) 1 D67H Sicca syndrome (25) 54 (GI) - Dyspepsia / Extensive upper gastrointestinal tract ulceration A / 7.6 
3 (F) 1 D67H Sicca syndrome (11) 27 (GI) - Dyspepsia / Gastritis A / 21.6 
4 (F) 2 D67H Liver rupture (24) 24 (Liver) S Haemorrhage / Haemorrhagic gastritis and ulceration A / 5.8 
5 (M) 2 D67H GI haemorrhage (9) 9 (GI) L, LN Haemorrhage / Multiple bleeding polyps from oesophagus to 
duodenum, haemorrhagic gastritis 
D / 17.9 
6 (M) 2 D67H Liver haematoma (34) 47 (GI) R, B Haemorrhage / Peptic ulcer, friable lesions A / 15.5 
7 (F) 3 D67H Renal dysfunction (67) 67 (Kidney) -  D / 4.8 
8 (F) 3 D67H None/FHx 72 (-) -  D / 2.0 
9 (M) 4 D67H Sicca syndrome (20) 22 (Kidney) R, S Dyspepsia and diarrhoea / Normal A / 29.6 
10 (F) 4 D67H Renal dysfunction (51) 51 (Kidney) - Anaemia / - A / 12.1 
11 (F) 4 D67H Renal dysfunction (51) 51 (-) S Haemorrhage, diarrhoea / - D / 10.9 
12 (F) 5 D67H Sicca syndrome (13) 34 (Liver) L, S, B Abdominal pain / Peptic ulcer, friable lesions A / 9.1 
13 (F) 6 I56T Renal dysfunction (70) 71 (-) B  D / 5.8 
14 (F) 7 W64R Sicca syndrome (13) 34 (GI) S, LN Haemorrhage / Peptic ulcer, friable lesions A / 6.6 
15 (F) 7 W64R GI haemorrhage (52) 52 (GI) S Haemorrhage / Peptic ulcer, friable lesions A / 10.5 
16 (M) 8 D67G Renal dysfunction (29) 32 (Spleen) S, B, SP  A / 1.8 
 
S= Sicca syndrome, B= Bruising, FHx = Family history, LN=Lymphadenopathy, SP=Splenic rupture, R=Renal dysfunction, L=Liver rupture 
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Figure 4.1  Family tree of patient 14.  The proband is indicated by the arrow.  Circles represent females and squares represent males.  The 
diamonds with boxes below them represent the number (as stated in the box) of unaffected siblings who are either asymptomatic or negative 
for the ALys mutation.  Dead individuals are indicated by a diagonal line through the symbol.   
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also had endoscopically confirmed friable lesions which presented with early satiety and 
haematemesis, respectively.  The proband‟s nephew (Figure 4.1, CIV), developed 
abdominal pain secondary to peptic ulceration at the age of 14 years.  Two first cousins 
of the proband, (Figure 4.1, BIV and BII), developed anaemia on the background of 
overt gastrointestinal haemorrhage in their third decade which was associated 
respectively with oesophageal haemorrhagic nodules and gastric friable lesions.  
 
Clinical Course and Outcome 
Endoscopic investigation during the course of the illness was prompted by GI 
haemorrhage in 6 (38%) cases (Figure 4.2), by dyspepsia in 2 cases and by nausea and 
vomiting in 1 case.  Nine of 10 patients who underwent oesophagogastroduodenoscopy 
had endoscopic abnormalities such as peptic ulceration (4 cases), oesophageal or gastric 
nodules and haemorrhagic gastritis.  Contact bleeding was observed on several 
endoscopic evaluations, even at points where the mucosa looked macroscopically 
normal and in the absence of clotting or platelet abnormalities.  The 4 patients with 
peptic ulceration all received proton pump inhibitor (PPI) therapy although whether this 
was clinically beneficial is not clear; at least one patient had further GI bleeding whilst 
on chronic PPI therapy.  Several patients (Table 4.1, Patients 6, 9 and 11) had diarrhoea 
associated with weight loss and another (Patient 14) had a spontaneous small intestinal 
perforation which required resection and subsequent intestinal anastomosis, suggesting 
fragility of the intestinal wall from amyloid infiltration.  Patient 6 had steatorrhoea with 
a faecal fat concentration of 60 mmol/l (normal <18 mmol/l) and subsequently 
presented with intestinal perforation secondary to a combination of diverticular disease 
and extensive GI amyloid infiltration, for which he required a Hartmann‟s procedure.  
Despite extensive hepatic infiltration by amyloid by the time of diagnosis, liver 
function tests remained relatively preserved with a normal bilirubin in all patients, and a
72 
 
Figure 4.2  Oesophagogastroduodenoscopic views of the stomach of Patient 4 with 
ALys after presentation with upper gastrointestinal tract haemorrhage : antral 
gastritis (top) and haemorrhagic gastritis of the fundus with ulceration (arrow). 
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mildly elevated alkaline phosphatase (median (range) 77 (62-295) U/L) and aspartate 
aminotransferase values in only 2 and 4 cases respectively.  Median (range) serum 
albumin at diagnosis was 43 (27-50) g/L.  Three patients (Table 4.1, Patients 4, 5 and 
12) spontaneously ruptured their livers aged 24, 15 and 34 years respectively; each 
underwent emergency orthotopic liver transplantation (OLT) accompanied by 
perioperative splenectomy because of splenic fragility.  The remaining OLT recipient 
(Patient 15) underwent the transplant because she had heavy hepatic amyloid infiltration 
and a strong family history (mother and sister) of spontaneous liver rupture.  Patients 4 
and 5 were siblings and there had been a history of spontaneous hepatic rupture in both 
their father and paternal grandfather.  The mother of Patient 12 also had a spontaneous 
hepatic rupture.   
At census, there were no hepatic graft failures 1.7, 5.8, 9.0 and 11.0 years from 
OLT.  Serial SAP scintigraphy however, showed asymptomatic amyloid recurrence 
within ~3 years in 2 patients (Table 4.1; Patients 4 and 5; Figure 4.3) and amyloid was 
present in the graft of a third OLT recipient (Patient 12) by the time she first presented 
to the NAC 7.8 years after the procedure.  There was no evidence of amyloid recurrence 
in the remaining patient at census 1.7 years after OLT. 
Ten cases presented with or developed sicca syndrome during follow-up, due to 
presumed salivary gland infiltration by amyloid.  Sicca syndrome frequently pre-dated 
the diagnosis of amyloidosis by several (range 3-30) years.  Other forms of „soft tissue‟ 
amyloid infiltration manifested as petechiae in 5 patients and 2 patients (Patients 5 and 
14) had evidence of amyloidotic lymphadenopathy; the latter was widespread in Patient 
14 and was similarly so in 3 affected siblings and a third degree relative (Figure 4.1). 
Amyloidotic renal dysfunction occurred in 7 patients during the course of their 
illness and was progressive, culminating in end-stage renal disease (ESRD) in 5 of these 
cases (Table 4.1; Patients 7, 9, 10, 11 and 16).  Median (range) 24 hr urinary protein 
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Figure 4.3  Serial anterior whole body 
123
I-SAP scintigraphy of Patient 4 after OLT - recurrence and progression of lysozyme amyloid in the 
liver graft after OLT for hepatic rupture and progression of amyloid in a splenunculus 5 (left), 41 (middle) and 65 (right) months after OLT. 
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loss among those presenting with renal dysfunction was only 0.3 g (0-4.0 g); a single 
patient had nephrotic-range proteinuria but was not clinically nephrotic.  There was no 
evidence of renal dysfunction in the remaining 9 patients during follow-up.  Median 
time to end-stage renal failure from discovery of renal dysfunction by Kaplan-Meier 
analysis was 11.0 years.   
Living donor renal transplantation (RTx) was undertaken in 3 patients 
(Table 4.1; Patients 9, 10 and 16), pre-emptively in 2 cases and 0.2 years after ESRD in 
Patient 10.  All 3 patients were alive at census 6.6, 0.8 and 1.8 years after RTx 
respectively, without evidence in any graft of amyloid recurrence.  RTx is also known 
to have taken place in 2 relatives with ALys of patients in this cohort without evidence 
of graft failure after 8 years (brother of Patient 10) and 8 months (niece of Patient 14) 
from RTx.   
The median estimated survival from diagnosis of amyloidosis in this series was 
17.9 years (Figure 4.4) and despite median follow-up from symptom onset of 24.7 years 
only 4 of 15 patients died (one patient remained asymptomatic throughout her disease 
course and was therefore excluded from the latter analysis). 
 
Discussion 
The hereditary non-neuropathic systemic amyloidosis syndromes are characterised by 
an autosomal dominant mode of inheritance and are typically associated with variable 
penetrance.  Hereditary fibrinogen A-α chain and apolipoprotein AII amyloidosis cause 
renal failure, apolipoprotein AI amyloidosis is associated with renal, hepatic and cardiac 
disease and gelsolin amyloidosis with corneal lattice dystrophy, cranial neuropathy and 
occasionally, renal failure.
57
  ALys is the most clinically heterogeneous condition in this 
group and may mimic the more common AL amyloidosis.
72
  ALys is very penetrant  
 
76 
 
Figure 4.4  Kaplan-Meier survival from diagnosis of amyloidosis in ALys patients. 
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however, and a family history of amyloidosis is usually present in marked contrast to 
other forms of hereditary systemic amyloidosis.
67,152
  Distinguishing between ALys and 
AL amyloidosis is critical for correct patient management.  The median survival of 
nearly 18 years from diagnosis in ALys contrasts systemic AL amyloidosis in which the 
median survival with modern chemotherapy regimens is ~3-4 years from diagnosis.  In 
fact, median survival in the absence of chemotherapy among patients with AL 
amyloidosis is ~1 year, whereas there is no role for chemotherapy in ALys.  One patient 
in this series (Table 4.1; Patient 7) received inappropriate chemotherapy for presumed 
AL amyloidosis prior to review in the NAC.  It is imperative therefore, that patients 
with systemic amyloidosis are screened for a family history of similar disease and 
undergo genetic sequencing, particularly if the amyloid fibril protein remains uncertain 
despite immunohistochemical staining of amyloidotic tissue, which may be the case in 
up to 40% of patients with AL amyloidosis.
67
   
Symptomatic gastrointestinal amyloid is relatively unusual in the other forms of 
hereditary non-neuropathic systemic amyloidosis but appears prevalent in this ALys 
cohort.  Gastrointestinal haemorrhage associated with endoscopically visible, friable 
lesions was common in this series, and has previously been reported in a French family 
with ALys.
153
  It would seem sensible therefore to give consideration to lifelong 
prophylactic proton pump inhibitor use in patients with ALys who have GI amyloid to 
try and reduce risk of upper GI tract haemorrhage.  Whether this practice is clinically 
beneficial however, cannot be concluded from this case series.  Three patients in this 
series had severe diarrhoea and weight loss including one with fat malabsorption 
suggestive of small intestinal amyloid, which has also been reported previously in 
ALys.
154
   
Hepatic amyloid, detected by SAP scintigraphy, was virtually universal at 
diagnosis in these patients, along with a large total body amyloid burden.  Interestingly, 
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liver function tests were barely deranged and remained relatively stable during follow-
up, which contrasts AL amyloidosis in which patients with similar SAP scintigraphic 
appearances have markedly deranged liver biochemistry and may develop hepatic 
decompensation.
155
  Both this and the finding that median time from presentation with 
renal dysfunction to ESRD in this cohort was 11.0 years indicate that the natural history 
of ALys is markedly slower than AL and other types of hereditary amyloidosis.
152,156
  
The mechanism by which amyloid accumulation in native organs appears to abate in 
ALys, once patients have accumulated a large total body amyloid burden, remains 
unclear.   
Hepatic haemorrhage and/or rupture occurred in 3 of 12 (25%) patients with 
ALys associated with the D67H variant in this series.  Since the diagnosis of amyloid 
was only established after liver rupture in all 3 of these cases, it may be that the 
prevalence suggested here is falsely high.  Patient 5‟s explanted liver was noted to be 
fragile and friable with loss of the reticulin framework
157
 and that of Patient 4 was 3 kg, 
which is approximately twice the weight of a normal liver.
158
  Although the extent of 
amyloid infiltration may contribute to risk of haemorrhage, it is notable that liver 
rupture in AL amyloidosis, which can also be associated with massive hepatomegaly is 
exceptionally rare.  Emergency OLT among these 3 patients was life-saving and appears 
to have a good outcome in terms of graft survival, despite evidence of amyloid 
recurrence in the graft, with 100% 1- and 5-year graft survival in this small series.  One 
of the cohort had a “prophylactic” OLT on a background of extensive hepatic 
amyloidosis and a family history of hepatic rupture.  In a climate of donor shortages, the 
merits of such an approach remain uncertain.  It would however seem reasonable to 
recommend a pre-emptive OLT assessment in those with confirmed ALys, particularly 
if there is a family history of hepatic rupture or hepatic haematoma.   
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Soft tissue amyloidosis, one manifestation of which is sicca syndrome, is 
recognised in both ALys and AL amyloidosis.
33,159
  Sicca syndrome frequently predated 
vital organ dysfunction in this cohort and should prompt a search for amyloid deposits 
in any patient with a family history of ALys.  Indeed, 2 patients in this series were 
diagnosed in precisely this fashion.  Artificial saliva or tears may provide symptomatic 
relief.  Other „soft tissue‟ manifestations of amyloid in this cohort were bruising and 
lymph node enlargement, which are usually considered to be almost pathognomonic of 
AL amyloidosis.
72
  Patient 14 had evidence of widespread amyloidotic 
lymphadenopathy, which has not been reported before in ALys. 
Renal dysfunction is common in all forms of hereditary non-neuropathic 
systemic amyloidosis and 5 of 16 cases in this series reached ESRD.  Age at 
presentation and rate of renal progression varied widely, even among patients from the 
same family who carry the same mutation, evident from Family 4 in this series and 
consistent with previous reports.
148,160,161
  Despite a large total body amyloid burden and 
a complete lack of available therapy to halt amyloid accumulation in ALys, outcomes 
among 3 RTx recipients were excellent with functioning renal allografts and no 
recurrence of amyloid 0.8, 1.8 and 6.6 years after RTx.  To date, there has never been a 
report of renal allograft failure secondary to recurrent amyloid in ALys despite ongoing 
production of amyloidogenic precursor protein.
147,161,162
 
 
Conclusion 
ALys is a rare form of hereditary non-neuropathic systemic amyloidosis which is 
clinically heterogeneous and may present with hepatic rupture, gastrointestinal 
haemorrhage, sicca syndrome, purpura and petechiae, lymphadenopathy or renal 
dysfunction.  There is considerable overlap between the clinical features in ALys and 
AL amyloidosis and it is important to distinguish between these diagnoses since there is 
80 
 
no role for chemotherapy in ALys.  Clinical penetrance in the presence of an 
amyloidogenic lysozyme mutation is high, evident by the obvious family history in all 
cases within this cohort.  Although there is no amyloid-specific therapy for ALys, which 
is therefore managed symptomatically, the condition has a slow natural history and 
amyloid accumulation may abate in some patients.  RTx for ESRD and OLT for cases 
of liver rupture appear to be very successful with excellent medium-term graft function 
and patient survival.   
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Chapter 5 
A prospective study of nutritional status in AL 
amyloidosis 
 
Introduction 
Weight loss is common amongst patients with AL amyloidosis but is frequently not 
appreciated.
163
  Reduced food intake and/or increased energy expenditure secondary to 
metabolic derangements may contribute.  Studies of weight loss in other diseases, 
typically cancers, have focused on the complex interplay of cytokines, such as TNF-α, 
IL-1, IL-6 and IFN-γ,164 which may exert their effects on the gastrointestinal tract or 
central nervous system.
165
  This metabolic syndrome of cachexia can negatively impact 
upon quality of life, response to therapy and survival.
166
  
Weight loss has been found to be a predictor of poorer survival in patients with 
AL amyloidosis.
22,167,168
  One prospective study of 106 patients with AL amyloidosis 
highlighted that weight loss was a prominent feature, especially in those with cardiac 
amyloid and identified several simple anthropometric and biochemical measures of 
nutritional state that correlated with survival in a heterogeneous population which 
comprised patients, who had received treatment (the majority) as well as those who 
were treatment-naive.
163
  There has only been one previous published study that has 
included a formal assessment of nutritional status prior to commencement of 
chemotherapy and this study looked at its impact on quality of life (QOL) in patients 
with AL amyloidosis.
116
  QOL is a multi-layered subjective experience governed by 
several parameters.
169
  Attempts have been made to give it weight and incorporate it 
into decision-making when considering treatment regimens for different diseases.
170
  
Inclusion of QOL during assessment of clinical state is often considered „holistic‟ and 
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since it takes into account physical, psychological and social factors, is considered by 
some to be essential whenever the benefits of interventions are being determined, 
especially among individuals with potentially fatal conditions in whom a cure may not 
be the primary objective.  One prospective study determined QOL in patients with AL 
amyloidosis who were treated with high-dose melphalan and autologous stem cell 
transplantation and found measurable and sustained improvements in QOL.
171
  There 
have been several studies looking at the relationship of nutritional status and QOL in 
other patient groups; the elderly,
172
 dialysis patients,
173
 and patients with various 
cancers.
174-176
   
 
Methods 
 
Aims 
The aim of this study was to determine the disease-specific clinical and biochemical 
parameters associated with malnutrition in consecutive, newly-diagnosed, 
treatment-naïve patients with AL amyloidosis and furthermore the effect of malnutrition 
on QOL and survival.  There has been a lot of research into prognostic models of 
survival in systemic AL amyloidosis, with a focus on the effect of cardiac amyloid on 
such.  Hence there has been widespread interest in staging systems incorporating 
cardiac parameters, such as the Mayo staging system.
112
  Malnourished status 
potentially encompasses the impact of other affected organs besides the heart and 
another aim of the study was to assess its strength as a prognostic tool versus the Mayo 
staging system.  There was use of a nutritional assessment tool with a continuous 
scoring system (Patient-Generated Subjective Global Assessment) for these purposes 
with the view that if there was a significant influence of malnutrition on QOL and 
survival then such a tool might be useful to gauge the benefits of a nutritional 
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intervention on these two important patient outcomes, as has been proven in other 
conditions in which this tool has been used.
177
 
 
Patients 
All eligible patients who were reviewed at the UK National Amyloidosis Centre (NAC) 
between April and December 2009 were invited to participate in the study.  Inclusion 
criteria were as follows: 18 years and over; newly diagnosed biopsy-proven AL 
amyloid; no prior chemotherapy but requiring chemotherapy for systemic AL 
amyloidosis; able to give written informed consent for entry into the study.  Exclusion 
criteria were as follows: localised AL amyloidosis, non-AL amyloidosis or suspected 
AL amyloidosis.   
Each patient was assessed at baseline and at 6 monthly intervals until death or 
census.  Census occurred in September 2011, more than 18 months after enrolment into 
the study of the last patient.  Baseline evaluation included the following: detailed 
clinical assessment including lying and standing blood pressure and nutritional status; 
biochemical tests of renal (including proteinuria) and hepatic function, assessment of 
NT-proBNP and Troponin T concentration, serum free light chain concentration and 
immunoelectrophoresis of serum and urine, electrocardiography and echocardiography.  
Organ involvement by amyloid was determined according to the international consensus 
criteria.
114
 and Mayo disease stage was defined according to cardiac biomarkers, as 
previously described.
112
   
Nutritional assessments, including body mass index (BMI) and Patient-
Generated Subjective Global Assessment (PG-SGA) were carried out on patients at 
their baseline visit to the NAC.  BMI forms a part of the Malnutrition Universal 
Screening Tool, which is a tool supported by the Britsh Association of Parenteral 
Nutrition (http://www.bapen.org.uk) to assess nutritional risk and which also comprises 
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assessment of weight loss over the prior 3-6 months and whether there has been or will 
be no oral intake for >5 days.  A BMI< 20kg/m
2
 is the cut-off for nutritional risk 
according to this tool and was taken as the cut-off for analysis in this study.  QOL was 
assessed at baseline visit with the EORTC QLQ-C30 questionnaire.  An attempt was 
made to acquire information on other follow-up outcomes besides survival, such as 
cause of death, via a letter sent to the referring doctor and GP (Appendix 2), but there 
were few responses and those that were received were often incomplete or lacked 
sufficient detail. 
 
Statistical analysis 
Disease and patient-specific factors associated with the PG-SGA score were identified 
through linear regression analysis.  Cut-points for the factors were chosen by their 
clinical relevance or in line with previously published data.  All factors which were of 
statistical significance (p<0.10) in univariable analyses were included in the 
multivariable analysis.  The assumptions underlying the regression analysis were 
checked by a study of the residuals and found to be satisfactory.  Kaplan-Meier analysis 
and log-rank tests were used to assess and compare the survival experience between 
different categories of PG-SGA score of the patients in the cohort.  A Cox proportional 
hazards regression analysis was performed to assess the independent effect on survival 
of PG-SGA after adjusting for those variables found to be significantly associated with 
survival in univariable Kaplan-Meier analyses.  The Pearson correlation coefficient was 
determined to assess the linear relationship between the QOL score (both the global 
score and each of the functional and symptom scale components) and the actual value of  
PG-SGA.  To overcome the problem of multiple testing for these coefficients, a 
significance level of 0.01 was used.   
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Results  
 
Patient characteristics 
One hundred and ten (66 male) consecutive, newly diagnosed, treatment–naïve patients 
with systemic AL amyloidosis were enrolled into the study between April and 
December 2009.  Patient characteristics are summarised in Table 5.1.  Median (range) 
age of presentation to the NAC was 66 (42-88).  Median (range) time from symptom 
onset to baseline evaluation was 6 (0-28) months.  Eighty-one patients (74%) had a 
lambda light chain secreting plasma cell dyscrasia and 29 patients (26%) an 
amyloidogenic kappa-secreting plasma clone.  Thirty-five patients (32%) had single 
organ involvement by amyloid, 46 (42%) had 2 organ involvement and 29 (26%) had 3 
or more organs involved according to the international amyloid consensus criteria.  The 
kidneys (85 patients) and heart (69 patients) were the commonest organs to be affected 
by amyloid.  Mayo disease stage at baseline was I, II and III in 16, 35 and 59 patients 
respectively. 
 
Scored PG-SGA assessment 
At baseline evaluation sixty-six patients (60%) stated that they had lost weight over the 
preceding 6 months, of whom 15 patients had noticed weight loss over the preceding 2 
weeks.  Food intake, as estimated by the patient, was less than normal over the previous 
month in 61 (55%) patients, normal in 45 (41%) and increased in 4 (4%) cases.  Diet 
was quantitatively reduced but remained qualitatively unchanged among 51/61 (84%) 
patients who had eaten less over the preceding month and was both quantitatively and 
qualitatively altered among the remainder.  The main reasons for reduced food intake 
were reduced appetite (43%), altered taste of food (27%), early satiety (25%) and 
fatigue (21%) (Table 5.2).   
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Table 5.1  Patient characteristics at recruitment. 
  
 
Patient characteristics at baseline Value 
Total number (N) of patients 110 
Age at recruitment; median years  
(Inter-quartile range(IQR)) 
66 (60, 74) 
BMI at recruitment; median kg/m
2
 (IQR) 25 (23, 29) 
Gender; N. (%):  
Male 
Female 
 
66 (60.0%)
 
44 (40.0%) 
Plasma cell dyscrasia; N. (%):  
Kappa 
Lambda 
 
29 (26.4%)
 
81 (73.6%) 
Amyloid organ involvement (by the 
international amyloid consensus criteria); 
N. (%): 
1 
2  
≥3  
 
 
 
35 (31.8%)
 
46 (41.8%)
 
29 (26.4%) 
Kidney involvement; N. (%): 85 (77.3%) 
Cardiac involvement; N. (%): 69 (62.7%) 
Liver involvement; N. (%): 16 (14.6%) 
Gastrointestinal involvement; N. (%): 5 (4.6%) 
Autonomic neuropathy; N. (%): 16 (14.6%) 
Peripheral neuropathy; N. (%): 10 (9.1%) 
CKD Stage, N. (%) 
≤3 
>3 
 
86(78.2%) 
24(21.8%) 
PG-SGA score; median (IQR) 9.5 (2, 14) 
Dialysis; N. (%): 9/85 (10.6%) 
Proteinuria; median g/L (IQR) 2.6 (0.6, 6.2) 
Albumin (normal ≥35); median g/L (IQR) 33 (25.75, 40) 
Bilirubin (normal <19); median µg/L (IQR) 7 (4, 11.5) 
Gamma-glutamyl transferase (normal 
≤61); median U/L (IQR) 
54 (28, 177) 
Alkaline phosphatase (normal ≤129); 
median U/L (IQR) 
105 (70, 175) 
Mayo Stage; N. (%): 
I 
II 
III 
 
16 (14.5%) 
35 (31.8%) 
59 (53.7%) 
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Table 5.2  Symptoms impeding food intake at recruitment. 
  
Symptoms impeding food intake Number (Percent) patients 
Number of patients 110 
No symptoms 47 (42.7%) 
Lack of appetite 47 (42.7%) 
Food tastes strange 30 (27.3%) 
Early satiety 27 (24.6%) 
Fatigue 23 (20.9%) 
Dry mouth 23 (20.9%) 
Problems swallowing 18 (16.4%) 
Nausea 13 (11.8%) 
Pain 12 (11.0%) 
Food smells disagreeable 9 (8.2%) 
Constipation 9 (8.2%) 
Other factors 9 (8.2%) 
Mouth ulcers 8 (7.3%) 
Diarrhoea 8 (7.3%) 
Vomiting 5 (4.6%) 
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The PG-SGA score indicated that 14 (13%) patients needed no additional 
nutritional recommendations (score of 0-1), 24 (22%) cases required nutritional 
education with pharmacological intervention for management of symptoms (score of 2-
3), and 72 (65%) patients required specialist nutritional intervention including 57 (52%) 
cases who were critically in need of nutritional intervention (score ≥9) (Figure 5.1).  
Only 4 (<4%) patients had a BMI <20 at baseline, and there was no correlation between 
BMI and nutritional state, as assessed by PG-SGA (r=-0.14).  
Factors significantly associated with a higher PG-SGA score in the multivariable 
regression analysis are outlined in Table 5.3.  An elevated alkaline phosphatase, 
presence of autonomic neuropathy, a greater number of organs involved by amyloid and 
a higher Mayo stage were significantly and independently associated with a higher PG-
SGA score. 
 
Quality of life  
There was a highly significant and consistent relationship between PG-SGA score and 
QOL measures by the EORTC QLQ-C30 (Table 5.4).  Higher PG-SGA scores were 
associated with poorer overall QOL (p<0.0001).  There was also a significant 
association between higher PG-SGA scores and lower scores in all of the functional 
scales (p<0.001) and a significant inverse correlation with all of the symptom scales or 
items except for dyspnoea (p≤0.01).  
 
Survival 
At census with a median (range) follow-up period of 1.2 (0 – 2.4) years, 63 (57%) 
patients died.  PG-SGA score at baseline was the only independent predictor of patient 
survival [HR: 6.2 (95% CI: 1.2-32.4) for a PG-SGA score 4-8 versus a PG-SGA score 
0-1 (p=0.03) and HR: 6.4 (95% CI: 1.4-30.2) for a PG-SGA score >8 versus a PG-SGA
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Figure 5.1  PG-SGA scores at recruitment. 
 
Nutritional recommendations: 
 
0–1 : does not require nutritional intervention.  
2–3 : patients and relatives require nutritional education provided by a specialist in 
nutrition (or other clinician) with pharmacological intervention based on the symptoms 
and the patient‟s data. 
4–8 : requires intervention of a specialist in nutrition in conjunction with the attending 
physician based on the patient‟s data and symptoms. 
≥9 : indicates a critical need to improve the management of the patient‟s symptoms 
together with a nutritional intervention. 
 
 
 
0-1
2-3
4-8
≥ 9
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Table 5.3  Clinical factors associated with PG-SGA score at recruitment. 
 
Characteristic Unadjusted analysis Multivariable analysis 
Regression coefficient 
(95%CI) 
P-value Regression coefficient 
(95%CI) 
P-value 
ALP (IU/l) 
 > 129 versus ≤129 
 
4.69 (2.17, 7.21) 
 
<0.001 
 
3.61 (1.30, 5.91) 
 
0.002 
CKD  
4-5 versus 1-3 
 
1.66 (-1.58, 4.85)  
 
0.30 
  
PNS 4.64 (0.23, 9.05) 0.04 -0.37 (-4.76, 4.02) 0.87 
ANS  7.83 (4.48, 11.18) <0.001 4.33 (0.55, 8.1) 0.03 
N. organs involved  
1-2 
≥3 
 
Ref 
7.95 (5.44, 10.46) 
 
 
<0.001 
 
Ref 
4.26 (1.07, 7.44) 
 
 
0.009 
Mayo Stage                              
Stage 1                                        
Stage 2                                        
Stage 3 
 
Ref 
2.84 (-0.93, 6.62) 
7.04 (3.52, 10.57) 
 
 
0.14 
<0.001 
 
Ref 
1.65 (-1.65, 4.95) 
3.84 (0.64, 7.03) 
 
 
0.32 
0.02 
Proteinuria   
(g/24hrs)             
 < 0.5                                                                 
0.5-3 
  > 3 
   
 
Ref
2.41 (-1.11, 5.93) 
-2.06 (-5.37, 1.24) 
 
 
 
0.18 
0.22 
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Table 5.4  Median (IQR) QOL scores according to PG-SGA score at recruitment. 
 
QOL Parameter Patient Generated Subjective Global Assessment Score 
0-1 2-3 4-8 ≥9 P-value 
Functional Scale 
Global QOL 
Physical functioning 
Role functioning 
Emotional functioning 
Social functioning 
Cognitive functioning 
 
75(54.2-83.3) 
89.2(80.0-93.3) 
100(70.9-100) 
91.7(68.8-97.9) 
100 (66.7-100) 
100 (83.3-100) 
 
62.5(50.7-66.7) 
66.7(58.3-81.7) 
50(33.3-83.3) 
83.3(66.7-91.7) 
83.3(66.7-100) 
83.3(79.2-100) 
 
 
41.7(33.3-66.7) 
60(46.7-83.4) 
33.3(16.7-66.7) 
83.3(54.2-91.7) 
66.7(33.3-83.3) 
100(83.3-100) 
 
33.3(16.7-43.8) 
40(26.7-66.7) 
16.7(0-50) 
66.7(41.7-83.3) 
33.3(0-50) 
66.7(50-100) 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
Symptom scale 
Fatigue 
Appetite loss 
Nausea and vomiting 
Pain 
Dyspnoea 
Insomnia 
Constipation 
Diarrhoea 
Financial impact 
 
16.65(2.8-30.5) 
0(0-0) 
0(0-0) 
0(0-16.7.7) 
33.3(0-33.3) 
16.65(0-33.3) 
0(0-0) 
0(0-0) 
0(0-0) 
 
 
33.3(22.2-47.2) 
0(0-0) 
0(0-0) 
0(0-16.7) 
66.7(33.3-66.7) 
33.3(0-50) 
0(0-33.3) 
0(0-0) 
0(0-33.3) 
 
44.4(33.3-61.5) 
33.3(0-50) 
16.6(0-33.3) 
0(0-16.7) 
66.7(33.3-100) 
33.3(0-66.7) 
0(0-16.7) 
0(0-33.3) 
0(0-0) 
 
77.8 (66.7-88.9) 
66.7(33.3-100) 
16.7(0-33.3) 
33.3(0-66.7) 
50(33.3-100) 
33.3(0-100) 
33.3(0-16.65) 
0(0-33.3) 
0(0-33.3) 
 
<0.001 
<0.001 
<0.001 
<0.001 
0.34 
0.001 
<0.001 
<0.03 
0.01 
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score 0-1 (p=0.02)] (Table 5.5).  Figure 5.2 shows patient survival stratified by PG-SGA 
score at baseline. 
 
Discussion 
Nutritional issues are prevalent and often not appreciated among patients with AL 
amyloidosis.
163
  BMI is relatively easy to calculate but its use in isolation has become 
relatively obsolete in the face of increasing global obesity.
178
  In this study <4% patients 
had a BMI <20 and there was no correlation between BMI and PG-SGA score.  Weight 
loss is another marker of malnutrition but it is subjective, often approximate and does 
not take into account the kinetics of that loss or presence of oedema or fluid retention.
179
  
Use of other objective parameters of nutritional status (anthropometric, biochemical and 
immunological) to assess nutritional state is also questionable since non-nutritional 
factors may affect these parameters.
180
   
The PG-SGA includes both subjective and objective assessments of symptoms 
as well as physical features suggestive of malnutrition, and is quick and easy to 
implement, making it attractive as a nutrition assessment tool.
181
  Symptoms impeding 
food intake such as appetite loss, nausea and early satiety, all of which affected patients 
in this study, are included in the assessment.  Since improvement in nutritional status is 
unlikely unless such symptoms can be reversed, PG-SGA data may well aid appropriate 
nutritional intervention in such patients. 
Several amyloid-related factors were associated with malnutrition among 
patients in this study including multisystem organ involvement.  Both abnormal alkaline 
phosphatase and Mayo stage were also independently associated with malnutrition 
suggesting a possible contribution from hepatic and cardiac amyloid (causing hepatic 
congestion from fluid overload) in the case of the former and cardiac and renal 
infiltration by amyloid in the case of the latter.  Hepatic AL amyloid infiltration, 
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Table 5.5  Factors at baseline associated with risk of death in AL amyloidosis patients. 
Characteristic Univariable Multivariable 
Hazard ratio (95% 
CI)  
P-value Hazard ratio (95% CI)  P-value 
PG-SGA    
0-1 
2-3 
4-8 
>9 
 
Ref 
4.47 (1.00, 20.03) 
8.13 (1.77, 37.32) 
8.77 (2.11, 36.49) 
 
 
 
0.05 
0.007 
0.003 
 
Ref 
3.34 (0.67, 16.72) 
6.17 (1.18, 32.42) 
6.37 (1.35, 30.15) 
 
 
0.14 
0.03 
0.02 
CKD stage 
4-5 versus 1-3 
 
1.33 (0.74, 2.37) 
 
0.35 
  
Mayo 
Stage 1 
Stage 2 
Stage 3 
 
Ref 
1.71 (0.63, 4.68) 
3.60 (1.42, 9.13) 
 
 
0.30 
0.007 
 
Ref 
0.94 (0.32, 2.75) 
1.66 (0.59, 4.68) 
 
 
0.91 
0.34 
ALP (IU/l) 
>129 versus <129 
 
1.04 (0.62, 1.73) 
 
0.89 
  
PNS 
 
1.13 (0.49, 2.62) 0.78   
ANS 
 
1.44 (0.75, 2.76) 0.28   
Number organs 
>3 versus 1-2 
 
 
1.81 (1.06, 3.07) 
 
0.03 
 
0.99 (0.54, 1.80) 
 
0.97 
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Figure 5.2  Kaplan-Meier estimates of survival from presentation according to 
PG-SGA score at presentation (p=0.001). 
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typically associated with a large amyloid burden, has previously been reported to cause 
weight loss.
35
  Cardiac cachexia is a well-known complication of heart failure from a 
variety of causes,
182
 and might be expected in association with an amyloid 
cardiomyopathy.
163
  It should be noted however that the specific causes of a raised 
alkaline phosphatase were not ascertained in this study.  These include potential 
contributions from a low vitamin D level and bone-derived alkaline phosphatase, as 
well as a raised alkaline phosphatase from a hepatic source.  Reduced dietary intake and 
renal disease may contribute to deficiencies of vitamin D and may be assessed via food 
diaries and assay of serum 25-hydroxyvitamin D, respectively.  Alkaline phosphatase 
isoenzyme analysis may help differentiate hepatic from bone-derived alkaline 
phosphatase.   
This study demonstrates a strong association between malnutrition and poor 
QOL among patients with AL amyloidosis.  This association was consistent across 
almost all individual parameters of the EORTC QLQ-C30, as well as the global QOL 
score.  An association between malnutrition and poor quality of life has previously been 
demonstrated for a wide range of malignant conditions
175,183
 as well as certain non-
malignant diseases.
184
 
The relationship between malnutrition and survival has been studied in 
malignant
185
 and non-malignant disease.
186
  Among patients with AL amyloidosis 
enrolled into this study, PG-SGA score at baseline was independently associated with 
survival.  Interestingly it was the only significant parameter in a multivariable model 
incorporating, amongst other parameters, the Mayo staging system, which has been well 
documented as a strong prognostic indicator in systemic AL amyloidosis.
112
  The 
dominance of cardiac amyloid, which the Mayo staging system is a measure of, and its 
impact on prognosis in AL amyloidosis is evident from data on patient deaths secondary 
to AL amyloidosis from the Italian amyloidosis centre (Pavia), of which 75% were 
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attributable to cardiac amyloid.
187
  One possible explanation for the potency of the PG-
SGA as a prognostic tool is that it might also take into account other factors not 
accounted for by the Mayo staging system.  Such factors might include autonomic 
neuropathy and hepatic amyloid, both of which are recognised as firstly causing weight 
loss
188
 and furthermore negatively impacting upon survival.
32,155
  They were each 
independently and significantly associated with higher PG-SGA scores in this study.   
The mechanisms of malnutrition in systemic diseases are poorly understood, but 
are likely to be multifactorial.  Abnormalities of carbohydrate, protein and lipid 
metabolism have been described in malnutrition and result in loss of lean body mass 
and fat.
189,190
  Increased energy expenditure secondary to hypermetabolism culminates 
in progressive wasting.
191
  In cancer patients, tumour-associated metabolic 
abnormalities frequently prevent restoration of muscle mass by nutritional provision.  
Malnutrition then evolves into a cancer-driven cachexia due to complex interactions 
between pro-inflammatory cytokines (e.g. interleukin-1, interleukin-6) and host 
metabolism.
192
  Several of the factors impeding food intake in the present study, such as 
nausea and early satiety could be the result of such metabolic changes.  Cancer therapies 
themselves can have a significant effect on nutritional indices via a number of 
mechanisms such as nausea, vomiting, anorexia and a hypercatabolic state.
193
  This 
depends upon the specific cytotoxic drug, dose, duration, and general health of the 
patient.  Furthermore, a poor nutritional state can affect pharmaco-kinetics of cytotoxic 
drugs, which exacerbates toxicity and reduces tumour response to drugs.
194
  Although 
these aspects were not formally evaluated in the present study, it is quite feasible that 
similar mechanisms contribute to progressive malnutrition in patients with AL 
amyloidosis.  Early diagnosis and intervention against malnutrition are therefore 
imperative.   
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The current study provides a platform upon which to base future studies of 
nutritional intervention in AL amyloidosis.  It would be useful to determine whether 
nutritional status affects tolerability and toxicity of treatment and hence treatment 
response.  Furthermore, whether malnutrition continues to impact on QOL after patients 
have completed chemotherapy for AL amyloidosis and whether nutritional intervention 
can result in improvement in QOL and survival needs to be studied.  The PG-SGA is 
potentially a good tool for examining this question since it provides a score which is a 
continuous variable unlike other nutritional assessment tools, which are often 
categorical.  On serial analysis therefore a change in PG-SGA score may demonstrate a 
subtle change in nutritional status, which may not be apparent on assessment with 
categorical tools.
177
 
 
Conclusion 
In summary, prospective use of the PG-SGA, in 110 newly-diagnosed unselected 
consecutive patients with AL amyloidosis showed a strong association between 
malnutrition and poor QOL and reduced overall survival.  The American Society of 
Oncology recommends that cancer treatments should be evaluated according to patient-
derived outcomes such as QOL rather than clinician-derived outcomes such as tumour 
and biomarker response rates.
195
  This study validates an assessment tool, with which to 
examine whether nutritional intervention in patients with AL amyloidosis influences the 
course of the disease or the toxicity and efficacy of therapy. 
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Chapter 6 
Renal AA amyloidosis associated with 
inflammatory bowel disease 
 
Introduction 
Systemic AA amyloidosis is the second commonest form of systemic amyloidosis in the 
developed world.  It may occur in association with any kind of chronic inflammatory 
condition of which inflammatory bowel disease (IBD) is one.  The amyloid precursor 
protein in AA amyloidosis is the N-terminal fragment of the acute phase reactant serum 
amyloid A protein (SAA), which is synthesised in the liver.   
The clinical phenotype and natural history of AA amyloidosis in IBD has largely 
been reported in case reports and small series.  The current study focuses on amyloid 
burden, organ dysfunction, disease progression and the relationship of these features to 
biochemical markers of inflammation.  There is a further detailed analysis of these 
features in a sub-group of patients who had renal transplants after reaching end-stage 
renal disease (ESRD). 
 
Methods 
The study included 26 patients followed prospectively at the NAC between 1989 and 
2010.  Diagnosis of AA amyloidosis was confirmed in 25 patients by histology and in 1 
patient by non-invasive means.  Inclusion criteria were amyloid deposition on SAP 
scintigraphy; evidence of chronic inflammation on the background of histologically 
confirmed inflammatory bowel disease; no mutations in the genes encoding 
transthyretin, fibrinogen A-α chain, apolipoprotein AI, apolipoprotein AII, and 
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lysozyme (to rule out hereditary forms of amyloidosis);
67
 a negative serum free light 
chain assay and negative serum and urine immunofixation to rule out AL 
amyloidosis.
27
.  A biopsy was performed if any of these criteria were not met. 
Patients attended the NAC for their initial diagnostic evaluation and were 
followed at regular (6 monthly to annual) intervals for evaluation of organ function and 
monitoring of whole body amyloid load by serial 
123
I-SAP scintigraphy.  Serial 
electrocardiography and echocardiography to evaluate for cardiac amyloid was also 
performed.  Blood samples for SAA and C-reactive protein (CRP) analyses were 
obtained at a frequency of 1-3 monthly between visits to assess levels of inflammation.  
Listing for renal transplantation (RTx) and transplant protocols in those patients who 
had reached ESRD was dependant on local transplant centre practice.  
 
Results 
 
Baseline characteristics of inflammatory bowel disease 
Baseline characteristics of IBD in the 26 patients are listed in Table 6.1.  Of these 
patients, 22 (14 male) had Crohn‟s disease (CD) and 4 (2 male) had ulcerative colitis 
(UC).  The median (range) age of onset of CD was 23 (9 - 62).  Fourteen of the patients 
with CD had a Crohn‟s colitis, 10 patients had ileal CD and 6 patients more extensive 
small intestinal disease.  Fifteen patients with CD had intestinal resections; nine had 
large intestinal resections, 4 had small intestinal resections and 2 had both.  Suppurative 
features occurred in 10 patients with CD – a fistula in 1 case, abscesses in 3 cases and a 
combination of the two in 5 cases.  Six of 8 patients with abscesses had perianal 
abscesses with one patient requiring a defunctioning colostomy for such.  The 4 patients 
with UC were diagnosed at the ages of 23, 33, 57 and 61.  They had no suppurative 
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Table 6.1(a)  Baseline characteristics of patients – IBD and systemic amyloidosis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 - I=ileum S=small intestine C-colonic; 
b
 – IA=intra-abdominal abscess PA=perianal abscess F=Fistulae; c – O=oxalate stones AS=ankylosing spondylitis 
G=gallstones A=IBD-related arthropathy EP=episcleritis EN=erythema nodosum I=iritis M=oral ulcers; 
d
 – A=azathioprine ASA=5-aminosalicylates 6-MP – 
6-Mercaptopurine S=steroids M=methotrexate T=anti-TNF α agents C=cyclosporine E=elemental diet U=unknown; e –S=spleen A=adrenal L=liver 
 
 
Patient 
 
 
Age at 
diagnosis of 
IBD/ 
CD or UC 
Site of 
IBD
a
 
Suppurative 
complications
b
 
Extra-intestinal 
complications
c
 
Surgical Treatment of IBD Medical 
Treatment 
of IBD
d
 
Age of 
diagnosis of 
amyloidosis 
SAP  
scintigraphy 
- Extra-renal 
amyloid
e
 
Dead (D) or 
Alive (A)/ Age at 
census or of 
death 
1  62/CD I IA O  U 67 S A/78 
2  33/CD I,C  AS  S, A, ASA 53 S D/55 
3  11/CD S,C F - Ileorectal  G Colectomy and ileostomy, small 
intestinal resections 
S, A, T 31 S/A A/36 
4  33/CD I  EP, G,A Right hemicolectomy S, A, T 61 S/A A/66 
5  53/CD I   Ileal resection S, A, ASA 70 S D/71 
6  47/CD C    S, ASA 63 S A/69 
7  16/CD C  EN Panproctocolectomy A 36 S/A A/47 
8  30/CD S,C   Panproctocolectomy U 44 S/A D/44 
9   19/CD S,I IA F – enteroenteric    Ileal resection U 37 S/A D/37 
10  21/CD S PA, F - perianal  Small intestinal resections S, A, T 54 S/A/L D/58 
11  12/CD C   Colectomy and ileorectal anastomosis A, ASA, T 29 S/A A/33 
12  54/CD S,C    S, A 54 S/A A/56 
13  24/CD C PA, F - perianal  Panproctocolectomy S, A 34 S A/38 
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Table 6.1(b)  Baseline characteristics of patients – IBD and systemic amyloidosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
a
 - I=ileum S=small intestine C-colonic; 
b
 – IA=intra-abdominal abscess PA=perianal abscess F=Fistulae; c – O=oxalate stones AS=ankylosing spondylitis 
G=gallstones A=IBD-related arthropathy EP=episcleritis EN=erythema nodosum I=iritis M=mouth ulcers; 
d
 – A=azathioprine ASA=5-aminosalicylates 6-MP – 
6-Mercaptopurine S=steroids M=methotrexate  T=anti-TNF α agents C=cyclosporine E=elemental diet U=unknown; e –S=spleen A=adrenal L=liver 
 
Patient 
 
Age at 
diagnosis of 
IBD/CD or UC 
Site of 
IBD
a
 
Suppurative 
complications
b 
Extra-
intestinal 
complications
c
 
Surgical Treatment of IBD Medical 
Treatment of 
IBD
d
 
Age of 
diagnosis of 
amyloidosis 
SAP 
Scintigraphy – 
extra-renal 
amyloid
e
 
Dead (D) or 
Alive (A)/ Age 
at census or 
of death 
14  22/CD C  I,AS  S, ASA 29 S/A D/30 
15 12/CD I PA   S, T 25 S/A A/28 
16 30/CD C PA M Defunctioning colostomy A, 6-MP, T 50 S A/50 
17  24/CD I  AS Small intestinal resections S, A, ASA, M 36 S A/48 
18 18/CD S,C PA, F - perianal G Panproctocolectomy and ileostomy, Small 
intestinal resections 
U 38 S A/49 
19  18/CD I,C PA, F - perianal EN Right hemicolectomy , sigmoid colostomy S, A, C 34 S/A A/47 
20 9/CD I,C  EN Right hemicolectomy S, A, E 32 S/A A/57 
21  24/CD C   Panproctocolectomy and ileostomy ASA 25 S A/60 
22 15/CD I  EN,M  S, ASA 22 S/L D/39 
23 61/UC C  AS  S 77 S D/78 
24 57/UC C   Panproctocolectomy - 64 S D/67 
25 23/UC C    S,ASA 26 S A/33 
26 33/UC C  AS  S, ASA 63 S/L A/70 
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features and only one of them (Patient 24; Table 6.1) needed surgical intervention.  She 
had a panproctocolectomy. 
Extra-intestinal manifestations of IBD occurred in 11 of the 22 patients with CD.  
Ocular complications (iritis, uveitis and episcleritis) occurred in 3 cases, erythema 
nodosum in 4 cases and oral apthous ulceration in 2 cases.  In 4 patients with small 
intestinal disease there was evidence of gallstone disease (3 cases) and renal oxalate 
stones (1 case).  Ankylosing spondylitis occurred in 3 patients and another 2 had a 
peripheral arthropathy attributed to CD.  The only extra-intestinal manifestations in the 
4 patients with UC was ankylosing spondylitis in 2 cases.  
 
Baseline characteristics of systemic amyloidosis 
In all cases the diagnosis of IBD pre-dated the diagnosis of systemic amyloidosis.  The 
histological diagnosis of amyloid was made from renal biopsies in 23 cases, an 
appendicectomy specimen in 1 case and an intestinal resection specimen in 1 case.  
Immunohistochemistry with anti-SAA antibodies was positive in all cases (Figure 6.1).  
Only 1 patient (Patient 2; Table 6.1) did not have a histological diagnosis of amyloid 
but she had unequivocal renal and splenic amyloid on her SAP scan typical of AA 
amyloidosis, proteinuric renal dysfunction, a background of chronic inflammation 
associated with CD, no evidence of a plasma cell dyscrasia and no genetic mutations 
recognised in causing any of the known forms of hereditary systemic amyloidosis.   
The median (range) time from diagnosis of CD to diagnosis of systemic 
amyloidosis was 16.3 years (0.3-33.2).  In the 4 patients with UC the time from 
diagnosis of UC to diagnosis of systemic amyloidosis was 3.1, 7.0, 16.0 and 29.9 years.  
All of the patients in the current series had impaired renal function and/or evidence of 
proteinuria at the time of diagnosis.  This was the presenting clinical feature in all 
except Patient 16, who was referred by a cardiologist because he had echocardiographic  
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Figure 6.1  Renal biopsy (glomerulus) with AA amyloid deposition - with positive 
Congo-red uptake (top), red-green birefringence when the same section is viewed 
under cross-polarised light (middle) and immunohistochemical staining with a 
monoclonal antibody confirming the presence of serum amyloid A protein within 
the deposits (bottom). 
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features of cardiac amyloid when he was investigated for non-specific chest pain.  At 
the time of his diagnosis he had SAP scintigraphic evidence of renal and splenic 
amyloid, proteinuric renal dysfunction, AA-type amyloid on a renal biopsy and neither 
evidence of a clonal disorder nor possession of a genetic mutation that might encode for 
a hereditary form of amyloidosis.  Ten patients had already reached ESRD requiring 
renal replacement therapy prior to their first review at the NAC, 3 of whom had already 
undergone RTx. 
In addition to renal amyloid there was evidence of splenic amyloid in all patients 
on SAP scintigraphy at their baseline visits (Figure 6.2).  In 3 patients there was also 
evidence of hepatic amyloid on SAP scintigraphy.  These patients did not have 
hepatomegaly and had normal liver synthetic function.  Thirteen patients had evidence 
of adrenal amyloid on SAP scintigraphy.  Two of these patients had Addison‟s disease 
but of note both had had long-term prior steroid use.  One further patient, who had taken 
prolonged steroid courses, also had Addison‟s disease but he did not have adrenal 
amyloid on SAP scintigraphy. 
 
Clinical course of systemic amyloidosis 
The cohort of 26 patients, which included 6 patients with CD who had RTx, were 
followed for a median (range) time of 4.1 (0-20.0) years.  In 5 patients, who did not 
require RTx (Patients 4, 7, 11, 13 and 26; Table 6.1) there was improvement in 
proteinuric renal dysfunction with complete resolution of nephrotic-range proteinuria 
over 5.6, 9.0, 3.5, 4.3 and 6.6 years respectively.  They had median serial SAA values of 
12, 3, 5, 10 and 7 mg/l and median CRP values of 2, 2, 2, 5 and 5 mg/l respectively 
during these periods.  In keeping with their normal or very mildly elevated 
inflammatory markers they had well-controlled symptoms of IBD.   
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Figure 6.2  Serial anterior whole body SAP scintigraphy of Patient 22 after renal 
transplantation - hepatic and splenic amyloid with no evidence of renal graft 
amyloid in the left iliac fossa 6.9 years after transplantation (left) and progression 
of hepatic amyloid and development of graft amyloid 8.1 years after 
transplantation (right). 
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All of the other 21 patients had evidence of progressive renal dysfunction and/or 
progressive proteinuria.  During follow-up in addition to the 10 patients, who presented 
to the NAC after having reached ESRD there were 5 further patients who progressed to 
ESRD during follow-up.  The median time from proteinuric renal dysfunction to ESRD 
by Kaplan – Meier estimate in the entire cohort was 6.3 years.  The median (range) rate 
of renal decline in the entire cohort was eGFR loss -9 (-294 to +7) ml/min/year.  Five 
patients (Patients 3, 12, 15, 17 and 19; Table 6.1), who had progressive renal 
dysfunction had serial blood tests over >6 months (median (range) period of 62.4 (8.2-
155.3) months) to assess inflammation prior to ESRD or RTx.  Their median SAA 
values were 46, 16, 25, 18 and 26 mg/l respectively and their median CRP values were 
25, 8, 6, 1 and 13 mg/l respectively during the respective periods.  The potential lack of 
correlation between SAA and CRP is particularly apparent in the case of Patient 17 in 
whom serial CRP values were consistently 1 mg/l despite consistently elevated SAA 
levels.  
Five patients (Patients 11, 12, 13, 18 and 24; Table 6.1) had 
hypotensive/hypovolaemic episodes which precipitated rapidly progressive renal 
dysfunction.  Patients 12, 18 and 24 rapidly progressed to ESRD after developing sepsis 
requiring hospitalisation.  Patient 12 had normal renal function despite proteinuria prior 
to hospital admission.  Patients 11 and 13 were diagnosed with renal amyloid after a 
significant and acute deterioration in renal function from a baseline of mild renal 
dysfunction, after surgery for their IBD.  Subsequent tight inflammatory control in both 
cases resulted in resolution of proteinuria.   
There was no evidence of a peripheral or autonomic neuropathy in any patient 
during follow-up.  Patient 16 was the only patient who had echocardiographic evidence 
of cardiac amyloid during follow-up. 
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Outcomes of renal transplantation 
Six patients had RTx after reaching ESRD (Table 6.2).  Four patients had 
deceased-donor transplants and 2 patients had live-related transplants.  The median 
(range) time from ESRD to RTx in this group of patients was 1.7 (0.2 – 7.8) years.  
Four grafts (Patients 17, 18, 19 and 20; Table 6.2) were functioning at census 0.8, 3.2, 
4.2 and 20.1 years after RTx.  There was no evidence of amyloid recurrence in these 
grafts on serial SAP scans over the course of 0.8, 2.5, 3.2 and 19.5 years after RTx, 
respectively.  Furthermore there was no evidence of proteinuric renal dysfunction in any 
of these patients during follow-up.  One graft (Patient 22; Table 6.2) failed 14.5 years 
after RTx with evidence of amyloid recurrence in the graft on SAP scintigraphy more 
than 6 years before graft failure.  Another patient (Patient 21; Table 6.2), whose graft 
had survived 24.6 years, was being considered for a pre-emptive second live-related 
renal transplant, as he was approaching ESRD at census.  There had been neither 
evidence of recurrent graft amyloid on his serial SAP scans nor evidence of significant 
proteinuria after RTx to suggest ongoing amyloid deposition in the graft.  His 
progressive renal dysfunction was attributed to recurrent urolithiasis. 
The median serial SAA and CRP values after RTx in the 6 transplant recipients 
are outlined in Table 6.2.  In 4 patients (Patients 18, 19, 20 and 21; Table 6.2) the 
median SAA and CRP values during follow-up, which of note was more than 20 years 
in Patients 20 and 21, were in single figures and there was no evidence of graft amyloid 
recurrence in any of their grafts.  In the 2 other patients (Patients 17 and 22; Table 6.2) 
the median serial SAA values after RTx were 19 mg/l and 40 mg/l respectively and the 
median serial CRP values were 8.5 mg/l and 5 mg/l respectively.  The potential 
discrepancy in the levels of these 2 acute phase reactants is again highlighted here.  The 
former patient‟s graft had no evidence of amyloid recurrence at census but he had only
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Table 6.2  Characteristics of patients with AA amyloidosis secondary to CD who had RTx. 
 
 
 
Patient Time from 
ESRD to RTx 
(yrs) 
Type 
of 
graft
a
 
Median 
SAA/CRP 
(mg/l) after 
RTx 
Recurrence of graft amyloid on 
SAP scan
b
/ Time of recurrence 
after RTx (yrs) or time of last 
SAP scan with no evidence of 
recurrence after RTx (yrs) 
Graft failure
c
/ Time 
from RTx to graft 
failure or census 
(yrs) 
Dead (D) or Alive 
(A)/ 
Time from RTx to 
census or death 
(yrs) 
17 2.5 L 40/5 N/0.8 N/0.8 A/0.8 
18 7.3 D 4.5/1.5 N/2.5 N/3.2 A/3.2 
19 7.8 D 3/3 N/3.2 N/4.2 A/4.2 
20 0.2 L 7/2 N/19.5 N/20.1 A/20.1 
21 1 D 5/3 N/22.2 N/24.6 A/24.6 
22 0.3 D 19/8.5 Y/8.1 Y/14.5 D/16.1 
 
a – L=live-related graft  D=deceased donor graft; b and c – Y=yes  N=no 
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been followed for 0.8 years after RTx and the latter‟s graft failed because of recurrent 
amyloid 14.5 years after RTx.   
 
Survival 
During follow-up, which was over a median (range) period of 4.1 (0-20) years, 9 
patients in the cohort died at a median (range) age of 55 (30-75).  The median survival 
by Kaplan-Meier estimate from diagnosis of amyloid was 16.9 years.  Two patients, 
both of whom required renal replacement therapy, died from myocardial infarction, 2 
died from pneumonia, 1 from intestinal perforation and peritonitis and 1 
post-operatively after cardiac valve replacement.  In the 3 remaining cases the causes of 
death were not known.   
 
Discussion 
The association between IBD and amyloidosis was first described in 1936.
196
  It has 
evolved from a post-mortem diagnosis
197
 into a pre-mortem diagnosis.
198
  This is 
probably due to an increased appreciation of this association together with 
improvements in diagnostic techniques for amyloid including better histological 
diagnosis with immunohistochemistry and SAP scintigraphy.
199
 
There have been several studies estimating the incidence of systemic 
amyloidosis associated with IBD.  In the USA this incidence has been estimated as 
0.9% in CD and 0.07% in UC.
200
  In Northern Europe the incidence of systemic 
amyloidosis secondary to CD has been estimated as 0.8% with a ten-fold increase in 
risk compared to UC.
201
  These incidence studies, which are more than a decade old, 
may not be relevant to the present day.  Results from one epidemiological study of CD 
from Leiden University Hospital suggested that the incidence of amyloidosis secondary 
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to CD is falling.
202
  This could in part be because of improved treatments, especially 
with the addition of biologic therapies to the treatment armamentarium.   
The current study is not a study of incidence but there is a very obvious 
discrepancy in the number of referrals of patients with CD compared to UC to the only 
amyloidosis centre in the UK, which corroborates the results from other studies.
200,201
  
One possible explanation for this is the larger acute phase response seen in CD 
compared to UC,
203
 which may be explained by the higher prevalence of suppurative 
features in the former.  In the current study 10 of 23 patients had fistulae and/or 
abscesses.  Fifteen of 22 cases of CD in the study of Greenstein et al.
200
 and 13 of 18 
cases in the study of Wester et al.
201
 also had similar features.  Another possible 
explanation for the apparent discrepancy in risk of development of amyloidosis between 
CD and UC is that whereas surgery can be a definitive treatment in UC by completely 
removing the inflammatory source, as in Patient 24 who had complete resolution of 
nephrotic-range proteinuria after panproctocolectomy, in CD as the entirety of the 
gastrointestinal tract can be affected surgery may not be as efficacious in reducing 
inflammation.  It is also worth highlighting that the extra-intestinal manifestations of 
IBD in isolation can provide a significant inflammatory stimulus.  Ankylosing 
spondylitis, for example, which occurred in two of the patients with UC, is recognised 
in its own right as causing AA amyloidosis.
204
 
The fact that all patients in the current cohort had proteinuric renal dysfunction 
highlights the fact that AA amyloidosis is a disease of the kidneys.  It should be noted 
however that there are a number of other potential causes of renal dysfunction in 
patients with IBD.  These include interstitial nephritis secondary to 5-aminosalicylates, 
glomerulonephritis, renal oxalate stones and proximal tubular defects.
205
  Furthermore 
those patients with severe IBD are at risk of sepsis and surgery, both of which may 
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result in hypotensive episodes and hence precipitate acute tubular necrosis, which can 
contribute to chronic renal impairment.   
Hepatic amyloid was evident in 3 patients on SAP scintigraphy in the current 
series but was of no clinical significance with respect to liver synthetic function.  
Hepatic amyloid in the context of AA amyloidosis in a SAP scintigraphic study at the 
NAC was found to confer a reduced survival risk.
42
  Two of the 3 cases with hepatic 
amyloid in the current series died, 4 and 17 years after diagnosis of amyloid.  It is 
probably indicative of a large amyloid burden in the setting of AA amyloidosis.  Only 
one patient in the current study had echocardiographic features of cardiac amyloid.  He 
was awaiting an endomyocardial biopsy at census.  This feature is unusual in the 
context of AA amyloidosis.  At the NAC only 2 of 374 patients with AA amyloidosis 
followed over 15 years till 2005 had echocardiographic evidence of cardiac amyloid.
39
  
The current series highlights the benefits of good inflammatory control in 
systemic AA amyloidosis associated with IBD.  There is evidence that if serial SAA 
values are maintained below 10 mg/l in inflammatory conditions causing AA 
amyloidosis then one can achieve amyloid regression and improvement of amyloidotic 
organ function and improved survival.
41
  This is highlighted in those patients in the 
current series in whom complete resolution of proteinuria was achieved when median 
SAA values were mainatined ≤12 mg/l during follow-up.  The case of Patient 17 
highlights the importance of monitoring serial SAA levels rather than CRP levels in 
patients with IBD and systemic AA amyloidosis.  His CRP levels were consistently 
1mg/l during follow-up, which in isolation could give the sense of good inflammatory 
control.  His serial SAA levels (median value 18mg/l) were however disproportionately 
high, indicative of ongoing inflammation, and as a result he had progressive renal 
dysfunction secondary to ongoing amyloid deposition, which culminated in ESRD. 
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The benefits of inflammatory control in terms of improvement of amyloidotic 
organ dysfunction are not dependant on type of medical treatment administered or 
whether surgical resection of the inflammatory source is pursued but on how efficacious 
a given intervention is in reducing SAA levels.  In this series however those patients in 
whom complete resolution of proteinuria was achieved had significant lengths of 
diseased intestine resected, resulting in reduction of inflammation.  Fifteen of 22 
patients with CD (68%) had some form of intestinal surgery in this series.  This 
percentage, although of a small number of patients, is more than the 43% from one 
epidemiological study of CD from Wales over a similar time period.
206
  Intestinal 
surgery in CD is warranted with severe disease and hence is probably a surrogate 
marker of inflammatory risk and the risk of developing amyloidosis.  It is worth 
highlighting that this series spans more than 20 years.  Treatments have changed over 
this time period including availability and use of biologic therapy, which has 
revolutionised treatment of IBD.  Furthermore, some drugs such as 5-aminosalicylates, 
which were used as the mainstay of treatment in some of the patients with CD in this 
series are now considered to be less effective as anti-inflammatory drugs in CD 
compared to UC.
207
   
A feature of amyloidotic kidneys, which was apparent in this cohort is the risk of 
decompensation in the face of sepsis, hypotension or other physiological stresses.  This 
phenomenon occurred in 5 cases, three of whom had surgery prior to acute deterioration 
of renal function and three of whom progressed rapidly to ESRD.  This risk would give 
further weight to careful evaluation for proteinuric renal dysfunction with regular urine 
dipstick analysis in patients with IBD and ongoing inflammation.  A positive dipstick 
should prompt investigation for systemic AA amyloidosis.  If systemic amyloidosis is 
confirmed there should be tight control of inflammation guided by serial SAA values, 
aggressive treatment of sepsis and careful hydration during and after surgery. 
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The graft and patient survival in all patients who had RTx after reaching ESRD 
in the current series was excellent and appears quite comparable to RTx in other renal 
diseases (http://www.uktransplant.org.uk).  There was only 1 graft failure, 14.5 years 
after RTx in Patient 22, who was also the only patient in the transplanted group to die 
during follow-up, 16.1 years after RTx.  His graft failed because of ongoing 
inflammation and recurrent graft amyloid, interestingly with a time lag of more than 6 
years between SAP scintigraphic evidence of recurrent graft amyloid and subsequent 
graft failure.  During follow-up, like Patient 17, he had disproportionately high serial 
SAA levels when compared to serial CRP levels.  It would appear feasible to 
recommend RTx in selected patients with IBD who have reached ESRD secondary to 
AA amyloidosis.  There should be tight control of inflammation, as assessed by serial 
SAA levels, in tandem with planning for RTx and this should be maintained after RTx.   
 
Conclusion 
Systemic AA amyloidosis occurs more commonly in CD than UC.  This may be 
explained by the more pronounced acute phase response seen in CD, which may in turn 
be related to a higher prevalence of suppurative features in CD.  AA amyloidosis in the 
context of IBD is a disease of the kidneys characterised by progressive proteinuric renal 
dysfunction.  In those with well-controlled inflammation, guided by serial SAA levels 
rather than CRP levels, one may see amyloid regression and improvement of organ 
function.  Amyloidotic kidneys are sensitive to physiological stresses.  Therefore 
aggressive treatment of sepsis or hypotension in those with confirmed amyloid is 
imperative.  In those who progress to ESRD and have RTx both graft and patient 
survival are good.  To prevent graft amyloid recurrence it is important that there is tight 
inflammatory control, again guided by serial SAA values. 
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Chapter 7 
Solid organ transplantation in AL amyloidosis 
 
Introduction 
Systemic AL amyloidosis may present with dysfunction of a single organ or 
alternatively there may be amyloid deposition and dysfunction of multiple organ 
systems concomitantly.  Deposition of amyloid in the kidneys presents with varying 
degrees of proteinuric chronic kidney disease (CKD) and may lead to end-stage renal 
disease (ESRD).  AL amyloid deposits in the heart typically cause a restrictive 
cardiomyopathy and diastolic dysfunction.  Once CHF has supervened in AL 
amyloidosis, prognosis is poor with a median survival of 4-6 months.
28
  Hepatic AL 
amyloid can present indolently with hepatomegaly or deranged liver function tests or 
occasionally with liver failure or hepatic rupture,
208
 and is usually associated with 
presence of extensive extra-hepatic deposits.
42
  Hyperbilirubinaemia in the context of 
hepatic AL amyloid confers a particularly poor prognosis of <4 months.
35
  
Despite considerable advances in chemotherapy in recent years leading to 
improved median survival times,
187
 a significant proportion of patients have advanced, 
unsalvageable organ dysfunction by the time they are diagnosed with systemic AL 
amyloidosis, and the majority of patients continue to die from their disease.  
Furthermore, patients with advanced cardiac and hepatic involvement are usually too 
unwell at presentation to tolerate the doses of chemotherapy that are required to 
successfully suppress their underlying clonal disease. 
The role of solid organ transplantation in AL amyloidosis is contentious due to 
shortage of donor organs.  Previous small series have shown inferior outcomes with 
heart
209
 and kidney transplantation among patients with AL amyloidosis compared to 
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those with other causes of cardiac and renal failure, respectively.  Deaths have been 
associated with both recurrence of amyloid in the graft or progressive deposition of 
amyloid in non-transplanted organs.  This study presents the clinical management and 
outcome in 45 patients with AL amyloidosis over a 25 year period, who were selected 
to receive solid organ transplants, and highlights in particular, the disease-related and 
treatment-related factors that are likely to influence outcome with solid organ 
transplantation during the modern era of effective chemotherapy.   
 
Methods 
All patients who underwent renal, cardiac or liver transplantation for organ failure 
secondary to AL amyloidosis between 1984 and 2009 were identified from the UK 
National Amyloidosis Centre (NAC) database.  Only patients without multiple myeloma 
underlying their AL amyloidosis received solid organ transplants.  Additionally, 
selection criteria for renal and cardiac transplantation included absence of extensive 
disease outside the failing organ.  A good ECOG performance status was required for 
renal transplantation in contrast to cardiac transplantation, where performance status 
prior to the procedure was poor.  Patients who underwent orthotopic liver 
transplantation were those with a poor prognosis due to extensive liver amyloid 
associated with clinical decompensation.  Among patients with systemic AL 
amyloidosis followed at the NAC during the 25 year period, the 45 patients presented 
here were not the only cases who fulfilled the above criteria; listing for solid organ 
transplantation was also dependent upon attitudes to transplantation in AL amyloidosis 
within each transplant centre, which varied substantially.   
The diagnosis of amyloidosis was confirmed histologically in all cases.  Among 
cases where amyloid was confirmed histologically but immunohistochemical staining 
with antibodies against all known amyloid fibril proteins excluded AA amyloidosis but 
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was non-diagnostic of AL type, the following criteria were required for inclusion; 
evidence of a clonal B cell dyscrasia; absence of amyloidogenic mutations in the genes 
encoding transthyretin, fibrinogen A α-chain, apolipoprotein AI, apolipoprotein AII and 
lysozyme (to rule out hereditary forms of amyloidosis);
67
 absence of a chronic 
inflammatory disorder.  
Assessment at the baseline NAC visit, repeated 6 to 12 monthly, included 
clinical evaluation, detailed biochemical tests of renal and hepatic function, serum and 
urine immunoelectrophoresis, electrocardiographic and echocardiographic studies.  
Serial whole body anterior and posterior scintigraphic imaging was undertaken to 
establish baseline and change in whole body amyloid load, as previously described.  
Organ involvement by amyloid was determined according to international consensus 
criteria.
114
  Baseline haematological investigations included bone marrow aspirate, 
trephine and skeletal survey.  Serum free light chains (FLCs) were prospectively 
followed at 1-3 monthly intervals in all patients after January 2002 and, prior to this 
date, were measured retrospectively from stored sera obtained during all visits to the 
NAC.  A complete clonal response (CR) following chemotherapy was defined as no 
evidence of a monoclonal protein on serum and urine immunoelectrophoresis and 
normalisation of the FLCs in the context of normal renal function or normalisation of 
the FLC ratio in the context of renal impairment.  No response (NR) was defined as a 
reduction of less than 50% of the serum paraprotein or the amyloidogenic FLC.  A 
partial hematologic response (PR) following chemotherapy was defined as any response 
not fulfilling the criteria for CR or NR.  
Pre-operative transplant assessments and post-operative immunosuppression 
regimens were according to local protocols in each case.  Different regimens of 
chemotherapy and/or stem cell transplantation were administered at different times in 
relation to solid organ transplantation in each of the patient groups.   
117 
 
Results 
 
Liver transplantation 
Nine patients, all of whom had a dominant hepatic presentation of amyloidosis, received 
orthotopic liver transplantation (OLT) for systemic AL amyloidosis (Table 7.1).  Three 
cases had underlying lambda light chain secreting plasma cell dyscrasias and 6 had an 
amyloidogenic kappa secreting clone.  Median (range) age at diagnosis of amyloidosis 
was 56 (range 29-66) years and median (range) time from symptom onset to diagnosis 
of amyloidosis was 2.3 (0-10.6) months.  Median (range) time from diagnosis to OLT 
was 5.5 (1.5-10.5) months.  Pre-OLT SAP scintigraphy revealed a large total body 
amyloid load in all cases.  Patients were followed for a median (range) of 0.9 
(0-12.5) years from OLT.  
One and 5-year patient survival from transplantation among those receiving 
OLT was 33% and 22% respectively.  Causes of death among the six patients who died 
within the first year were as follows: intraoperative death due to cardiac 
decompensation (1 case), sepsis (3 cases), sudden unexplained death (1 case) and 
declining renal function (1 case). 
Three patients (5, 7 and 9; Table 7.1) were too unwell to receive chemotherapy 
at any point during the course of their illness and died within 5 months of OLT.  The 
remaining 6 patients received chemotherapy, including stem cell transplantation after 
OLT in 3 cases (Patients 1, 2 and 8; Table 7.1).  Two patients without extra-hepatic 
organ dysfunction at the time of OLT, both of whom subsequently underwent and 
responded to stem cell transplantation (Patients 1 and 2), were alive at census 12.5 and 
5.7 years after OLT without evidence of graft failure despite asymptomatic recurrence 
of liver amyloid.  Among the 4 remaining cases to receive chemotherapy, 3 died within 
2 years of OLT despite achieving a clonal
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Table 7.1  Characteristics and outcome among 9 patients with systemic AL amyloidosis who underwent liver transplantation 
 
Patient 
No/ 
a
Sex
 
Age at 
symptom 
onset 
b
Extra-hepatic 
organ 
involvement  
at presentation 
by consensus 
criteria 
Time 
from 
diagnosis 
of 
amyloid 
to OLT 
(months) 
 
c
Treatment 
pre-OLT/ 
treatment 
post-OLT 
d
Clonal 
response to 
treatment 
Timing 
of clonal 
response 
relative 
to OLT 
(months) 
Clonal 
relapse 
after 
treatment 
(Yes/No) 
Recurrence 
of graft 
amyloid by 
SAP 
scintigraphy 
Timing of 
amyloid 
recurrence or 
last SAP scan 
after OLT with 
no evidence of 
recurrence 
(months) 
e
Dead / 
Alive 
Time 
from 
OLT to 
census 
or death 
(years) 
1 (M) 
2 (M) 
3 (M) 
4 (M) 
5 (M) 
6 (F) 
7 (F) 
8 (F) 
9 (F) 
54 
44 
61 
31 
66 
63 
56 
29 
60 
N 
N 
N 
N 
K,H,A 
K,H 
H 
N 
G 
6 
9 
5 
6 
2 
8 
1 
10 
2 
N/S 
N/C+S 
C/C 
C/N 
N/N 
N/C 
N/N 
C/S 
N/N 
CR 
PR 
PR 
NR 
N/A 
CR 
N/A 
PR 
N/A 
+60 
+17 
+10 
- 
- 
+24 
- 
-4 
- 
N 
N 
N 
- 
- 
N 
- 
N 
- 
Y 
Y 
Y 
N 
N 
N 
- 
- 
- 
31 
7 
10 
11 
3 
24 
- 
- 
- 
A 
A 
D 
D 
D 
D 
D 
D 
D 
12.5 
5.7 
0.9 
0.9 
0.4 
2 
0 
0.4 
0.3 
 
a
 - M=Male F=Female  
b 
- N=None, K=Kidneys, H=Heart, A=Autonomic nervous system, G=Gastrointestinal tract 
c
 - N=None, C=Chemotherapy, S=Stem cell transplantation 
d
 - NR=No response, PR=Partial response, CR = Complete Response, N/A = Not applicable 
  
e
 - A=alive, D=dead 
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response with chemotherapy (Patients 3, 6 and 8).  The remaining case who did not 
achieve a clonal response to chemotherapy (Patient 4) died 0.9 years after OLT. 
Four patients (Patients 1 to 4) developed rapidly progressive proteinuria 
following OLT associated with pre-existing renal amyloid deposits.  Interestingly, this 
occurred even in patients 1 and 2, despite good clonal responses to chemotherapy.  
Patient 1, who had a clonal CR with stem cell transplantation, underwent cadaveric 
renal transplantation 9.4 years after OLT.  His CKD had been thought to be 
multifactorial from amyloid, hypertension and immunosuppression.  There was no 
evidence of recurrent renal amyloid in the graft by SAP scintigraphy 2.5 years after 
renal transplantation, despite deterioration of renal allograft function to an eGFR of 
29 ml/min at the time of census.   
 
Renal transplantation 
Twenty-two patients, all of whom presented with renal dysfunction, received renal 
transplants (19 deceased donor and 3 live donor) after reaching end-stage renal failure 
secondary to AL amyloidosis (Table 7.2).  Twelve patients had an underlying lambda 
light chain secreting plasma cell dyscrasia and 10 had an amyloidogenic kappa clone.  
Median (range) age at diagnosis of amyloid was 54 (41-68) years and median (range) 
time from symptom onset to diagnosis was 5.8 (0-58.2) months.  Median (range) time 
from diagnosis to renal transplantation was 55.0 (12.3-204.6) months and from 
commencement of dialysis to renal transplantation was 26.7 (0.8-98.3) months.  Median 
(range) follow-up from renal transplantation was 4.8 (0.2-13.3) years. Only 3/22 
patients had amyloidotic extra-renal organ dysfunction at the time of renal 
transplantation; of the liver (Patient 4; Table 7.2), heart (Patient 17) and nerves (Patient 
21) in one case each.  Seventeen of 22 patients had SAP scintigraphy before renal
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Table 7.2(a)  Characteristics and outcome among 22 patients with systemic AL amyloidosis who underwent renal transplantation. 
 
a
 - M= male F= female;  
b
 - N=none L=liver H=heart P=peripheral neuropathy A=autonomic neuropathy; 
c
- N=none S=stem cell transplantation 
C=chemotherapy; 
d
 - NA=not applicable NR=no response PR=partial response CR=complete response; 
e
- Y=yes N=no NA=not applicable; 
f
 - Y=yes N=no 
 
 
Patient 
No / 
a
Sex 
Age at 
symptom 
onset 
b
Extra-renal 
organ 
involvement 
at RTx 
Time from 
diagnosis of 
amyloid to 
RTx 
(months) 
c
Chemotherapy 
treatment 
pre-RTx / 
post-RTx 
d
Clonal 
response 
to 
treatment 
Timing of 
clonal 
response 
relative 
to RTx 
(months) 
e
Clonal relapse 
after initial (1
st
 
line) 
chemotherapy 
Timing of 
clonal 
relapse 
relative to 
RTx 
(months) 
f
Graft 
failure / 
time from 
RTx to 
failure 
(years) 
Dead 
(D) 
/ Alive 
(A) 
Time 
from RTx 
to 
census 
or death 
(years) 
 1 (F) 40 N 84 S/N CR -75 N  N A 4.7 
 2 (M) 56 N 52 C+S/N PR -42 N  N A 2 
 3 (F) 41 L 68 C/C PR -63 Y -9 N A 7.6 
 4 (F) 62 N 12 N/C NA  NA  N D 5.8 
 5 (F) 50 N 39 C/C NA  NA  Y/13.1 D 13.3 
 6 (F) 46 N 55 C/N PR -42 N  N A 6.3 
 7 (F) 61 N 66 N/C PR 79 N  N D 7.5 
 8 (M) 57 N 32 C+S/N PR -24 Y 50 N A 5.3 
 9 (F) 51 N 57 C+S/N CR -50 N  N A 7.5 
10 (M) 57 N 55 C/N PR -44 N  N D 0.2 
11 (F) 60 N 115 C/N CR -85 Y 28 N A 2.7 
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Table 7.2(b)  Characteristics and outcome among 22 patients with systemic AL amyloidosis who underwent renal transplantation. 
 
 
 
 
 
 
 
 
 
 
 
 
a
 - M= male F= female;  
b
 - N=none L=liver H=heart P=peripheral neuropathy A=autonomic neuropathy; 
c
- N=none S=stem cell transplantation C=chemotherapy; 
d
 - NA=not applicable NR=no response PR=partial response CR=complete response; 
e
- Y=yes N=no NA=not applicable; 
f
 - Y=yes N=no 
Patient 
No / 
a
Sex 
Age at 
symptom 
onset 
b
Extra-renal 
organ 
involvement 
at RTx 
Time from 
diagnosis 
of amyloid 
to RTx 
(months) 
c
Chemotherapy 
treatment 
pre-RTx / 
post-RTx 
d
Clonal 
response 
to 
treatment 
Timing of 
clonal 
response 
relative 
to RTx 
(months) 
e
Clonal 
relapse after 
initial (1
st
 line) 
chemotherapy 
Timing of 
clonal 
relapse 
relative to 
RTx 
(months) 
f
Graft 
failure / 
time from 
RTx to 
failure 
(years) 
Dead 
(D) 
/ Alive 
(A) 
Time 
from RTx 
to 
census 
or death 
(years) 
12 (M) 49 N 30 C/C NA  NA  N D 6.5 
13 (M) 45 N 160 C/N PR -138 N  N A 3.9 
14 (M) 54 N 66 C/N PR -48 N  N A 4.7 
15 (F) 43 N 204 C/C NA  NA  N D 5.3 
16 (F) 66 N 28 C/N NR  NR  N D 4.8 
17 (F) 65 H 61 N/N NA  NA  N D 1.9 
18 (F) 53 N 62 C/C NA  NA  N A 9.8 
19 (F) 58 N 48 C+S/N PR -30 N  N D 1.3 
20 (F) 41 N 123 C/N NA  NA  Y / 0.9 D 2.8 
21 (M) 45 P, A 32 C/C PR -25 Y 3 N A 1.3 
22 (M) 63 N 51 C/C PR -45 N  N A 0.5 
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transplantation with extra-renal amyloid deposits evident by this technique in all but one 
such case.  
There were no perioperative deaths.  By Kaplan-Meier analysis, median 
estimated patient survival from diagnosis was 13.0 years, from dialysis was 9.1 years 
and from renal transplantation was 6.5 years.  Among 10 patients who died, cause of 
death was sepsis (6 cases), gastrointestinal haemorrhage (1 case; Patient 20), cardiac 
decompensation (1 case; Patient 10) and was unknown in 2 cases.  The patient who died 
of cardiac failure did not have echocardiographic features of cardiac amyloidosis 
pre-operatively but was discovered at autopsy to have coronary vessel amyloid in the 
absence of myocardial infiltration.   
Nineteen patients received chemotherapy or SCT before renal transplantation to 
try and halt amyloid deposition and thereby prevent progressive impairment of their 
native amyloidotic kidneys.  Acute irreversible kidney injury and dialysis dependence 
associated with hypotension was precipitated in 4 of 5 patients who underwent SCT 
(Patients 1, 2, 8 and 19), the remaining case (Patient 9) being dialysis-dependent prior to 
SCT.  Due to the lack of a pre-chemotherapy FLC sample, 4/19 patients were not 
evaluable for a clonal response.  Among 15 evaluable patients, 14 had a clonal response 
to treatment (11 PR, 3 CR) and 1 (Patient 16) had NR.  All of the complete responders 
(Patients 1, 9 and 11) were alive at census, with 2 cases (Patients 1 and 9) maintaining a 
clonal CR for 10.9 and 11.7 years respectively from 1st line treatment.  Three patients 
(Patients 4, 7, 17) in whom the diagnosis of AL amyloidosis was not confirmed prior to 
renal transplantation, did not receive chemotherapy before renal transplantation.  Patient 
17 did not receive chemotherapy at any point.  Ten patients received chemotherapy after 
renal transplantation, 8 of whom had received chemotherapy earlier in the course of 
their disease.  No transplant failed due to recurrent amyloid despite evidence of amyloid 
within the renal allografts of 5 patients (Patients 5, 7, 12, 14 and 18) detected by SAP 
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scintigraphy a median (range) of 5.6 (4.4-7.8) years from renal transplantation.  Two 
grafts failed, one from chronic allograft nephropathy (Patient 5) and one from scarring 
related to recurrent transplant pyelonephritis (Patient 20).  One case (Patient 18) 
developed proteinuria from graft amyloid 6.2 years after renal transplantation but this 
resolved after successful chemotherapy with preservation of renal allograft function at 
census 3.6 years later. 
 
Cardiac transplantation 
Fourteen patients, 13 of whom presented with advanced cardiac failure and 1 of whom 
developed cardiac amyloidosis during follow-up for gastrointestinal amyloid, received 
cardiac transplants (Table 7.3).  Eleven cases had an underlying lambda light chain 
secreting plasma cell dyscrasias and 3 cases had an amyloidogenic kappa clone.  
Median (range) age at diagnosis of amyloidosis was 52 (38 to 58) years and median 
(range) time from symptom onset to diagnosis was 10.0 (1.0-25.1) months.  Median 
(range) time from diagnosis to cardiac transplantation was 6.3 (0-73.6) months.  Median 
follow-up from cardiac transplantation was 4.4 (0-10.1) years.  At the time of cardiac 
transplantation, 8 patients had no extra-cardiac amyloid according to international 
amyloid consensus criteria; 4 had amyloidotic dysfunction of 1 other organ and 2 
patients had dysfunction of 2 other organs.   
Median survival from cardiac transplantation by Kaplan-Meier analysis was 7.5 
years for the entire cohort.  There were 2 peri-operative deaths (Patients 12 and 13; 
Table 7.3) one from left ventricular failure and another from high right-sided cardiac 
pressures, shown at autopsy to be due to pulmonary amyloid.  Among 8 patients who 
underwent SCT after cardiac transplantation, median survival from cardiac 
transplantation was 9.7 years compared to 3.4 years among cases that did not undergo
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Table 7.3  Characteristics and outcome among 14 patients with systemic AL amyloidosis who underwent heart transplantation. 
 
a
Patient 
No / 
Sex 
b
Age at 
symptom 
onset 
c
Extra-cardiac 
amyloid 
Pre-HTx 
(Consensus 
criteria) 
Diagnosis to 
HTx 
(months) 
d
Chemotherapy 
treatment  
pre-HTx /  
post-HTx 
e
Clonal 
response to 
treatment 
Time to clonal 
response 
relative to 
HTx (months) 
f
Clonal 
relapse 
after initial 
treatment 
Timing of 
clonal 
relapse 
relative 
to HTx 
(months) 
g
Recurrence 
of amyloid by 
echo / Time to 
recurrence  
(months) 
Dead  
(D) / 
Alive 
(A) 
Time 
from HTx 
to 
census 
or death 
(years) 
h
Cause 
of death 
1 (M) 58 N 9 C/C+S PR -7 Y 18 Y / 97 A 9 N/A 
2 (F) 59 N 10 C/C+S PR -1 Y 15 N A 4.7 N/A 
3 (M) 52 P 32 C/S PR -13 N  N A 2.2 N/A 
4 (F) 57 N 1 N/S CR 19 N  N A 1.8 N/A 
5 (M) 43 K 2 N/S CR 5 N  N D 10.1 SCD 
6 (M) 51 K 5 N/C CR 43 N  Y / 28 D 9.7 IC 
7 (M) 51 N 8 N/S PR 23 Y 82 Y / 82 D 9.7 PCA 
8 (M) 55 N 5 N/C+S CR 30 Y 83 Y / 83 D 7.5 PCA 
9 (M) U N 0 N/C NR    U D 4.6 PEA 
10 (F) 51 K, P 26 C/N PR -16 Y 17 N D 4.1 PEA 
11 (F) 50 K, L 9 N/C NR    N D 2.7 PEA 
12 (M) 51 G 74 C/N PR -65 Y -1 N D 0.0 PF 
13 (M) 46 N 2 N/N N/A    N/A D 0.0 LA 
14 (M) 38 N 3 N/C+S PR 4 N  Y / 23 D 2.8 PCA 
a - M=Male F=Female; b and g – U=unknown; c – N=none P=peripheral neuropathy K=kidneys G=gastrointestinal tract L=liver; d – N=none C=chemotherapy S=stem cell 
transplantation; e –N/A=not applicable NR=no response PR=partial response CR=complete response; f and g – Y=yes N=No; h – N/A=not applicable SCD=sudden cardiac death 
IC=ischaemic colitis PCA=progressive cardiac amyloidosis PEA=progressive extra-cardiac amyloidosis PF=pump failure LA=lung amyloid 
 
 
125 
 
SCT (P=0.01).  No patient who underwent SCT after cardiac transplantation had major 
extra-cardiac organ dysfunction at the time of SCT.  
All patients received chemotherapy during the course of their disease apart from 
the single case (Patient 13; Table 7.3), who died peri-operatively.  Five patients were fit 
enough to receive chemotherapy before cardiac transplantation (Patients 1, 2, 3, 10 and 
12) and they all achieved a partial haematological response.  All but 3 cases (Patients 
10, 12 and 13) received chemotherapy after cardiac transplantation, including SCT in 8 
patients.  
Amyloid recurred in the cardiac allografts of 5 patients (Patients 1, 6, 7, 8, 14), 
all of whom had persistence or relapse of their haematological disease, and was first 
detected a median of 82.6 (22.6-96.8) months from cardiac transplantation.  Four of 
these 5 cases died and a further 3 cases died from progressive extra-cardiac amyloid 
(Patients 9, 10, 11).  There was a single unexplained sudden cardiac death in a patient 
who remained in haematological CR (Patient 5) which was not felt to be associated with 
progressive amyloidosis.   
 
Discussion 
This is the largest series of both cardiac and renal transplantation for systemic AL 
amyloidosis and reports the first cohort of patients with decompensated hepatic AL 
amyloidosis to undergo OLT.  Outcomes among OLT recipients were poor, in marked 
contrast to outcomes following heart and kidney transplantation which, in this highly 
selected and monitored group of patients, were relatively good.   
Despite recent advances in management of AL amyloidosis,
72,187
 many patients 
continue to present with advanced, irreversible amyloidotic end-organ damage and 
nearly 30% die within 1 year of diagnosis.
187
  The role of solid organ transplantation in 
AL amyloidosis remains contentious due to concerns about recurrence within the graft 
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and progressive disease outside the graft.  Most series of renal
210
 and cardiac 
transplantation
209
 in amyloidosis however, pre-date the discovery that systemic 
chemotherapy which successfully suppresses monoclonal light chain production can 
halt ongoing AL amyloid deposition.
27,76
  Some published transplant series even include 
patients with unknown or multiple amyloid types.
211,212
   
The patients reported here were carefully selected for their transplant procedure.  
Selection criteria for cardiac transplantation included advanced cardiomyopathy, age 
under 60 years, and absence of myeloma or extensive extra-cardiac amyloidosis.  On the 
basis of the significantly prolonged survival among patients who received SCT after 
cardiac transplantation in this series, compared to those who did not, there is evidence 
that only patients who are predicted to be fit enough to receive SCT after the cardiac 
transplant procedure should be listed for cardiac transplantation.  Patients with advanced 
amyloid cardiomyopathy, are usually too unwell to tolerate aggressive chemotherapy 
before cardiac transplantation, and given their predisposition to sudden cardiac death, 
should probably be listed for urgent cardiac transplantation with a view to subsequent 
SCT.  Selection criteria for renal transplantation included ESRD, age under 70 years, 
absence of myeloma or extensive extra-renal amyloidosis, ECOG performance status of 
1 or 2, and, wherever possible, sufficient suppression of the underlying plasma cell 
dyscrasia by chemotherapy to prevent ongoing amyloid accumulation according to 
serial SAP scans.  Importantly, only 3/22 patients in this series were in clonal CR prior 
to renal transplantation although they had nearly all received chemotherapy and 
achieved at least a clonal PR.  The evidence from this series, like other series,
213
 is that 
chemotherapy should usually be administered prior to consideration of renal 
transplantation in systemic AL amyloidosis.  Although reasonable outcomes have 
previously been reported with renal transplantation followed by autologous stem cell 
transplantation in a small number of patients with AL amyloidosis,
214
 it is apparent from  
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experiences at the NAC that stem cell transplantation and/or chemotherapy is associated 
with a significant risk of irreversible renal allograft dysfunction.  Selection criteria for 
OLT included decompensated hepatic AL amyloidosis, age under 70 years and absence 
of clinically significant cardiac involvement by amyloid.  Analogous to recipients of 
cardiac allografts, patients with decompensated liver disease are usually too unwell to 
receive chemotherapy prior to OLT, and the patients reported in the current series were 
scheduled to receive chemotherapy or SCT after OLT.   
OLT was associated with poor outcomes, mainly due to presence of extensive 
extra-hepatic amyloid,
215
 which, even if clinically silent at the time of OLT, usually 
caused sufficient organ dysfunction after the transplant procedure to compromise 
administration of chemotherapy aimed at halting ongoing amyloid deposition.  In this 
series 4/9 (44%) OLT recipients were too unwell to receive chemotherapy at any stage 
after the transplant, all of whom died within 1 year of the procedure.  Among 5/9 
patients who did receive chemotherapy after OLT, only two were alive at census 
including one who developed subsequent ESRD, the remaining 3 deaths occurring 0.4, 
0.9 and 2 years after OLT.  The 1- and 5-year patient survival following OLT of 33% 
and 22% respectively in this series compares very poorly to all-cause OLT survival 
estimates which exceeds 87% and approaches 75% respectively in the USA
216
 and 82% 
and 71% respectively in Europe (http://www.eltr.org), and, in the context of donor 
organ shortages, does not encourage consideration of OLT in systemic AL amyloidosis 
generally.   
Outcomes with renal transplantation in this cohort were good.  Interestingly, no 
renal allografts failed from recurrent amyloid despite the fact that only 3 patients 
achieved a clonal CR with chemotherapy.  Two of ten deaths in renal transplant 
recipients were related to extra-renal amyloid deposits.  There is evidence in this series 
that renal transplantation should generally be offered only to AL patients with a 
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preserved ECOG performance status and little or no clinically significant extra-renal 
amyloidosis, who have achieved at least a clonal PR with prior chemotherapy.  One area 
of contention is whether dialysis-dependent patients without extra-renal amyloidosis 
should receive chemotherapy whilst on dialysis, the sole purpose of which is to achieve 
a clonal response in order to permit listing for renal transplantation, or whether such 
patients should undergo renal transplantation followed by chemotherapy/SCT to prevent 
ongoing amyloid deposition.
214
  This series, which reports the best outcomes of any to 
date, supports attempting to achieve a clonal response prior to renal transplantation.  
The median patient survival of 6.5 years from renal transplantation is impressive 
considering the patients were transplanted over the course of 15 years and included 3 
cases in whom the diagnosis of AL amyloidosis was unknown at the time of renal 
transplantation.  In addition, the median patient survival from dialysis of 9.1 years in 
these 22 patients is distinctly better than the 3.6 years from dialysis in non-transplanted 
AL amyloidosis ESRD patients at the NAC,
70
  although much of this difference is likely 
to reflect selection bias.   
Survival among patients presenting with advanced cardiac AL amyloidosis in 
the absence of cardiac transplantation remains dismal.
112
  Up to one third of patients 
with AL amyloidosis die within 12 months of diagnosis, frequently from cardiac 
involvement.
187
  Furthermore, even among patients who survive for longer than 12 
months, quality of life is generally poor with persistent and severe limitation of physical 
activity.  The median patient survival from cardiac transplantation of 9.7 years among 
those who received subsequent SCT in this series is comparable to US „all-cause‟ 
cardiac transplant survival.
217
  Successful outcomes among patients with dominant and 
isolated cardiac AL amyloidosis who receive sequential cardiac and stem cell 
transplantation have been widely reported in recent years.
218,219
  There is evidence that 
this approach should be adopted by cardiac transplant units worldwide.  Although 
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successful outcomes have been reported in small numbers of patients with 
chemotherapy followed by cardiac transplantation,
220
 cumulative evidence would favour 
urgent cardiac transplantation followed by SCT in such cases due to the risks of 
chemotherapy in patients with advanced cardiac amyloidosis.  Whenever there is likely 
to be a substantial delay before the cardiac transplant however, careful administration of 
high dose dexamethasone or bortezomib, both of which have the potential to induce a 
rapid clonal response whilst preserving the option of harvesting stem cells in the future, 
should be considered. 
 
Conclusion 
In summary, this series provides support for continued cardiac and renal transplantation 
for carefully selected patients with AL amyloidosis, but shows that OLT for 
decompensated hepatic AL amyloidosis, is probably not an appropriate use of donor 
organs which continue to be in short supply.  Solid organ transplantation in AL 
amyloidosis should always be accompanied by chemotherapeutic strategies to halt 
ongoing amyloid production. 
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Chapter 8 
Hepatic amyloidosis – A ten-year biopsy study 
(2000-2009) 
 
Introduction 
Hepatic amyloid is frequently present in patients who develop systemic amyloidosis and 
may occur without derangement of liver function tests and without symptoms.
42
  It is 
most commonly seen in AL amyloidosis
42
 where it might present indolently with 
hepatomegaly or deranged liver function tests or occasionally as liver failure
221
 or 
hepatic rupture.
208
  Those patients with a dominant hepatic presentation of AL 
amyloidosis have historically been deemed to have a poor prognosis, particularly in the 
context of hyperbilirubinaemia.  In one study of patients followed prior to the year 2000 
a bilirubin >34 µmol/l was associated with survival of only 1 month.
35
  Patients with 
systemic amyloidosis may present with dominant hepatic features where a diagnosis of 
amyloid is made unexpectedly by liver biopsy.  This study outlines the clinical features, 
treatment strategies and outcomes in such patients presenting over a ten year period 
from 2000 to 2009 at the NAC.   
 
Aims 
The first aim of this study was to try and provide a diagnostic algorithm for 
gastroenterologists should a diagnosis of amyloid be made unexpectedly by liver biopsy 
in patients presenting with deranged liver functions tests and/or hepatomegaly.  The 
second aim was to evaluate the role of chemotherapeutic treatments in the modern era of 
treatment in those patients with dominant hepatic AL amyloidosis to see if a survival 
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benefit could be conferred in historically what has been a group that has been perceived 
to have a poor prognosis.
35
 
 
Methods 
 
Patients 
Between January 2000 and November 2009 all patients in whom amyloid was 
diagnosed unexpectedly by liver biopsy, were identified from the database at the NAC.  
Typing of amyloid was supported by immunohistochemical analysis of biopsies, 
evaluation for a plasma cell dyscrasia with serum and urine electrophoresis and the 
serum free light chain assay and assessment of inflammation with CRP and SAA 
analyses.  Exclusion or confirmation of hereditary systemic amyloidosis was achieved 
by genetic sequencing of genes known to encode for variant proteins with 
amyloidogenic potential.
67
  Specific sampling by laser microdissection (LMD) and 
tandem mass spectrometry (MS)-based proteomic analysis was used to characterise 
amyloidosis secondary to Leucocyte cell-derived chemotaxin 2 (LECT-2).
109
   
Assessment at the baseline NAC visit, repeated 6 to 12 monthly, included 
clinical evaluation, detailed biochemical tests of renal and hepatic function, assessment 
of serum and urine immunoelectrophoresis, serum free light chain analysis, 
electrocardiographic and echocardiographic studies.  Whole body anterior and posterior 
scintigraphic imaging was undertaken to establish whole body amyloid load.  Organ 
involvement was classified according to the international amyloid consensus criteria in 
those patients with AL amyloidosis.
114
 
Different regimes of chemotherapy and/or stem cell transplantation were 
administered to those patients with AL amyloidosis according to protocols at local 
treatment centres, if they were deemed fit enough to tolerate treatment.  Serial 
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serum-free light chains (FLC) were determined in all patients after 2003 and 
retrospectively sought by analysis of stored sera, if available, to elucidate treatment 
responses to chemotherapeutic agents.  Healthy, polyclonal FLC concentrations rise 
progressively through advancing stages of chronic kidney disease (CKD),
222
 which 
impedes the monitoring of monoclonal light chain disorders.  In this study, the value of 
the FLC „monoclonal component‟ was estimated by subtracting the concentration of the 
uninvolved light chain from that of the amyloidogenic light chain, the FLC difference 
(dFLC), a strategy that has lately been validated in myeloma.
223
  The FLC response to 
chemotherapy was defined as the percentage of the dFLC at baseline that remained 
following treatment.  Serial SAA levels, to assess adequacy of anti-inflammatory 
treatment in those patients with AA amyloidosis, were monitored at a frequency of 1-3 
monthly.   
 
Statistical analysis 
Patient follow-up was censored in November 2009, and in the single patient who was 
lost to follow-up, at their last clinic visit prior to this date.  Kaplan-Meier analyses and 
Cox proportional hazards regression were used to investigate factors associated with 
overall survival of patients with AL amyloidosis.  To validate use of dFLC for 
calculation of response to chemotherapy in AL amyloidosis, time-updated dFLC 
response was included as a co-variate in the survival analysis.  All factors which were of 
statistical significance (p<0.05) in univariate analyses and/or clinical significance were 
included in multivariate analysis.  Cut points were chosen by their clinical relevance.  
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Results 
 
Patient characteristics 
Ninety-three patients had a dominant hepatic presentation of systemic amyloidosis with 
amyloid identified unexpectedly by liver biopsy.  Eighty-two biopsies were via the 
percutaneous route, 7 were transjugular biopsies and 4 were obtained at laparoscopy or 
laparotomy.  Eighty-four patients (55 male) had systemic AL amyloidosis (Table 8.1).  
Nine patients had other forms of systemic amyloidosis – systemic AA amyloidosis (2 
patients), TTR-type (ATTR) amyloidosis (3 patients), hereditary apolipoprotein AI 
(AApoAI) amyloidosis (3 patients), and LECT-2 amyloidosis (1 patient) (Table 8.2). 
 
Systemic AL amyloidosis - baseline characteristics 
Of the 84 patients with systemic AL amyloidosis, 2 patients (2%) had no evidence of a 
clonal disorder on serum or urine analysis.  The diagnosis of AL amyloidosis in these 2 
patients was based upon immunohistochemical analysis, clinical features and exclusion 
of hereditary forms of amyloidosis.  Sixty-one cases (73%) had evidence of an 
abnormal monoclonal protein on serum or urine electrophoresis and 73/80 cases (91%) 
had evidence of a light chain excess at presentation.  The median (range) age of 
diagnosis was 61 years (30-84).  Involuntary weight loss had occurred in 65 patients 
(77%) by the time of diagnosis.  The presenting symptomatology was typically 
non-specific and included lethargy in 40 patients (48%), abdominal discomfort in 20 
(24%), appetite loss in 26 (33%), nausea in 21 (25%) and early satiety in 24 (29%) 
patients.  The median (range) time from symptom onset to diagnosis was 0.7 years 
(0-2.9).  At the time of diagnosis 83 patients (99%) had hepatomegaly, 21 (25%) were 
jaundiced and 10 (12%) had ascites.  No patient was encephalopathic at diagnosis.  
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Table 8.1  Baseline laboratory markers in AL amyloidosis patients. 
 
Test Patient  
number 
Patient 
frequency 
Median 
(Range) 
Normal 
values 
Bilirubin (µmol/l) 
<19 
≥19 
84  
44 (52.4%) 
40 (47.6%) 
16.5 (5, 401) <19 
Alkaline phosphatase (U/l) 
<516 
(4 times upper limit of normal) 
≥516 
84  
36 (42.9%) 
 
48 (57.1%) 
560 (90, 3891) 35-129 
Gamma-glutamyl transferase (U/l) 
<62 
≥62 
78  
1 (1.3%) 
77 (98.7%) 
604.5 (47, 
5837) 
8-61 
Aspartate aminotransferase (U/l) 
<55.5  
(1.5 times upper limit of normal) 
≥55.5 
84  
44 (52.4%) 
 
40 (47.6%) 
49 (17, 223) <37 
Alanine aminotransferase (U/l) 
<41 
≥41 
78  
35 (44.9%) 
43 (55.1%) 
43 (12, 231) <41 
Platelets (x10
9
/l) 
<401 
≥401 
84  
58 (69.1%) 
26 (31.0%) 
344.5 (132, 
820) 
140-400 
CKD Stage 
0-2 
3-5 
84  
44 (52.4%) 
40 (47.6%) 
2 (0, 5)  
Albumin (g/l) 
<35 
≥35 
84  
43 (51.2%) 
41 (48.8%) 
34 (15, 56) 35-50 
Prothrombin time (seconds) 
≤16 
>16 
79  
53 (67.1%) 
26 (32.9%) 
15.2 (11.6, 
28.3) 
12-16 
Proteinuria (g/24 hours) 
<0.5 
0.5-3 
>3 
81  
23 (28.4%) 
36 (44.4%) 
22 (27.2%) 
1.3 (0, 11.4) <0.15 
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Table 8.2  Characteristics of non-AL amyloidosis patients. 
 
Patient 
number 
Sex
1
 Amyloid 
Type
2
 
(mutation) 
Histological 
localisation 
of amyloid 
Age of 
diagnosis 
Organ 
involvement
3
  
SAP scan 
– total 
body 
amyloid 
load 
(organs 
involved)
4
 
Bilirubin 
at 
diagnosis 
(µmol/l)  
ALP at 
diagnosis 
(U/l) 
AST 
at 
diagnosis(U/l) 
Alive (A) 
or Dead (D) 
/Age at 
census or 
death 
1 M AA Parenchyma 74 K/L L (L,S,K) 13 748 29 A/82 
2 F AA Parenchyma 42 K/L L (L,S,K) 6 105 48 A/43 
3 F ATTR 
(V122I) 
Vascular 82 H None 33 154 63 A/85 
4 M ATTR 
(V122I) 
Vascular 79 H None 15 290 29 D/80 
5 M ATTR 
(T60A) 
Vascular 69 H None 12 203 26 A/75 
6 M AApoAI 
(G26R) 
Parenchyma 55 K/L M (L/S) 15 290 54 A/60 
7 F AApoAI 
(G26R) 
Parenchyma 50 K/L S (L/S) 12 552 104 A/56 
8 M AApoAI 
(G26R) 
Vascular 46 K/L S (S) 6 463 49 D/51 
9 M LECT-2 Vascular 52 K S (S) 12 68 25 A/55 
1
Sex : M=male, F=female 
2
Amyloid type : AA = Systemic AA amyloidosis, ATTR = Hereditary transthyretin-related amyloidosis, LECT-2 = Leucocyte cell-derived 
chemotaxin-2 amyloidosis 
3
Organ involvement : K=kidney, H=heart, L=liver 
4
SAP scan – total body amyloid load : L=large, M=moderate, S=small (Organs involved on SAP scan : L=liver, S=spleen, K=kidney) 
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The baseline haematological and biochemical parameters of these patients are 
outlined in Table 8.1.  All patients had abnormal liver function tests except one who 
was investigated with a liver biopsy for hepatomegaly.  The most common biochemical 
abnormality was a raised alkaline phosphatase which occurred in 80 cases 
(95%).  The median alkaline phosphatase in this group was more than 4 times the upper 
limit of normal.  Sixty cases (71%) had a raised aspartate aminotransferase with a 
median value that was just less than 1.5 times the upper limit of normal.  Serum 
bilirubin was abnormal in 40 cases (48%) and prothrombin time was prolonged in 26/80 
cases (33%).  Nine patients (11%) had no evidence of renal dysfunction, 13 patients 
(16%) had CKD stage 1, 22 patients (27%) had CKD stage 2 and the remainder (46%) 
had markedly abnormal renal function with an eGFR ≤60 ml/min.  
SAP scintigraphy was performed in all cases at baseline except one.  It identified 
a large or moderate total body amyloid load in 10 (12%) and 73 (88%) cases 
respectively.  Hepatic and splenic amyloid was universal on all SAP scans (Figure 8.1).  
Extra-hepatic amyloid, as assessed by the international amyloid consensus criteria, was 
common by the time of diagnosis, with 43 patients (51%) having ≥2 organ involvement 
(Table 8.3).  Only 11 cases (13%) had no evidence of extra-hepatic amyloid.  Among 
the 73 patients with extra-hepatic amyloid, the kidneys (62 cases - 85%) and heart (39 
cases - 53%) were the commonest organs involved (Table 8.3).  
 
Systemic AL amyloidosis – clinical course 
Fifty-four (64%) patients died during follow-up.  After one year, two years, three years, 
four years and five years 45% (95% CI: 35% to 56%), 62% (95% CI: 51% to 72%), 
63% (95% CI: 52% to 74%), 67% (95% CI: 56% to 78%) and 70% (95% CI: 58% to 
81%) patients had died respectively.  The median survival by Kaplan-Meier estimate 
from diagnosis of amyloid in the entire cohort was 1.2 years (Figure 8.2).
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Figure 8.1  Anterior-posterior whole body SAP scintigraphic view of a patient with 
AL amyloidosis treated successfully with chemotherapy – pre-treatment image 
(left) with massive hepatic and splenic amyloid with little blood pool and 
post-treatment image (right) showing marked regression of amyloid from the liver 
and spleen and a more visible blood pool accompanied by normalisation of liver 
function tests. 
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Table 8.3  Extra-hepatic organ involvement by the international amyloid consensus 
criteria at baseline in AL amyloidosis patients. 
 
 
Organ involved Number of patients Percentage 
Kidneys 62 84.9 
Heart 39 53.4 
Peripheral neuropathy 6 8.2 
Autonomic neuropathy 16 21.9 
Gastrointestinal tract 4 5.5 
Soft tissue 6 8.2 
No extra-hepatic organ 11 13.1 
One extra-hepatic organ 30 35.8 
Two extra-hepatic organs 29 34.5 
Three or more extra-hepatic organs  14 16.7 
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Figure 8.2  Kaplan-Meier plot showing the time to death from biopsy diagnosis of 
amyloid in AL amyloidosis patients. 
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Chemotherapy including stem cell transplantation, was administered to 62 patients 
(74%), with evaluable clonal responses in 58 cases.  The remainder died before 
treatment could be administered or were deemed too unwell to tolerate treatment.   
Liver transplantation (OLT) was undertaken in 3 patients for decompensated 
liver disease.  One patient with cardiac amyloid died intra-operatively at the age of 56 
because of cardiac decompensation secondary to hypotension during surgery.  Another 
patient was transplanted at the age of 61 and died from pseudomonal septicaemia 1.1 
years after OLT.  He received chemotherapy before and after OLT and had a >50% 
dFLC response but despite this developed progressive cardiac amyloidosis.  The patient 
who was alive and well at census 5.5 years after OLT had a stem cell transplant after 
OLT and achieved a >50% dFLC response.  
Factors at presentation associated with increased mortality on multivariable 
analysis (Table 8.4) were older age (relative risk of death, 1.69 for each additional 
decade [95% CI, 1.23 to 2.35];p=0.001), cardiac amyloid (relative risk of death, 2.29 if 
present [95% CI, 1.23 to 4.24];p=0.009), hyperbilirubinaemia (relative risk of death, 
2.33 if the serum bilirubin was raised [95% CI, 1.14 to 4.77];p=0.02) and 
hypoalbuminaemia (relative risk of death, 3.41 if the serum albumin was low [95% CI, 
1.49 to 7.83];p=0.004).  There was also a clear trend between risk of death and 
magnitude of dFLC response to chemotherapy (relative risk of death of 0.75 [95% CI, 
0.33 to 1.68;p=0.02] for patients achieving a 50-90% dFLC response and 0.15 [95% CI, 
0.04 to 0.58;p=0.02] for patients achieving a >90% dFLC response, compared to 
patients achieving <50% dFLC response).  
 
Systemic AA amyloidosis 
Two patients, both of whom were alive at census 1.2 and 8.4 years after diagnosis, had 
systemic AA amyloidosis with a large total body amyloid load on SAP scintigraphy and 
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Table 8.4  Factors at diagnosis associated with risk of death in AL amyloidosis patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Time-updated FLC response 
 
 
 
 
Unadjusted analysis  Multivariate analysis 
Characteristic Hazard ratio 
(95% CI) 
P-value Hazard ratio 
(95% CI) 
P-value 
Age; for each 10 years older 1.39 (1.08, 1.79) 0.01 1.69 (1.23, 2.35) 0.001 
 
Organ involvement: 
Cardiac amyloid; (Yes vs No) 2.33 (1.35, 4.01) 0.002 2.29 (1.23, 4.24) 0.009 
 
Biochemical markers: 
Bilirubin; ≥19umol/l versus <19umol/l 2.80 (1.61, 4.87) <0.0001 2.33 (1.14, 4.77) 0.02 
Albumin; <35 g/L versus ≥35 g/L 4.25 (2.31, 7.80) <0.0001 3.41 (1.49, 7.83) 0.004 
ALP; >516 IU/L versus ≤516 IU/L 3.04 (1.68, 5.50) <0.0001 0.91 (0.37, 2.24) 0.85 
AST; ≥55.5 IU/L versus <55.5 IU/L 2.77 (1.60, 4.80) <0.0001 1.39 (0.69, 2.83) 0.36 
 
Other factors:     
  
Response to treatment*; 
                      <50% dFLC response 
                      50-90% dFLC response 
                      >90% dFLC response 
 
Ref 
0.80 (0.36, 1.74) 
    0.22 (0.06, 0.77) 
0.03  
Ref 
0.75 (0.33, 1.68) 
    0.15 (0.04, 0.58) 
0.02 
Year of biopsy; (2005-09 versus 2000-04) 0.80 (0.46, 1.39) 0.43 0.86 (0.46, 1.59) 0.62 
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evidence of proteinuric renal dysfunction (Table 8.2).  One patient (Patient 1; Table 
8.2), whose deranged liver function tests prompted a liver biopsy, developed 
amyloidosis on the background of chronic inflammation associated with a paraspinal 
abscess, which occurred after septicaemia following an intestinal perforation 30 years 
prior to diagnosis of amyloid.  The other patient (Patient 2; Table 8.2) was co-infected 
with HIV and hepatitis C.  She had a liver biopsy to investigate for potential hepatic 
fibrosis.  The potential sources of inflammation in her case were recurrent skin 
abscesses at the sites of intravenous drug usage and bronchiectasis.  With abstinence 
from intravenous drug usage, scrupulous treatment of infections with antibiotics and use 
of regular intravenous immunoglobulin therapy for bronchiectasis her serial SAA values 
normalised during follow-up and there was resolution of proteinuria and regression of 
amyloid on serial SAP scans within 1 year. 
 
Hereditary systemic amyloidosis 
Six patients, all of whom had no family history of amyloidosis, had hereditary forms of 
systemic amyloidosis (Table 8.2).  Three of these cases had genetic mutations that 
encode for variant transthyretin.  Two patients of Afro-Caribbean ethnicity were 
heterozygous for the V122I mutation (Patients 3 and 4; Table 8.2) and one patient of 
Irish ethnicity was heterozygous for the T60A mutation (Patient 5; Table 8.2).  In all 3 
cases hepatomegaly and deranged liver function tests prompted liver biopsies.  Hepatic 
amyloid was visualised in the vasculature and not in the parenchyma in all.  There was a 
corroborative lack of hepatic uptake on SAP scintigraphy in these patients.  The 
deranged liver function tests and hepatomegaly in these cases, unlike in the previously 
described cases of the acquired forms of systemic amyloidosis, were secondary to 
cardiac failure and hepatic congestion on the background of an amyloid cardiomyopathy 
rather than hepatic parenchymal infiltration with amyloid.  The diagnosis of amyloid 
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was quite incidental in each of these cases, as the hearts were the only organs that were 
functionally affected by amyloid, with no clinically significant extra-cardiac amyloid in 
any case.  The subsequent management of these patients utilised standard heart failure 
treatments.  One patient who was heterozygous for the V122I mutation died 1.5 years 
after diagnosis and the other 2 patients were alive 3 and 5.8 years after diagnosis.  
Three further cases had genetic mutations that encode for variant apolipoprotein 
AI (Patients 6, 7 and 8; Table 8.2).  In 2 of these cases, both of whom were alive at 
census, there was evidence of hepatic parenchymal amyloid on liver biopsy.  Liver 
function tests were stable for 4.9 (Patient 6; Table 8.2) and 6.0 (Patient 7; Table 8.2) 
years after diagnosis of amyloid with no evidence of progressive amyloid deposition on 
serial SAP scans, suggestive of a slow turnover of amyloid.  The former patient reached 
end-stage renal failure, which on retrospect most probably was secondary to renal 
amyloid and had a renal transplant before the correct diagnosis of amyloidosis was 
made by liver biopsy.  The latter case presented with renal dysfunction before diagnosis 
of amyloid, which did not progress during follow-up.  The third case (Patient 8; Table 
8.2) had hepatic vascular amyloid and no parenchymal amyloid in his liver biopsy and 
like the ATTR patients in this series had no evidence of hepatic amyloid on SAP 
scintigraphy.  His deranged liver function tests were secondary to a non-amyloid 
cardiomyopathy and associated hepatic congestion.  He, like Patient 6, developed renal 
dysfunction which progressed to end-stage renal failure 4 years prior to a liver biopsy 
diagnosis of amyloid and died 5.1 years after this diagnosis.  
 
LECT-2 amyloidosis 
Patient 9 (Table 8.2), who was alive at census 3.5 years after diagnosis of amyloid, had 
LECT-2 amyloidosis.  He had hepatitis C and had a liver biopsy to investigate for 
potential fibrotic liver disease.  Amyloid was seen only in his hepatic vasculature on 
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histological analysis.  On baseline SAP scintigraphy he had splenic, renal and adrenal 
amyloid and had no evidence of progressive amyloidosis on serial SAP scans till 
census.  During follow-up he had stable renal and hepatic biochemistry. 
 
Discussion 
A dominant hepatic presentation of systemic amyloidosis is relatively less common than 
dominant presentations associated with other amyloidotic organs.  At the NAC over the 
10 year period of this study 93/3348 (3%) new cases of systemic amyloidosis were 
diagnosed unexpectedly by liver biopsy.  If hepatic amyloid is suspected clinically the 
current recommendations from the British Society of Gastroenterology are that 
diagnosis by percutaneous liver biopsy should be avoided as there is a risk of 
haemorrhage.
65
  In the current series only 2/82 (2%) percutaneous liver biopsies were 
complicated by non-fatal haemorrhage.   
Although abnormalities in liver biochemistry were present in all except 2 cases 
in the current series, it should be noted that such abnormalities can be unrelated to 
hepatic amyloid in patients with systemic amyloidosis.  Alkaline phosphatase levels, for 
example, can be raised on the background of systemic inflammation.  In a series of 374 
patients with AA amyloidosis at the NAC one third had an elevated alkaline 
phosphatase but had no evidence of hepatic amyloid on SAP scintigraphy.
39
  Cardiac 
failure, secondary to an amyloid cardiomyopathy, may also cause derangement of liver 
function tests and hepatomegaly through hepatic congestion.  This can lead to elevations 
in alkaline phosphatase and aminotransferases, which typically tend to be relatively 
subtle.
224
  Consistent with this in the current series some of the heredo-familial forms of 
systemic amyloidosis were diagnosed through liver biopsies of congested livers because 
of an isolated amyloid cardiomyopathy. 
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The vast majority of patients in the current series had AL amyloidosis.  Extra-
hepatic organ involvement, mostly in the heart and kidneys was present in most of these 
patients.  Cardiac amyloid, in particular, had a significant impact on survival on 
multivariable analysis.  Hypoalbuminaemia also impacted on survival and is a marker of 
both proteinuric renal dysfunction and also reduced liver synthetic function and is hence 
a surrogate marker of multisystem disease.  The median survival of 1.2 years by 
Kaplan-Meier estimate from diagnosis of AL amyloid in the current series is likely to be 
an overestimate as several patients with hepatic presentations of systemic AL 
amyloidosis were too unwell to come for assessment at the NAC.  Despite the poor 
prognosis historically associated with hepatic AL amyloid
35
 there is supportive evidence 
in this study that, in the current era of chemotherapeutic regimes, in those who achieve a 
good clonal response to chemotherapy there is potential for amyloid regression from 
organs (Figure 8.1), for improvement of organ function and most importantly for a 
survival benefit to be conferred.  This is even more apparent in those who had a >90% 
dFLC response to chemotherapy, who had a fivefold reduction in their mortality risk 
when compared to those who had a 50-90% dFLC response.  There is a case therefore 
for chemotherapy to be administered to those who are fit enough to tolerate it with the 
aim of a quick and deep clonal response.  With newer chemotherapeutic agents such as 
the proteosome inhibitors this could potentially be achieved with good effect.
80
  The 
role of OLT in those patients with decompensated liver disease is unclear.  It may 
prolong patient survival but from what little data is available in the literature this 
survival is poor compared to other liver diseases culminating in liver transplantation and 
in the current climate of donor shortages OLT in systemic AL amyloidosis is not a 
proven treatment strategy.
221
 
A hepatic presentation of AA amyloidosis is relatively rarer with only 2 such 
cases in the current series over a ten-year period.  In the series of 374 patients with AA 
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amyloidosis at the NAC followed till 2005 proteinuric renal dysfunction dominated, 
occurring in 97% cases, with a median survival in this group of 11 years.
39
  Hepatic 
amyloid on the background of AA amyloidosis in a 
123
I-SAP scintigraphic study at the 
NAC, negatively impacted upon survival.
42
  In the context of AA amyloidosis it 
probably represents a large disease burden.  However with adequate suppression of 
inflammation and maintenance of SAA values <10 mg/l, as occurred in one of the 
patients in this series, one can see amyloid regression from amyloidotic organs and 
stabilisation or improvement of organ function.
41
   
Several hereditary forms of systemic amyloidosis were identified by liver biopsy 
in this series.  Hepatic amyloid secondary to AApoAI occurred in 2 cases.  Like AL 
amyloidosis, it is recognised as a cause of elevations in serum alkaline phosphatase and 
gamma-glutamyl transferase and also in causing decompensated liver disease.
225
  Some 
of the other hereditary cases in the series had an isolated amyloid cardiomyopathy, 
which is indistinguishable from that of AL amyloidosis,
226
 and had amyloid in the 
vasculature of their liver biopsies rather than parenchymal amyloid.  The abnormal liver 
function tests that led to liver biopsies in these 3 cases were secondary to cardiac 
congestion because of a TTR-type amyloid cardiomyopathy (Patients 3, 4 and 5; Table 
8.2).  ATTR is not recognised as causing hepatic amyloid
29
 and the diagnosis of 
systemic amyloidosis in these cases on retrospect was quite incidental and relied on the 
systemic nature of amyloid deposits throughout the vasculature.  The cardiac failure 
secondary to a TTR-type amyloid cardiomyopathy may be more subtle than other forms 
of cardiac failure.  There may be more dominant features of right-sided heart failure 
such as ascites and hepatomegaly.
226
  Such a clinical presentation may prompt a 
clinician to suspect liver disease and hence pursual of a liver biopsy. 
LECT-2 amyloidosis was discovered recently
227
 and was identified 
unexpectedly in one case in the current series when a biopsy was pursued to investigate 
147 
 
for potential fibrotic liver disease in the context of hepatitis C infection.  It has also 
previously been diagnosed in 3 others cases with viral hepatitis, who have been 
followed at the NAC.  In these cases it was characterised by hepatic and renal amyloid 
and slowly progressive organ dysfunction.
228
  LECT-2 is thought to be a growth factor 
or chemokine.
227
  It may have a role in liver regeneration and injury
229
 and this could be 
a potential mechanistic link between viral hepatitis and this form of amyloidosis.  
Any form of systemic amyloidosis can present with dominant hepatic features 
culminating in the diagnosis of amyloid by liver biopsy.  AL amyloidosis is by far the 
commonest form in this setting.  Correct diagnosis of amyloid type is imperative as 
prognosis and treatments vary significantly between these types.  The hereditary 
amyloidosis syndromes, for example, have overlapping features with AL amyloidosis 
but whereas chemotherapy has a role in the latter it has no role in the former.
67
  The 
difficulty in diagnosing hereditary amyloidosis is further compounded by the frequent 
absence of a family history, as the encoding mutations are often variably penetrant.  As 
well as confirming amyloid type a comprehensive evaluation for extra-hepatic amyloid 
is also very important as it often co-exists with hepatic amyloid, impacts upon prognosis 
and often alters the approach to treatment.  Figure 8.3 provides a potential algorithm for 
gastroenterologists in assessing patients with amyloid diagnosed by liver biopsy. 
 
Conclusion 
A hepatic presentation of systemic amyloidosis culminating in a liver biopsy when 
amyloid is not suspected is a relatively rarer presentation of systemic amyloidosis.  
Correct diagnosis of amyloid type is imperative as prognosis and treatments are vastly 
different between the different amyloid types.  This mode of presentation is most 
commonly associated with AL amyloidosis but AA amyloidosis and heredo-familial 
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Figure 8.3.  An algorithm for the typing of amyloid confirmed on liver biopsy and 
the subsequent assessment of systemic amyloidosis. 
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fibril proteins or laser 
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(MS)-based proteomic 
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characterise amyloid 
type 
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systemic 
amyloidosis 
Family history of 
cardiac, renal or 
neurological disease 
or systemic 
amyloidosis 
? AA amyloidosis 
Assessment for a 
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inflammatory 
condition with 
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and previous CRP 
levels 
? AL amyloidosis 
Assessment for a 
plasma cell dyscrasia 
with serum/urine 
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bone marrow aspirate 
and skeletal survey. 
 
Assessment for extra-hepatic amyloid 
Renal : urine dipstick to assess for proteinuria 
Cardiac : electrocardiography and echocardiography 
Soft tissue amyloidosis, peripheral and autonomic neuropathy : clinical assessment 
 
Referral to an amyloid centre 
Assessment for the 
amyloidogenic 
precursor protein 
 
AL- Serum free 
light chain analysis 
 
AA – Serum 
amyloid A protein 
analysis 
 
Hereditary – gene 
sequencing 
Assessment of 
extrahepatic organ 
involvement 
 
Renal – 24 hour 
proteinuria 
 
Cardiac – Detailed 
echocardiography +/-
cardiac MRI +/- 
cardiac biomarkers 
 
Amyloid load – 123I 
SAP scintigraphy 
 
Monitoring and Treatment 
AL – Chemotherapy guided by serial serum free light chain analysis 
AA – Anti-inflammatory treatment to reduce serial SAA levels 
Hereditary – Supportive treatment (e.g. treatment of heart failure) or organ 
transplantation for failing organ function (e.g. renal transplantation) 
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forms of amyloid can also present in this manner.  In the setting of AL amyloidosis this 
presentation confers a poor prognosis, especially when there is concomitant cardiac 
amyloid, hypoalbuminaemia or hyperbilirubinaemia.  However in those with a good 
clonal response to chemotherapy a survival advantage can be conferred. 
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General Conclusions 
 
The studies in this thesis have highlighted several novel findings concerning the 
phenotype, investigation and management of the systemic amyloidosis syndromes.   
The role of solid organ transplantation appears to be differentially beneficial 
depending upon which organ is transplanted and in which form of systemic 
amyloidosis.  Liver transplantation, as a form of surgical gene therapy, is the only 
available treatment for familial amyloid polyneuropathy.  Most of its evidence relates to 
the V30M TTR variant.  FAP T60A, unlike the well-described FAP V30M, is 
characterised by a dominant cardiac phenotype rather than neuropathy, which appears to 
have a significant bearing on survival in affected individuals in a similar manner to the 
impact of cardiac amyloid in patients with AL amyloidosis.  Therefore careful 
evaluation for cardiac amyloid with echocardiography and cardiac biomarkers is 
warranted in this patient group to inform on prognosis.  Whereas liver transplantation 
can have a significant impact upon disease progression and survival in FAP V30M its 
role appears to be less compelling in those with FAP T60A and again this appears to be 
related to cardiac amyloid, which can act as a nidus for an accelerated amyloid 
cardiomyopathy secondary to wild-type transthyretin synthesised in the liver graft in the 
post-transplant setting.  An unexplored area in TTR-related cardiac amyloid is the role 
of cardiac biomarkers.  A possible extension from the study of NT-proBNP in this thesis 
would be the role of serial NT-proBNP assessment in FAP patients, which has been 
found to be of prognostic significance in patients with AL amyloidosis.  The role of  
cardiac MRI, which is a newer investigative modality, in the assessment of these 
patients could also potentially provide prognostic information.   
Solid organ transplantation appears to be more successful when used to replace 
failing amyloidotic organ function in the other forms of systemic amyloidosis.  ALys, 
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unlike other hereditary forms of systemic amyloidosis appears to be associated with 
mutations that are very penetrant and as a result affected individuals inevitably have a 
family history of associated features such as renal failure and hepatic rupture.  RTx and 
OLT for these respective complications appears to be successful with good graft and 
patient survival.  RTx also appears to be a feasible option in patients with AA 
amyloidosis and ESRD associated with IBD, provided that good inflammatory control, 
guided by serial SAA levels, is maintained.  In those with organ failure on the 
background of AL amyloidosis, RTx in those with a good ECOG performance status, 
isolated ESRD and a pre-transplant clonal response to chemotherapy and cardiac 
transplantation in those with isolated end-stage cardiac disease followed by SCT 
appears to be feasible with good graft and patient survival.  OLT in those with 
decompensated liver disease has poor graft and patient survival outcomes compared to 
OLT in other liver diseases.  Whereas those with end-stage cardiac disease are generally 
too unwell to receive any treatment of their clonal disorder before cardiac 
transplantation timing of treatment of an underlying clonal disorder relative to renal 
transplantation in this relatively fitter cohort is less clear-cut.  There is good rationale to 
treat the clonal disorder before renal transplantation to try and prevent amyloid 
recurrence in the graft but there are also potential advantages in performing 
transplantation first as the subsequent normal renal function would preclude the need 
for dose attenuation of chemotherapy and hence this would offer the best chance of a 
deeper clonal response and hence also potentially reduce the likelihood of graft amyloid 
recurrence in the longer term.  Studies to compare these two approaches are therefore 
warranted. 
There have been few studies of hepatic and gastrointestinal amyloid.  From 
studies in this thesis it would appear that in ALys hepatic amyloid is virtually universal 
at presentation, although liver biochemistry is rarely abnormal.  It is apparent from the 
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liver biopsy study that diagnosis of amyloid unexpectedly in this way in those with 
abnormal liver biochemistry and/or hepatomegaly is a rarer mode of presentation of 
systemic amyloidosis.  It is most commonly associated with AL amyloidosis, which in 
this setting appears to have a worse prognosis than other forms of amyloidosis 
presenting in a similar manner.  It can be concluded that correct diagnosis of amyloid 
type is imperative as both prognosis and treatments are very different between these 
types.  Awareness of the multisystem nature of the presentation of those with AL 
amyloidosis in a liver biopsy and assessment for potential extra-hepatic amyloid is 
extremely important as this confers a mortality risk.  AL amyloidosis with a dominant 
liver presentation has historically been associated with a poor prognosis but it would 
appear that if a good clonal response can be achieved with chemotherapeutic regimes in 
the modern era of treatment a survival advantage can be conferred.  This benefit could 
be further accentuated with newer agents such as the proteosome inhibitors and studies 
of these agents are required. 
Gastrointestinal symptoms secondary to amyloidosis may occur in the context of 
intestinal infiltration by amyloid, as is common in ALys which is associated with a high 
frequency of endoscopic abnormalities or be associated with an amyloidotic autonomic 
neuropathy, as probably occurred in the FAP T60A cohort.  Detailed evaluation to 
corroborate clinical suspicion of gastrointestinal dysmotility in this latter group has not 
been systematically studied and warrants further research with techniques such as 
gastric scintigraphy, radio-opaque marker assessment of colonic transit, wireless 
capsule motility studies, anorectal manometry and testing for small intestinal bacterial 
overgrowth, which can be associated with gastrointestinal dysmotility.  Systemic 
amyloidosis can cause an array of GI complications but, conversely, primary diseases of 
the gastrointestinal tract can cause amyloidosis.  IBD is one of the commonest causes of 
AA amyloidosis.  Its major mode of presentation is proteinuric renal dysfunction.  Early 
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diagnosis with urine dipstick is therefore very important and should prompt 
consideration of the diagnosis.  In those with well controlled inflammation, guided by 
serial SAA levels rather than CRP levels, one can see improvement of amyloidotic 
organ dysfunction.  There needs to be awareness of the risk of decompensation of 
amyloidotic kidney function in the face of physiological stresses such as hypotension 
associated with sepsis and instigation of measures to prevent this from happening. 
The study of nutritional status in AL amyloidosis is one of the largest 
prospective studies in systemic amyloidosis, performed to date.  Malnutrition is 
prevalent, particularly in the context of multisystem disease and is not only associated 
with a poor quality of life but is also independently associated with reduced survival.  It 
therefore provides another potential target for intervention studies, which have to date 
largely focused on chemotherapeutic strategies.  One potential intervention would be 
dietary advice and nutritional supplementation, which could be set up in the form of a 
randomised study.  Another potential area of research would be into the mechanisms of 
cachexia in AL amyloidosis with a focus on potentially causative cytokines such as 
TNF-α, IL-1 and IL-6 which could provide a pharmacological target. 
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Appendices 
   
Appendix 1 
 
Gene (exon) Forward primer sequence Reverse primer sequence 
Transthyretin(2) 5‟-TTTCGCTCCAGATTTCTAATAC-3‟ 5‟-CAGATGATGTGAGCCTCTCTC-3‟ 
Transthyretin (3) 5‟-GGTGGGGGTGTATTACTTTGC-3‟ 5‟-TAGGACATTTCTGTGGTACAC-3‟ 
Transthyretin (4) 5‟-GGTGGTCAGTCATGTGTGTC-3‟ 5‟-TGGAAGGGACAATAAGGGAAT-3‟ 
Apolipoprotein (3) 5‟-GGCAGAGGCAGCAGGTTTCTCAC-3‟ 5‟-CCAGACTGGCCGAGTCCTCACCTA-3‟ 
Apolipoprotein (4) 5‟-CACTGCACCTCCGCGGACA-3‟ 5‟- CTTCCCGGTGCTCAGAATAAACGTT-3‟ 
Fibrinogen (5) 5‟-AGCTCTGTATCTGGTAGTACT-3‟ 5‟- ATCGGCTTCACTTCCGGC-3‟ 
Lysozyme (2) 5‟-GTTATATTGTTCGTTGGTGT-3‟ 5‟- CATTTGTATTGAGTCTCAATTC-3‟ 
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Appendix 2 
UNIVERSITY COLLEGE MEDICAL SCHOOL 
NATIONAL AMYLOIDOSIS CENTRE 
 
 
 
Date 
 
 
Dear Haematologist, GP, referring doctor 
 
Re. Patient details 
 
We are trying to gather some information on the above patient here at our Centre. 
Below are some questions and we would be very grateful if you would be able to 
provide us with as much information as possible. We would be very grateful if you 
would kindly forward any relevant correspondences to us or failing that annotate on 
this letter and send it back. 
 
 
Did the patient receive any chemotherapy, and if so what regimen and how many cycles? 
 
 
Was there a response, and if so was it a partial or complete response? 
 
 
Was he/she hospitalised at any point and if so for how many days? 
 
 
If he/she was admitted to hospital, what was the reason for admission? 
 
 
Did he/ she receive any antibiotics for infections? If so what was the infection and how 
long were antibiotics given for? 
 
 
Is the above patient dead and if so when and what was the cause of death? 
 
Thank you very much for your time and assistance. 
 
Yours sincerely 
 
Dr Prayman Sattianayagam    
Clinical Academic Research Fellow                   
National Amyloidosis Centre 
Royal Free and University College Medical School 
Rowland Hill Street 
London  
NW32PF 
Tel: 020 7433 2770 
Email: p.sattianayagam@medsch.ucl.ac.uk 
Prof PN Hawkins PhD FRCP FRCPath Clinical Director 
020 7433 2815 (PA 2816)  p.hawkins@medsch.ucl.ac.uk 
Prof MB Pepys FRS, Head, Dept of Medicine 
020 7433 2802  m.pepys@medsch.ucl.ac.uk 
Dr JD Gillmore MD PhD MRCP, Senior Lecturer 
020 7433 2726  j.gillmore@medsch.ucl.ac.uk 
Dr HJ Lachmann MD MRCP, Senior Lecturer 
020 7433 2804  h.lachmann@medsch.ucl.ac.uk 
Dr AD Wechalekar MD MRCP MRCPath, Senior Lecturer 
020 7433 2758  a.wechalekar@medsch.ucl.ac.uk 
Dr P Sattianayagam MRCP, Clinical Fellow 
020 7433 2823  p.sattianayagam@medsch.ucl.ac.uk 
General Enquiries: 020 7433 2725 
Ramon Lamarca (Unit Secretary) 020 7433 2811 
